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Abstract 
The network activity of the hippocampal formation underlying learning and memory processes 
is regulated by a number of ionic conductances that determine the neuronal excitability and 
firing patterns of hippocampal pyramidal neurons. The slow Ca2+-activated K+ current (sIAHP) 
and its modulation by acetylcholine (ACh) and glutamate play a crucial role in shaping these 
intrinsic properties of hippocampal pyramidal neurons. sIAHP follows a train of action potentials 
and is characterised by its dependency on the rise of intracellular Ca2+ and its slow time course, 
displaying activation kinetics of hundreds of milliseconds and decaying over seconds. It is 
responsible for spike frequency adaptation that restricts repetitive firing in response to a 
prolonged stimulus. Hence the suppression of sIAHP by ACh and glutamate, through 
metabotropic receptors, leads to an enhanced excitability of hippocampal pyramidal neurons. 
The underlying signal transduction cascade used by ACh and glutamate to inhibit sIAHP is not 
fully characterised, involving the G-protein subunit Gαq, but not its classical signalling pathway 
via phospholipase C β (PLCβ) (Krause et al., 2002). Employing molecular biology and imaging 
techniques in heterologous expression systems this study establishes that the small GTPase 
RhoA acts as a signalling partner of Gαq, pointing to an involvement of both proteins in a 
common signalling pathway that mediates the suppression of sIAHP upon the stimulation of G-
protein coupled receptors (GPCRs) by cholinergic agonists in hippocampal pyramidal neurons. 
The introduction of activated and inactivated RhoA mutants into hippocampal pyramidal 
neurons by viral infection, and subsequent whole-cell patch clamp electrophysiology, showed 
that constitutively active RhoA-V14 reduces sIAHP significantly, mimicking the inhibitory effect 
of ACh, whereas sIAHP is unaffected in neurons expressing inactive RhoA-N19. An involvement 
of RhoA in the regulation of membrane excitability of hippocampal pyramidal neurons and 
thus in the shaping of neuronal activity on a relatively fast time-scale is a novel function for the 
small GTPase. 
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1.1 The Hippocampus 
1.1.1 Hippocampal function, neuroanatomy and circuitry 
The hippocampal formation (Fig. 1.1A), including dentate gyrus, hippocampus proper (divided 
into the cornu ammonis (CA) fields 1–3), subicular complex and entorhinal cortex, and the 
neighbouring structures of perirhinal and parahippocampal cortices are located in the medial 
temporal lobe and have been extensively studied for their role in memory acquisition and 
consolidation, spatial awareness and attention control. Furthermore, the hippocampus and 
associated structures are of interest to researchers as they are prone to generate epileptic 
seizures and to suffer from ischemic damage, and are greatly damaged in Alzheimer’s disease 
(Walker et al., 2007). The involvement of medial temporal lobe structures in the formation of 
declarative memory i.e. the conscious recollection of facts and events has been proposed after 
the study of patients with brain lesions to this area, the development of animal models and 
neuroimaging studies (Squire and Zola-Morgan, 1991; Squire et al., 2004). The discovery of 
place cells in hippocampus and the idea of the formation of cognitive maps have defined the 
role of the hippocampus in space awareness (O’Keefe and Dostrovsky, 1971; O’Keefe and 
Nadel, 1978).  
 
Figure 1.1 The hippocampal formation. (A) Schematic representation of the anatomical regions 
of the hippocampal formation (from Amaral and Lavenex, 2007). Inset shows a Nissl-stained transverse 
section of the rat hippocampal formation (from Amaral and Witter, 1989). (B) Diagram of the main 
excitatory connections in the hippocampal circuitry (adapted from Tsien et al., 1996). EC, entorhinal 
cortex; Para/PaS, parahippocampal cortex; Pre/PrS, perirhinal cortex; Sub/S, subiculum; CA, cornu 
ammonis; DG, dentate gyrus; pp, perforant pathway; mf, mossy fibres; sc, Schaffer collaterals; rc, 
recurrent collateral axons 
Due to its highly organised neuroanatomy the hippocampal formation and its circuitry has 
become a well studied area of the brain. At cytoarchitectonic level the hippocampal regions 
are organised in a laminar fashion. In the CA1–3 fields of the hippocampus proper as well as in 
the dentate gyrus the principal cells are arranged in tightly packed bands. Principal cells, 
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pyramidal neurons in the CA fields and granule neurons in the dentate gyrus, make up the 
majority of cells, while the interneuron population amounts to less than 10 % (Buhl and 
Whittington, 2007). The regions of the hippocampal formation are connected in a mainly 
unidirectional manner with the entorhinal cortex serving as the start and end point of the 
circuit loop, which the hippocampal formation uses to process information (Fig. 1.1B). The 
majority of neocortical input to the hippocampal formation is received by the entorhinal 
cortex, whose layer II neurons project, via the perforant pathway, to the dentate gyrus and 
provide over 80 % of its input (Kobayashi and Amaral, 1999). Via the mossy fibre pathway, the 
granule cells of the dentate gyrus connect with the pyramidal cells of CA3, which in turn 
provide the major input, the Schaffer collaterals, to the pyramidal cells of CA1. The loop is 
closed by projections to the entorhinal cortex from CA1 directly or indirectly via the subiculum. 
This circuit (Fig. 1.1B) describes the main excitatory connections within the hippocampal 
formation, but is a simplified version of the real network and additional intrinsic and extrinsic 
connections to and from various hippocampal fields also contribute. For example, the 
entorhinal cortex also projects to CA3, CA1 and subiculum directly and both dentate gyrus and 
the CA fields receive inputs from basal forebrain, hypothalamus and brain stem (Witter and 
Amaral, 2004; Amaral and Lavenex, 2007). Furthermore, the extensive inhibitory interneuron 
circuits play a pivotal role in shaping the network activity of the hippocampal formation 
(Spruston and McBain, 2007). Apart from glutamate as the main excitatory and GABA as the 
major inhibitory transmitter of the hippocampus formation, others neurotransmitters like ACh 
and the monoamines noradrenaline, dopamine, serotonin and histamine also contribute to the 
regulation of the hippocampal network (Kobayashi and Amaral, 1999). 
1.1.2 Glutamatergic and cholinergic systems in the hippocampus 
As mentioned, glutamate acts as the main excitatory transmitter of the hippocampal formation 
and is responsible for the excitatory synaptic transmission in the so-called tri-synaptic circuit 
i.e. projections from entorhinal cortex to dentate gyrus to CA3 and to CA1 described above. 
Glutamate mediates this transmission by activating ionotropic receptors, AMPA (GluA, 
nomenclature for proteins according to IUPHAR classification (Collingridge et al., 2009)) as well 
as NMDA (GluN) receptors, and the opening of these non-selective cation channels causes the 
postsynaptic neuron to depolarise. The role of kainate (GluK) receptors in synaptic 
transmission is not well characterised, but their activation by glutamate enhances the 
excitation of CA3 pyramidal neurons by mossy fibres (Castillo et al., 1997). NMDA receptor 
activation at Schaffer collateral/CA1 pyramidal neuron synapses and in particular the 
subsequent influx of Ca2+ induces changes in synaptic plasticity that is required for long-term 
potentiation (LTP) (Bliss and Collingridge, 1993). Ionotropic glutamate receptors are also 
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localised on inhibitory interneurons and their excitation contributes to the regulation of 
hippocampal network activity by various feed-forward and feed-backward circuits (Freund and 
Buzsáki, 1996; Jonas et al., 2004). 
On the other hand, glutamate also produces slower responses by acting on metabotropic 
glutamate receptors (mGluRs), which are coupled to heterotrimeric G-proteins and activate 
intracellular signalling cascades. Eight mGluR subtypes are known and they are classified into 
three groups according to sequence similarities and pharmacological and functional profiles: (I) 
mGlu1 and mGlu5, (II) mGlu2 and mGlu3 and (III) mGlu4, mGlu6, mGlu7 and mGlu8; with group (I) 
coupling to G-proteins of the Gq subfamily and activating PLCβ and group (II) and (III) signalling 
via G-proteins of the Gi subfamily and inhibiting adenylyl cyclase (AC) (Niswender and Conn, 
2010). mGluRs are localised mainly outside the pre- and postsynaptic areas and are thus 
thought to be activated by the spillover of glutamate from the synaptic cleft following high 
frequency release of glutamate from presynaptic terminals (Lujan et al., 1996; Luján et al., 
1997; Shigemoto et al., 1997). The modulatory effects of mGluR activation at presynaptic and 
postsynaptic sites influence synaptic transmission and neuronal excitability in the 
hippocampus formation. Furthermore, mGluRs have been linked to synaptic plasticity, since 
LTP induction has been shown to involve mGluR activation (Bashir et al., 1993; Anwyl, 2009). 
At the presynaptic neuron group II and III mGluRs inhibit glutamate release from principal 
neurons by acting as autoreceptors (Scanziani et al., 1997) and also suppress GABA release 
from interneurons (Semyanov and Kullmann, 2000; Kogo et al., 2004). This modulation of 
transmitter release by mGluRs is mediated by the suppression of voltage-gated Ca2+ (CaV) 
channels as well as by direct inhibition of the machinery involved in transmitter exocytosis 
(Scanziani et al., 1995; Takahashi et al., 1996; Anwyl, 1999; Cartmell and Schoepp, 2000). At 
the postsynaptic neuron the activation of the group I mGluRs, mGlu1 and mGlu5, causes 
depolarisation and leads to increased firing (Davies et al., 1995; Mannaioni et al., 2001). These 
mGluRs increase neuronal excitability by modulating various ion channels including Ca2+ 
channels (Swartz and Bean, 1992; Sahara and Westbrook, 1993), various K+ channels (Anwyl, 
1999) and non-selective cation channels (Crépel et al., 1994; Guérineau et al., 1995).  
In the hippocampal formation, the actions of the neurotransmitter ACh present a powerful 
system that modulates hippocampal network activity and oscillation state as well as synaptic 
plasticity by acting on nicotinic and muscarinic receptors. Cholinergic projections to the 
hippocampal formation originate in the medial septum nucleus and in the nucleus of the 
diagonal band of Broca and innervate the hippocampus via the fimbria-fornix pathway (Dutar 
et al., 1995). Cholinergic afferents form synaptic connections with principal cells as well as with 
interneurons, but also provide diffuse, non-synaptic transmission to the hippocampal 
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formation so-called volume transmissions (Frotscher and Léránth, 1985; Vizi and Kiss, 1998). A 
pivotal role of ACh in the hippocampal formation is its regulation of oscillation states such as 
the hippocampal theta rhythm, which is abolished when septohippocampal projections are 
damaged (Stewart and Fox, 1990; Buzsáki, 2002; Yoder and Pang, 2005). The synchronous 
membrane oscillations of 4–10 Hz are thought to constitute the temporal framework for the 
encoding of information. It allows for the precise firing of cells and influences synaptic 
plasticity, since LTP induction is known to be enhanced during the peak of theta wave (Huerta 
and Lisman, 1995). 
ACh activates muscarinic acetylcholine receptors (mAChRs) as well as nicotinic acetylcholine 
receptors (nAChRs). mAChRs (M) are GPCRs, of which five subtypes are known, M1–5. M1, M3 
and M5 couple to G-proteins of the Gq subfamily and activate PLCβ, while M2 and M4 coupled 
to G-proteins of the Gi subfamily cause the inhibition of AC (Caulfield and Birdsall, 1998). 
mAChRs are widely expressed throughout the brain with M1 being the prevalent receptor 
subtype, followed by M2 and M4 and then by M3 and M5 at low levels (Levey et al., 1991; 
Reever et al., 1997; van der Zee and Luiten, 1999). In the hippocampal formation M1 and M3 
receptors are predominantly located in principal cells (pyramidal neurons and granule cells), 
while M2 and M4 are found mainly in interneurons; the weak expression of M5 prevents a clear 
characterisation (Levey et al., 1995; van der Zee and Luiten, 1999; Volpicelli and Levey, 2004). 
The overall effect of postsynaptically located mAChRs is the increase in excitability of principal 
neurons caused by the modulation of various ionic conductance including several K+, mixed 
cation as well as Ca2+ currents (Cobb and Davies, 2005). mAChRs activation is also known to 
enhance the NMDA response of a hippocampal pyramidal neuron (Markram and Segal, 1990; 
Marino et al., 1998). On interneurons mAChRs cause depolarisation, but also mediate the 
inhibition of GABA release when located at synaptic terminals and thus have a strong 
regulatory control over hippocampal network activity (Pitler and Alger, 1992; Behrends and 
ten Bruggencate, 1993). This effect of presynaptic localised mAChRs is also observed on 
glutamatergic and, as autoreceptors, on cholinergic terminals (Raiteri et al., 1990; Rouse et al., 
1999).  
The second type of receptors activated by ACh is the group of nAChRs, which are ionotropic 
receptors permeable to Na+, K+ and Ca2+. In the hippocampus formation several nAChR 
subtypes are expressed presynaptically and postsynaptically, namely α7, α4β2 and α3β4 
(Alkondon and Albuquerque, 2004; Drever et al., 2011). Alpha7, the prevailing subtype and 
highly permeable to Ca2+, is also found at glutamatergic and GABAergic terminals, where it 
increases transmitter release and thus modulates synaptic transmission (Séguéla et al., 1993; 
Wonnacott, 1997; Fabian-Fine et al., 2001). Postsynaptically, the opening of nAChRs causes 
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depolarisation and increases intracellular Ca2+ levels. nAChRs are strongly expressed on 
GABAergic interneurons and their activation influences overall hippocampal network activity 
by modulating the excitability of hippocampal circuits and thus synaptic plasticity (Ji et al., 
2001; Drever et al., 2011).  
1.2 Afterhyperpolarizations 
Hippocampal network activity is regulated by a number of processes and various ionic 
conductances determine neuronal excitability and firing patterns of hippocampal pyramidal 
neurons, which in turn contributes to the encoding of information. K+ conductances, for 
example, have a major influence on these intrinsic neuronal properties and underlie 
afterhyperpolarization (AHP) that follows single or trains of action potentials. AHP controls the 
firing frequency of neurons and generates spike frequency adaptation. It consists of three 
distinct phases with fast (f), medium (m) and slow (s) kinetics (Fig. 1.2A; Alger and Nicoll, 1980; 
Hotson and Prince, 1980; Lancaster and Nicoll, 1987; Storm, 1987a and 1989), which are 
mediated by the opening of Ca2+-activated as well as voltage-gated K+ channels. While fAHP 
contributes to action potential repolarisation, mAHP is responsible for early and sAHP for late 
spike frequency adaptation i.e. the slowing down or termination of firing in response to a 
prolonged stimulus (Fig. 1.2B; Storm, 1990). AHP and its modulation play a crucial role in 
shaping neuronal excitability. 
 
Figure 1.2 Afterhyperpolarizations and the generation of spike frequency adaptation. (A) 
Afterhyperpolarizing potentials of fast (fAHP), medium (mAHP) and slow (sAHP) kinetics (from Sah, 
1996). The current IC is underlying fAHP, IM, IAHP and IC are underlying mAHP and sIAHP underlies sAHP 
(table). (B) The adaptation of the firing pattern in response to a prolonged stimulus is generated by 
mAHP, responsible for early spike frequency adaptation, and sAHP, underlying late spike frequency 
adaptation (adapted from Storm, 1990). 
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1.2.1 Fast afterhyperpolarization (fAHP) 
fAHP can be observed following a single action potential and the current underlying fAHP has 
been identified as IC, which displays rapid activation (1–2 ms) and deactivation kinetics (within 
tens of milliseconds), is sensitive to submillimolar concentrations of tetraethylammonium 
(TEA) and is mediated by the opening of large-conductance potassium (BK) channels (KCa1.1) 
(Brown et al., 1990; Storm, 1990). KCa1.1 channels are K
+ channels that display a single-channel 
conductance of 100–250 pS (Gribkoff et al., 2001). KCa1.1 channels are voltage- and Ca
2+-
dependent and thus activate in response to both membrane depolarisation and a rise of 
intracellular Ca2+, as is the situation during action potential generation. Both stimuli act 
allosterically to increase the open probability of the channel: Ca2+ sensitivity is increased at 
more depolarised potentials, just as high intracellular Ca2+ levels allow the channel to activate 
at more negative potentials (McManus, 1991; Cui et al., 2009). The opening of KCa1.1 channels 
contributes to spike repolarisation and hyperpolarisation, and acts as a feed-back mechanism 
to limit the activity of voltage-gated Ca2+ channels (CaV), with which they are closely associated 
(Berkefeld et al., 2006), and thus participates in the control of neuronal excitability.  
KCa1.1 channels consist of a pore-forming α subunit tetramer (Shen et al., 1994) and associated 
β subunits, of which four subunits (β1–4) are known (Orio et al., 2002). KCa1.1 channel α 
subunits have seven transmembrane segments (S0–6), an extracellular amino-terminus and a 
large intracellular carboxyl-terminus, and segments S1–6 show similarity to voltage-gated 
potassium (KV) channels in that S1–4 constitute the voltage sensor domain and S5–6 the pore-
forming domain (Meera et al., 1997). Unlike KV channels, voltage sensitivity is not 
predominantly conveyed by S4, but to a large extent also by residues on S2 and S3 (Ma et al., 
2006; Pantazis et al., 2010). The large carboxyl-terminus of the α subunit, around two-thirds of 
the total protein, contains the segments S7–10, two tandem RCK (regulator of K+ conductance) 
domains that constitute the channel’s gating ring and a highly conserved section of aspartate 
residues termed the “Ca2+ bowl” (Latorre et al., 2010). Partial deletions or point mutations of 
the Ca2+ bowl results in a reduction in Ca2+ sensitivity (Schreiber and Salkoff, 1997; Latorre and 
Brauchi, 2006). Ca2+ sensitivity is, however, not completely abolished, hence KCa1.1 channels 
must contain more than one Ca2+ sensor (Bao et al., 2002; Xia et al., 2002). Crystallography has 
verified the two tandem RCK domains and has established that the Ca2+ bowl is part of the 
second RCK, but no further Ca2+ sensing domains have been identified (Yuan et al., 2010). 
Despite being functional on their own, most α subunit tetramers associate with β subunits, 
which perform modulatory functions by influencing the KCa1.1  channels’ Ca
2+- and voltage 
sensitivity, kinetics as well as pharmacological profile (Orio et al., 2002). The β subunits consist 
of two transmembrane segments and have intracellular amino- and carboxyl-termini. 
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Functional coupling of the β subunits with α is achieved by contact of the first transmembrane 
segment of the β subunit with S1 and S2 of the α subunit and of the second transmembrane 
segment of the β subunit with S0 of the α subunit (Liu et al., 2010; Wu et al., 2013). β1 is 
mainly expressed in smooth muscles, β2 and β3 are found more widespread, but show limited 
expression in brain, while β4 is predominately expressed in neuronal tissue (Berkefeld et al., 
2010). Depending on subunit type, the assembly of β with α subunits can produce KCa1.1 
channels with diverse profiles. β1 co-assembly enhances Ca2+ sensitivity, which allows the 
channel to open at more negative potentials and to display greater open probabilities as well 
as slower activation and deactivation kinetics (Knaus et al., 1994; Bao and Cox, 2005). KCa1.1 
channels tend to be non-inactivating, whereas β2 association causes them to inactivate 
completely (Bentrop et al., 2001) and β3 association incompletely (Lingle et al., 2001). KCa1.1 
channels containing the β4 subunit display activation and deactivation kinetics that are 
modulated in a Ca2+-dependent manner (Brenner et al., 2000; Ha et al., 2004). KCa1.1 channels 
are blocked by submillimolar concentrations of TEA and by several toxins like charybdotoxin 
and iberiotoxin (Shen et al., 1994; Kaczorowski et al., 1996). Their pharmacological profile is 
influenced by the β subunits, for example, β2–4 association mediates a reduction in 
charybdotoxin sensitivity with β4 displaying the lowest affinity, while β1 association produces 
high affinity for charybdotoxin (Hanner et al., 1997; Meera et al., 2000; Berkefeld et al., 2010). 
In line with the properties of KCa1.1 channels, the generated current IC is abolished when Ca
2+ is 
removed, either extracellularly or by the Ca2+ chelator BAPTA (Lancaster and Nicoll, 1987; 
Storm, 1987a and b). EGTA, another Ca2+ chelator, does not bind Ca2+ fast enough to prevent 
KCa1.1 channel activation (Lancaster and Nicoll, 1987; Storm, 1987b; Berkefeld et al., 2006). 
This indicates the close proximity of KCa1.1 and CaV channels, estimated to be <30 nm for KCa1.1 
and CaV2.2/N-type in hippocampal pyramidal neurons (Marrion and Tavalin, 1998). 
Furthermore, IC is not modulated by neurotransmitters such as noradrenaline or the 
cholinergic agonist carbachol (CCh) (Brown and Griffith, 1983; Lancaster and Adams, 1986; 
Lancaster and Nicoll, 1987; Madison et al., 1987). Elimination of IC, either by the removal of 
Ca2+ or the application of TEA or other KCa1.1 channel blockers (charybdotoxin and iberiotoxin) 
causes an increase in action potential duration and the abolition of fAHP (Storm, 1987a) thus 
confirming the role of IC in spike repolarisation and as the underlying current for fAHP.  
1.2.2 Medium afterhyperpolarization (mAHP) 
Single as well as bursts of action potentials are followed by fAHP and then by an 
afterhyperpolarization with medium kinetics (mAHP), displaying an activation time of <5 ms 
and a decay phase lasting hundreds of milliseconds (Gustafsson and Wigström, 1981; Storm, 
1989). These kinetic properties and its influence on membrane repolarisation allow mAHP to 
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control interspike frequency and make it responsible for the early phase of spike frequency 
adaptation (Fig. 1.2B; Stocker et al., 1999; Shah et al., 2006). At hyperpolarized potentials 
mAHP is generated by Ih, a Cs
+-sensitive, mixed cation (K+ and Na+) current mediated by 
hyperpolarization-activated cyclic nucleotide-regulated (HCN) channels (Halliwell and Adams, 
1982; Storm, 1989; Gu et al., 2005). Four subtypes (HCN1–4) are known and HCN channels are 
tetramers with each subunit consisting of six transmembrane segments (S1–6) and 
intracellular amino- and carboxyl-termini. S4 functions as the voltage sensor and the pore 
forming region is located between S5 and S6. Activation of HCN channels is caused by 
hyperpolarization and is facilitated by the interaction with cyclic nucleotides (especially cyclic 
adenosine monophosphate; cAMP), which cause the channel to open faster (Biel et al., 2009).  
The currents underlying mAHP are IM, mediated by voltage-gated K
+ channels (KCNQ (KV7)), 
IAHP, generated by Ca
2+-activated small conductance K+ channels (SK (KCa2)) and to a small 
extent IC, which is caused by BK channels (KCa1.1). The contribution of IC is supported by the 
description of a fast Ca2+-dependent component of the mAHP as well as a reduction in early 
spike frequency adaptation upon blocking of KCa1.1 channels (Lancaster and Nicoll, 1987; 
Storm, 1989). 
KCNQ channels (KV7), responsible for IM (classically known as M-current), are activated by 
depolarisations exceeding -60 mV, display slow activation kinetics and deactivate over ~ 50 ms, 
and do not inactivate (Brown and Adams, 1980; Storm, 1990). The KV7 channel family 
comprises five members, of which KV7.1 is found predominantly in heart (Wang et al., 1996), 
while the other four, KV7.2–7.5, are expressed in the nervous system (Wang, H-S et al., 1998; 
Kubisch et al., 1999; Lerche et al., 2000; Schroeder et al., 2000). KV7 channels are formed by 
four subunits, which arrange around a central pore and each have six transmembrane 
segments (S1–6) and intracellular amino- and carboxyl-termini (Robbins, 2001; Howard et al., 
2007; Nakajo et al., 2010). The pore forming region of the subunits is located between S5 and 
S6, while the positively charged S4 serves as the voltage sensor. Unlike other KV channels, for 
which the T1 domain of the amino-terminus is responsible for tetramerization, the assembly of 
KV7 channels is mediated by their carboxyl- terminus (Haitin and Attali, 2008). The carboxyl-
terminus of KV7 channels is particularly long (300–500 residues) and its distal part contains a 
conserved region, the A-domain that comprises two coiled coil motifs (the A-domain head, also 
called tetramerizing coiled coil 1, and the A-domain tail (tetramerizing coiled coil 2)) and is 
crucial for channel assembly, tetramerization and trafficking (Schmitt et al., 2000; Schwake et 
al., 2000; Maljevic et al., 2003; Schwake et al., 2003; Howard et al., 2007). The proximal part of 
the carboxyl-terminus possesses two conserved motifs that constitute the binding site for the 
Ca2+ sensor calmodulin (CaM) (Wen and Levitan, 2002; Yus-Najera et al., 2002; Gamper and 
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Shapiro, 2003). CaM binds to KV7 channels constitutively, with or without Ca
2+ being present, 
and is essential for channel function as well as being implicated in the assembly and gating of 
some KV7 channels (Wen and Levitan, 2002; Shamgar et al., 2006). CaM mediates the Ca
2+ 
sensitivity of KV7 channels and is responsible for the inhibition of KV7 channels upon the rise of 
intracellular Ca2+ (Gamper and Shapiro, 2003). However, this CaM-mediated inhibition varies 
between different KV7 subunits with KV7.2, KV7.4 and KV7.5 channels being affected, while 
KV7.1 and KV7.3 are not (Gamper et al., 2005). 
In heterologous expression systems, all KV7 subunits are able to assemble as homomultimers 
and in certain combinations as heteromultimers, whereas under physiological conditions 
channels are thought to be mainly heteromultimers consisting of either KV7.2, KV7.4 or KV7.5 
subunits in combination with KV7.3 at equal stoichiometry, with KV7.2/7.3 being the 
predominant combination (Wang, H-S et al., 1998; Kubisch et al., 1999; Jentsch, 2000; 
Schroeder et al., 2000; Shah et al., 2002; Hadley et al., 2003; Bal et al., 2008). Furthermore, 
KV7.1 channels associate with members of the KCNE family, which encompasses five members 
(KCNE1–5) that act as auxiliary subunits for several KV channels and consist of one 
transmembrane segment with an extracellular amino-terminus and a cytosolic carboxyl-
terminus (Barhanin et al., 1996; Sanguinetti et al., 1996; McCrossan and Abbott, 2004). 
KV7.1/KCNE channels are proposed to consist of two KCNE β subunits assembled with four 
KV7.1 α subunits (Chen et al., 2003; Morin and Kobertz, 2008), although a variable 
stoichiometry of up to four KCNE subunits per KV7.1 tetramer has also been suggested (Wang, 
W et al., 1998; Nakajo et al., 2010). While KV7.1 channels produce fast activating currents, the 
association with KCNE1 β subunits results in slower activation kinetics and increased current 
amplitudes (McCrossan and Abbott, 2004). In the heart KV7.1/KCNE1 channels are responsible 
for IKs, the slow delayed rectifier current crucial for cardiac action potential repolarisation 
(Barhanin et al., 1996; Sanguinetti et al., 1996). 
IM resembles currents generated by KV7.2/7.3 channels (Wang, H-S et al., 1998), but it can also 
be produced by other combinations of neuronally expressed channels and thus, depending on 
neuron type, KV7 channels of different subunit compositions are likely to generate IM 
(Schroeder et al., 2000; Selyanko et al., 2000; Shah et al., 2002; Tzingounis and Nicoll, 2008; 
Brown and Passmore, 2009). In the hippocampus KV7.2/7.3 as well as KV7.3/7.5 channels along 
with some contribution of homomeric Kv7.2 and Kv7.5 channels are suggested to underlie IM 
(Shah et al., 2002; Peters et al., 2005; Tzingounis et al., 2010). IM is inhibited by mAChR 
agonists such as ACh and muscarine and its suppression can be reversed by the mAChR 
antagonist atropine (Halliwell and Adams, 1982; Storm, 1989). KV7 channels are also blocked 
by linopirdine (IC50: 3.7– >200 μM) and XE991 (IC50: 0.7–70 μM) as well as by TEA (IC50: 0.3–
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 >30 mM); sensitivity of KV7 subunits to the blockers is variable and the order for example with 
TEA is KV7.2 > KV7.4 = KV7.1 > KV7.5 > KV7.3 (Storm, 1989; Hadley et al., 2000; Schroeder et al., 
2000; Robbins, 2001). The activation of M1, mAChRs coupled to the pertussis toxin-insensitive 
G-proteins of the Gq family, mediates the inhibition of IM (Caulfield et al., 1994; Selyanko et al., 
2000) by decreasing the level of membrane phosphatidylinositol 4,5-bisphosphate (PIP2), which 
is required for KV7 channels to open (Zhang et al., 2003; Brown et al., 2007; Hernandez et al., 
2008). 
Small conductance potassium (SK) channels (KCa2), which generate IAHP, are Ca
2+-activated K+ 
channels that have a single channel conductance of ~10 pS and display activation kinetics of 5–
15 ms and deactivate over ~50 ms (Köhler et al., 1996; Xia et al., 1998; Stocker, 2004). The KCa2 
family encompasses three members (KCa2.1–2.3) that are expressed throughout the nervous 
system and each display a characteristic expression pattern that, in the case of KCa2.1 and 
KCa2.2, overlaps in some brain areas such as CA1–3 of hippocampus (Köhler et al., 1996; 
Stocker and Pedarzani, 2000; Sailer et al., 2002). Each subunit of the tetrameric channel 
comprises six transmembrane segments (S1–6) with a pore domain between S5 and S6 and 
cytosolic amino- and carboxyl-termini. Compared to KV channels, KCa2 channels have less 
positively charged residues in S4, which renders them voltage insensitive (Köhler et al., 1996; 
Stocker, 2004). KCa2 channels are activated by intracellular Ca
2+, towards which they display 
high sensitivity (EC50: 0.3–0.7 μM; (Köhler et al., 1996; Hirschberg et al., 1998; Xia et al., 1998; 
Hirschberg et al., 1999). However, instead of having an intrinsic Ca2+ binding motif, activation 
of KCa2 channels is mediated by the Ca
2+ sensor CaM, which constitutively binds to each of the 
four channel subunits (Xia et al., 1998; but see Halling et al., 2014). The CaM binding domain is 
located in the carboxyl-terminus of the KCa2 channel subunit, directly neighbouring S6, and the 
constitutive association of CaM with the CaM binding domain is mediated by amino acids in 
the carboxyl-terminal half of CaM, while two EF hand motifs at the amino-terminus of CaM are 
responsible for Ca2+ binding and channel gating (Keen et al., 1999). Crystallization studies have 
shown that when Ca2+ is bound, the amino-terminus of CaM is associated with the CaM 
binding domain of a second KCa2 subunit (dimerization; Schumacher et al., 2001). This is 
thought to cause conformational changes that are conveyed to S6 of the KCa2 channel subunits 
and result in channel opening. Because of the constitutive association between CaM and the 
KCa2 channel, changes to the intracellular Ca
2+ level are rapidly transduced to the channel. The 
Ca2+ sensitivity of KCa2 channels is modulated by additional binding partners to the KCa2 
channel/CaM complex, namely protein kinase CK2 and protein phosphatase 2A, which 
counterbalance each other: CK2 phosphorylates CaM when the channel is in the closed state 
and thus reduces Ca2+ sensitivity, while the dephosphorylation of CaM by protein phosphatase 
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2A occurs only when the channel is open and results in an increase in Ca2+ sensitivity (Bildl et 
al., 2004; Allen et al., 2007). Apart from conveying Ca2+ sensitivity to the KCa2 channel, CaM 
binding has also been implicated in the trafficking of the channel to the plasma membrane 
(Lee et al., 2003). In hippocampus, small conductance Ca2+-activated K+ channels, thought to be 
KCa2 channels, are localised in close proximity (50–150 nm) to CaV channels (CaV1.2 and 
CaV1.3/L-type Ca
2+ channels), which open during action potentials and causes the increase in 
intracellular Ca2+ that activates these K+ channels (Marrion and Tavalin, 1998). Other Ca2+ 
sources such as Ca2+ release from intracellular stores and the influx of Ca2+ through ligand-
gated ion channels (NMDARs and nAChRs) and CaV2.3 channels (R-type Ca
2+ channels) have 
also been shown to activate KCa2 channels (Adelman et al., 2012). 
Although heteromeric KCa2 channels are formed in heterologous expression systems 
(KCa2.1/2.2, Ishii et al, 1997; KCa2.1/2.3 and KCa2.2/2.3, Monaghan et al., 2004), their existence 
in native tissue is not well defined or has been excluded (no assembly between KCa2.2 and 
KCa2.3, Sailer et al., 2002). Members of the KCa2 channel family display different levels of 
sensitivity to the specific KCa2 channel blocker apamin, with KCa2.2 being the most sensitive 
(IC50: 27–140 pM), followed by KCa2.3 (IC50: 0.6–4.0 nM) and KCa2.1 (IC50: 0.7–12 nM) (Pedarzani 
and Stocker, 2008). At first, KCa2.1 was described as being apamin-insensitive (Köhler et al., 
1996; Ishii et al., 1997), but later studies determined its low apamin sensitivity (Shah and 
Haylett, 2000a; Strøbaek et al., 2000). Other toxins and compounds that inhibit KCa2 channels 
include scyllatoxin, tamapin, d-Tubocurarine (dTC), bicuculline and high millimolar 
concentrations of TEA (Pedarzani and Stocker, 2008). The modulation of KCa2 channels by 
neurotransmitters is not well established, but noradrenaline (Maingret et al., 2008) and ACh 
(Buchanan et al., 2010; Giessel and Sabatini, 2010) are suggested to inhibit KCa2 channels via 
associated kinases, namely protein kinase CK2 or protein kinase C (PKC). A role of glutamate 
and protein kinase A (PKA) in the modulation of KCa2 channels has also been suggested 
(Pedarzani and Stocker, 2008). 
In hippocampus, the existence of IAHP and its contribution to mAHP has been shown through its 
inhibition by apamin, which therefore establishes KCa2 channels as the channels generating this 
Ca2+-activated current (Stocker et al., 1999; Sailer et al., 2002). Moreover, KCa2 channel 
expression in hippocampus (Stocker et al., 1999; Stocker and Pedarzani, 2000; Sailer et al., 
2002) matches the reported distribution of apamin binding sites (Mourre et al., 1986; Gehlert 
and Gackenheimer, 1993). The most apamin-sensitive KCa2 channel subunit KCa2.2 is highly 
expressed, especially in CA1 and CA3, and is suggested to underlie IAHP, while KCa2.1, which is 
localised in the same regions, is not believed to play a role due to its lower apamin sensitivity, 
however, the contribution of heteromeric KCa2.1/2.2 channels to IAHP cannot be excluded 
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(Stocker and Pedarzani, 2000; Sailer et al., 2002). Studies of KCa2 channel knock-out mice have 
revealed the responsibility of KCa2.2 underlying IAHP, whereas the current is not affected in 
KCa2.1 and KCa2.3 knock-out mice, nevertheless a role of heteromeric KCa2.1/2.2 channels can 
also not be ruled out completely (Bond et al., 2004). The contribution of IAHP to mAHP in 
hippocampus is, however, contested by studies, which show an apamin-insensitive mAHP and 
suggest that only IM, IC and Ih underlie mAHP (Gu et al., 2005 and 2008). 
1.2.3 Slow afterhyperpolarization (sAHP) 
sAHP is observed after a train of action potentials and is characterised by its slow kinetics, its 
Ca2+ dependency as well as by its modulation by various neurotransmitters (Storm, 1990; Sah, 
1996). It is responsible for the late phase of spike frequency adaptation and thus restricts the 
repetitive firing of action potentials and contributes greatly to the control of neuronal 
excitability (Fig. 1.2B; Alger and Nicoll, 1980; Hotson and Prince, 1980; Madison and Nicoll, 
1982 and 1984; Lancaster and Nicoll, 1987). sAHP has been described in pyramidal neurons in 
CA1–3 of hippocampus as well as in the cortex and several other areas of brain, but is not as 
widely seen as mAHP (Stocker et al., 2004). sAHP activates over several hundreds of 
milliseconds and decays over seconds (Hotson and Prince, 1980; Lancaster and Adams, 1986; 
Sah and Clements, 1999; Gerlach et al., 2004), thus presents very slow kinetics compared to 
fAHP and mAHP. sAHP kinetics are highly temperature dependent, an increase in temperature 
results in faster activation and decay (Thompson et al., 1985; Lancaster and Adams, 1986).  
The K+ current underlying sAHP has been named sIAHP and its properties include voltage 
insensitivity, activation by Ca2+ and a single channel conductance of 2–5 pS (Hotson and Prince, 
1980; Lancaster and Adams, 1986; Sah and Isaacson, 1995). The search for the channel 
mediating sIAHP is hampered by the lack of specific blockers, since it is insensitive to non-
selective K+ channel blockers like TEA or 4-aminopyridine (4-AP) as well as the toxin apamin 
(Lancaster and Adams, 1986; Lancaster and Nicoll, 1987; Storm, 1989; Stocker et al., 1999). 
Reports proposing a block of the channel generating sIAHP by the clotrimazole analogues, 
UCL2027 and UCL2077, is the only exception (Shah et al., 2001 and 2006; Soh and Tzingounis, 
2010). 
The activation of sIAHP depends on intracellular Ca
2+ concentration (threshold at 
[Ca2+]i = 160 nM) (Abel et al., 2004) and can be eliminated by the removal of extracellular Ca
2+, 
the application of Ca2+ channels blockers like cadmium or the intracellular application of Ca2+ 
chelators such as EGTA and BAPTA (Schwartzkroin and Stafstrom, 1980; Madison and Nicoll, 
1982 and 1984; Lancaster and Adams, 1986; Zhang et al., 1995). The extracellular source of 
Ca2+ to activate sIAHP is via CaV channels, which open during action potential firing and the 
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involvement of CaV1 channels (L-type) has been determined by specific channel inhibitors such 
as isradipine and nifedipine, which suppress sIAHP (Tanabe et al., 1998; Shah and Haylett, 
2000b; Lima and Marrion, 2007). In contrast, inhibition of CaV2.1 (P/Q-type) and CaV2.2 (N-
type) channels does not suppress sIAHP (Tanabe et al., 1998; Lima and Marrion, 2007; but see 
Shah and Haylett, 2000b). Of the two main neuronal CaV1 channel subtypes the deletion of 
CaV1.3, but not CaV1.2, reduces sAHP (Gamelli et al., 2011). In addition to its direct action, Ca
2+ 
entering the cell through CaV channels also causes Ca
2+-induced Ca2+ release. Such a process 
contributes to the activation of sIAHP, since sIAHP is diminished when intracellular Ca
2+ stores are 
depleted by Ca2+ ATPase inhibitors or when Ca2+ release from stores is inhibited by the block of 
ryanodine receptors (RyR3) (Tanabe et al., 1998; Shah and Haylett, 2000b; van de Vrede et al., 
2007; but see Zhang et al., 1995). sIAHP amplitude is directly related to the amount of Ca
2+ 
entering the cell; increasing the duration and intensity of the depolarising step (or of the 
current pulses when recording sAHP) augments sIAHP amplitude with peak values being reached 
when [Ca2+]i reaches 250–350 nM (Abel et al., 2004), while changing Ca
2+
 does not affect sIAHP 
kinetics (Hotson and Prince, 1980; Gustafsson and Wigström, 1981; Madison and Nicoll, 1984; 
Lancaster and Adams, 1986; Gerlach et al., 2004). 
A key characteristic of sIAHP is its susceptibility to neurotransmitter modulation, which presents 
a way to control cell excitability and firing properties. sIAHP is suppressed by the monoamine 
neurotransmitters dopamine (Benardo and Prince, 1982; Pedarzani and Storm, 1995), 
histamine (Haas and Konnerth, 1983; Pedarzani and Storm, 1993), noradrenaline (Madison and 
Nicoll, 1982; Haas and Konnerth, 1983; Lancaster and Adams, 1986; Madison and Nicoll, 
1986a; Pedarzani and Storm, 1993; Blitzer et al., 1994) and serotonin (Andrade and Nicoll, 
1987; Colino and Halliwell, 1987; Pedarzani and Storm, 1993; Torres et al., 1995). Other 
neurotransmitters like glutamate (Charpak et al., 1990) and ACh (Cole and Nicoll, 1983; 
Madison et al., 1987) also suppress sIAHP. sIAHP modulation by neurotransmitter is not caused by 
changes to the Ca2+ influx into the cell given that Ca2+ spikes are not affected when sIAHP is 
blocked (Cole and Nicoll, 1983; Madison and Nicoll, 1986a; Knöpfel et al., 1990; Pedarzani and 
Storm, 1995). Monoamine neurotransmitters inhibit sIAHP by acting on GPCRs coupled to G-
proteins of the Gs family and thus via the second messenger cAMP, which is derived from ATP 
by Gαs stimulated AC and causes activation of PKA (Madison and Nicoll, 1986b; Pedarzani and 
Storm, 1993 and 1995; Torres et al., 1995). The suppression of sIAHP by monoamine 
neurotransmitters is prevented when PKA is blocked by the intracellular application of the PKA 
inhibitors, Rp-adenosine-3’,5’-cyclic monophosphorothioate (Rp-cAMPs) and Walsh peptide 
(PKI) (Pedarzani and Storm, 1993 and 1995). In contrast the application of either forskolin, 
which activates AC and thus increases cAMP levels, or cAMP analogues 8-bromoadenosine 
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3’,5’-monophosphate (8-Br cAMP) and 8-(4-chlorophenylthio) adenosine 3’,5’-cyclic 
monophosphate (8CPT-cAMP), suppress sIAHP and so behave like monoamine 
neurotransmitters (Madison and Nicoll, 1986b; Pedarzani and Storm, 1993; Torres et al., 1995). 
Thus inhibition of sIAHP seems to involve a phosphorylation step that alters the channel 
generating sIAHP either directly or via intermediate proteins (Nicoll, 1988; Pedarzani and Storm, 
1993). In contrast the signalling pathways to suppress sIAHP used by glutamate and ACh are not 
well identified. Both neurotransmitters activate GPCRs, mGluRs (Charpak et al., 1990) and 
mAChRs (Cole and Nicoll, 1983 and 1984), coupled to pertussis toxin-insensitive G-proteins 
(Dutar and Nicoll, 1988; Gerber et al., 1992). Unlike monoamine neurotransmitters, the 
suppression of sIAHP by glutamatergic and cholinergic agonists is not altered in the presence of 
PKA inhibitors, so neither glutamate nor ACh mediated signalling involves PKA (Gerber et al., 
1992; Pedarzani and Storm, 1993; Blitzer et al., 1994; Pedarzani and Storm, 1996). 
Furthermore, the modulatory effect of ACh and glutamate on sIAHP is not mediated by PKC 
either as PKC inhibitors do not affect sIAHP suppression (Gerber et al., 1992; Sim et al., 1992; 
Engisch et al., 1996). The suppression of sIAHP by ACh, but not by glutamate, is, however, 
reduced when CamKII is inhibited (Müller et al., 1992; Pedarzani and Storm, 1996). 
Ca2+ entering the cell during action potentials acts as an important signalling molecule before 
being sequestered (Berridge et al., 2003). The slow time course of sIAHP activation does not 
match the kinetics of the rise of intracellular Ca2+ during action potentials (Sah and Clements, 
1999). This discrepancy between sIAHP kinetics and Ca
2+ signalling has lead to a range of 
proposals for the underlying mechanism determining sIAHP kinetics. The first proposal suggests 
that once Ca2+ enters the cell it directly binds and activates the channel generating sIAHP and 
explains the slow time scale of sIAHP with a channel location distant from the site of Ca
2+ entry 
(Lancaster and Nicoll, 1987; Lancaster and Zucker, 1994). However, such a proposal for 
channel activation has been questioned, since the activation kinetics of sIAHP do not change in 
response to higher levels of intracellular Ca2+ (Gerlach et al., 2004) and the increase in sIAHP 
kinetics due to higher temperatures is too large to be explained by the simple diffusion of Ca2+ 
(Lee et al., 2005). The second proposal suggests that opening of the channel generating sIAHP 
might be the reason for the slow kinetics of sIAHP. The kinetics of sIAHP have been examined in 
response to the rapid rise or fall of intracellular Ca2+ following the photolysis of caged Ca2+ or 
Ca2+ buffers. One study reports a quick response of sIAHP to increasing and decreasing Ca
2+ 
concentrations, which would indicate an underlying channel with fast kinetics and a prominent 
role of Ca2+ diffusion and buffering for sIAHP kinetics (Lancaster and Zucker, 1994). In contrast, 
another study depicts a channel generating sIAHP with slow gating mechanisms, unaffected by 
rapid Ca2+ level changes, and proposes the direct binding of Ca2+ to the channel (Sah and 
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Clements, 1999). However, increasing the Ca2+ influx into the cell results in the shortening of 
activation times and thus questions the idea of intrinsically slow channel kinetics (Gerlach et 
al., 2004). One mechanism that might result in the slow activation of sIAHP, albeit an underlying 
channel with fast kinetics, is the delayed facilitation of CaV1 channels, which has been 
observed in response to a depolarising pulse or a train of action potentials at negative 
potentials (-20 – -60 mV) (Cloues et al., 1997; Bowden et al., 2001). A third proposal for the 
slow kinetics of sIAHP is its activation by Ca
2+-induced Ca2+ release, which would prolong the 
time until the channel is activated. However, it has been shown that Ca2+-induced Ca2+ release 
is not the sole mediator of sIAHP in hippocampus, but only contributed to its activation (Tanabe 
et al., 1998; Shah and Haylett, 2000b; van de Vrede et al., 2007). Lastly, the slow kinetics and 
temperature sensitivity of sIAHP have led to the proposal of a second messenger system and 
hippocalcin, a family member of the neuronal Ca2+ sensor proteins strongly expressed in 
hippocampus (Saitoh et al., 1994), as potential Ca2+ sensor for sIAHP (Tzingounis et al., 2007). 
Upon Ca2+ binding hippocalcin translocates to the cell membrane (Markova et al., 2008), where 
it is thought to gate the channel generating sIAHP given that this current is reduced in 
hippocalcin knock-out mice (Tzingounis et al., 2007). The absence of a Ca2+ sensing domain on 
the channel could explain the slow time course of sIAHP. Nevertheless sIAHP is not completely 
suppressed in hippocalcin knock-out mice and maybe hippocalcin is not the only Ca2+ sensing 
protein mediating sIAHP activation upon the rise of intracellular Ca
2+. Other neuronal Ca2+ 
sensor proteins are also expressed in hippocampus as well as in other brain areas that display 
sIAHP and could contribute to its activation (Paterlini et al., 2000). For example, hippocalcin 
expression in cortex is much lower than in hippocampus and neurocalcin δ, another neuronal 
Ca2+ sensor protein, has been shown to perform a comparable role in cortex and could act 
alongside hippocalcin in activating sIAHP (Villalobos and Andrade, 2010). 
Finding the channel generating sIAHP has been the focus of many studies since the early 
description of sIAHP. The channel underlying IC was suggested to also be responsible for 
generating sIAHP and the distinct time courses of the two currents were explained by different 
channel locations in relation to the site of Ca2+ entry i.e. channels generating IC being located 
close to CaV channels and the channels for sIAHP further away (Lancaster and Adams, 1986). 
However, it is accepted that KCa1.1 channels are responsible for IC and their characteristics, 
such as voltage and TEA sensitivity, fast kinetics and big conductance (section 1.2.1), do not 
match the profile of sIAHP. Another group of channel candidates for sIAHP emerged with the 
identification of KCa2 channels. Because they are voltage-independent and activated by Ca
2+, 
have smaller conductances than KCa1.1  channels and are sensitive to TEA only at high 
millimolar concentrations (section 1.2.2), they have been proposed to generate sIAHP (Lancaster 
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et al., 1991; Köhler et al., 1996; Marrion and Tavalin, 1998; Stocker et al., 1999; Bowden et al., 
2001). However, the apamin sensitivity of KCa2 channels complicates the picture: on the one 
hand it identified KCa2 channels as being responsible for apamin-sensitive IAHP (Stocker et al., 
1999), on the other hand KCa2 channels continued to be advocated as the ones generating 
apamin-insensitive sIAHP. This was mainly because the KCa2.1 subunit was initially described as 
apamin-insensitive and its expression overlapped with neurons displaying sIAHP (Köhler et al., 
1996; Ishii et al., 1997), but was eventually determined to be apamin-sensitive (Shah and 
Haylett, 2000a; Strøbaek et al., 2000). Additionally, heteromeric KCa2 channels with 
intermediate apamin sensitivity, such as KCa2.1/2.2 in heterologous expression system (Ishii et 
al., 1997), were thought to account for the different pharmacological and kinetic profiles of IAHP 
and sIAHP (Stocker et al., 1999), but their existence in native tissue has not been shown. In 
contrast, sIAHP has been recorded in all three KCa2 channel knock-out mice (Bond et al., 2004). 
Additionally, KCa2 channel can be discounted as the channel responsible for sIAHP as it displays 
much faster kinetics than seen for sIAHP and are thought to be closely located to CaV channels 
(Marrion and Tavalin, 1998) and thus to restricted domains of Ca2+, while sIAHP is activated by 
an increase in bulk intracellular Ca2+ (Abel et al., 2004). 
Furthermore, KV7 channels have recently been linked with the generation of sIAHP in dentate 
gyrus and CA3, because sIAHP is reduced in mice deficient in either KV7.2, KV7.3 or KV7.5 
(Tzingounis and Nicoll, 2008; Tzingounis et al., 2010). In addition KV7 channels, especially KV7.1 
and KV7.2, are blocked by UCL2077, which has been shown to inhibit sAHP (Shah et al., 2006), 
and are therefore implicated in underlying sIAHP (Soh and Tzingounis, 2010). Retigabine, an 
activator of KV7 channels, increases the rate of sIAHP activation (Kim et al., 2012). But questions 
remain on how a voltage-gated KV7 channel should be responsible for a current characterised 
as voltage-independent, activated by Ca2+ and insensitive to K+ channel blockers. A proposed 
mechanism for the activation of sIAHP involves PIP2, its expression level at the plasma 
membrane is known to be raised by Ca2+ and its participation in KV7 channel gating (Zhang et 
al., 2003; Hernandez et al., 2008) could promote their opening at more negative potentials 
(Andrade et al., 2012). Over-expression of phosphatidylinositol 4 phosphate 5-kinase (PIP5K), 
the phospholipid kinase catalysing the production of PIP2, enhances the Ca
2+ sensitivity of sIAHP, 
which suggests a common signalling pathway of Ca2+ and PIP2 to activate sIAHP (Villalobos et al., 
2011). Furthermore, the inhibition of PIP5K, for example by PKA (Park et al., 2001), would 
reduce available PIP2 and thus hinder KV7 channel activation, and could present the 
mechanism by which monoamine neurotransmitter suppress sIAHP (Andrade et al., 2012). KV7 
channels are also known to bind CaM, which in response to a rise in intracellular Ca2+ mediates 
their inhibition, albeit to different degrees (Delmas and Brown, 2005).  
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1.3 GPCRs and G-proteins  
Cholinergic and glutamatergic innervations of the hippocampus formation as well as the 
modulatory effect of ACh and glutamate on sIAHP have been outlined earlier (section 1.1.2 and 
1.2.3), but the mechanisms by which sIAHP is suppressed by these neurotransmitters are not 
fully identified. ACh and Glutamate exert their action on sIAHP via GPCRs, since agonists of 
mAChRs and mGluRs mimic and antagonists prevent the suppression of sIAHP by ACh and 
glutamate, while the modulation of sIAHP is unchanged in the presence of nicotinic 
acetylcholine receptor and ionotropic glutamate receptor blockers (Cole and Nicoll, 1983 and 
1984; Charpak et al., 1990; Ito et al., 1992; Davies et al., 1995). The two groups of GPCRs are 
subdivided into M1–5 (mAChR) and mGlu1–8 (mGluR) and various approaches have been used to 
determine the receptor subtypes mediating the actions of ACh and glutamate on sIAHP. In the 
case of ACh, both M1 and M3 are expressed in the principal cells of the hippocampus (Levey et 
al., 1995) and thus represent good candidates. M1 is the prevailing receptor subtype, but 
cholinergic agonists continue to suppress sIAHP when M1 is blocked by the M1 antagonist 
pirenzepin, the M1 toxin or by gene deletion (Rouse et al., 2000). The exclusion of M1, 
establishes a role of M3 in the modulation of sIAHP, which is supported by earlier 
pharmacological findings showing that the application of the M3 antagonist 4-DAMP prevents 
the cholinergic agonist-induced suppression of sIAHP (Pitler and Alger, 1990). An involvement of 
other mAChRs is unlikely on the basis of their expression and localisation (section 1.1.2) and 
results of pharmacological studies, in which the suppression of sIAHP by cholinergic agonists is 
maintained in the presence of M2 receptor antagonists (Dutar and Nicoll, 1988; Pitler and 
Alger, 1990). mGluRs are divided into three groups (I) mGlu1 and mGlu5, (II) mGlu2 and mGlu3 
and (III) mGlu4, mGlu6, mGlu7 and mGlu8, but only group (I) antagonists prevent the 
suppression of sIAHP by glutamatergic agonists (Davies et al., 1995; Gereau and Conn, 1995). 
mGlu5 is the prevailing subtype of the group (I) receptors expressed in CA1 pyramidal neurons 
(Shigemoto et al., 1992; Fotuhi et al., 1994; Romano et al., 1995) and specific mGlu5, but not 
mGlu1, antagonists block the suppression of sIAHP by glutamatergic agonists (Mannaioni et al., 
2001). 
The involvement of M3 and mGlu5 agrees with findings that the modulation of sIAHP by ACh and 
glutamate is mediated by GPCRs coupled to pertussis toxin-insensitive G-proteins of the Gq 
family (Dutar and Nicoll, 1988; Gerber et al., 1992; Offermanns et al., 1994; Blin et al., 1995; 
Pin and Duvoisin, 1995; Abdul-Ghani et al., 1996). Experiments in knock-out mice have shown 
that Gαq, but not Gα11, mediates the suppression of sIAHP by ACh and glutamate (Krause et al., 
2002). The activation of GPCRs coupled to Gαq stimulates PLCβ (Fig. 1.3; Smrcka et al., 1991; 
Arkinstall et al., 1995) leading to the hydrolysis of PIP2 to produce the second messengers 
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inositol 1,4,5-triphosphate (IP3), which causes the release of Ca
2+ from intracellular stores, and 
diacylglycerol (DAG), which in turn activates PKC (McLaughlin et al., 2002; Rhee, 2001). Both 
mAChRs (M1/3/5) as well as group (I) mGluRs (mGlu1/5) have been shown to couple to this 
second messenger system (Peralta et al., 1988; Abe et al., 1992; Berstein et al., 1992; Schoepp 
et al., 1999). However, this classical signalling pathway of GPCRs coupled to Gαq is not 
mediating the suppression of sIAHP by ACh and glutamate, since their modulatory effect on sIAHP 
is maintained in the presence of PLC inhibitors as well as in PLCβ knock-out mice (Krause and 
Pedarzani, 2000; Young et al., 2004). Additionally, the cholinergic and glutamatergic 
modulation of sIAHP is unchanged when IP3-sensitive stores are blocked by IP3 receptor 
antagonists (Krause and Pedarzani, 2000) or when PKC inhibitors are applied (Gerber et al., 
1992; Sim et al., 1992; Engisch et al., 1996). 
 
Figure 1.3 Gαq signalling. Following the activation by GPCRs, Gαq stimulates its canonical effector 
phospholipase C β, which leads to the production of the second messengers inositol 1,4,5-triphosphate 
and diacylglycerol. Apart from this classical signalling pathway, Gαq also signals via alternative effectors 
and is involved in controlling cellular microenvironments such as the cytoskeleton. Gαq signalling is 
assisted by accessory proteins, which for example support the coupling of Gαq with GPCRs, and is 
controlled by various regulators that for instance accelerate the intrinsic GTPase activity of Gαq. (from 
Sanchez-Fernandes et al, 2014) 
Since the ACh- and glutamate-induced suppression of sIAHP involves the GPCRs, M3 and mGlu5, 
and the Gq-protein, but not their principal signalling pathway, the Gq-protein must mediate the 
regulation of neuronal excitability in conjunction with other downstream effectors (Fig. 1.3). 
This question is central to this thesis and thus functions and properties of G-proteins will be 
examined closely. As seen above, G-proteins are coupled to GPCRs and link extracellular 
stimuli, which activate the receptors at the cell surface, to intracellular signalling cascades and 
thus determine a cell’s response. G-proteins belong to the superfamily of GTPases and are 
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heterotrimeric guanine nucleotide-binding proteins, which consist of α, β and γ subunits (Fung 
et al., 1981; Sternweis and Robishaw, 1984; Hamm and Gilchrist, 1996) and function as 
molecular switches alternating between inactive (GDP-bound) and active (GTP-bound) states. 
They are defined by their α subunit, whose sequence similarities and functional characteristics 
subdivide G-proteins into four families Gs, Gi, Gq and G12 (Simon et al., 1991; Wilkie et al., 
1992). Principally, G-protein α subunits (Gα) of the Gs (Gαs and Gαolf) and Gi (Gαi, Gαo, Gαz, but 
not Gαt and Gαgust (cGMP phosphodiesterase)) families target AC, which is either stimulated 
(Gs) or inhibited (Gi), with therefore opposite effects on intracellular cAMP levels. Αlpha 
subunits of the Gq family (Gαq, Gα11, Gα14, Gα15/16) activate PLCβ and cause the formation of 
second messengers IP3 and DAG (Fig. 1.3), while members of the G12-protein family (Gα12, 
Gα13) activate small GTPases of the Rho family (McCudden et al., 2005). In addition to the 
diversity of Gα, multiple subtypes of G-protein β (Gβ) and γ (Gγ) subunits have also been 
identified (Gβ1–5, Gγ1–12; Ray et al., 1995; McCudden et al., 2005) and unlike initial assumptions 
the Gβγ dimer does not only assist Gα coupling to GPCRs, but has its own array of cellular 
targets including ion channels like GIRK (Kir3) and CaV channels, PLCβ, AC, mitogen-activated 
protein kinases (MAPKs) and G-protein-coupled receptor kinases (GRKs) as well as small 
GTPases (Clapham and Neer, 1997; McCudden et al., 2005). 
Structurally, Gα consists of two domains that create a nucleotide-binding pocket: an α-helical 
domain and a Ras-like GTPase domain composed of α helices as well as β sheets (Fig. 1.4A and 
Fig. 2.1; Lambright et al., 1994). The Ras-like GTPase domain is conserved throughout the 
superfamily of GTPases, is responsible for the binding of the nucleotide and includes three 
flexible switch regions that mediate the conformational change of Gα depending on whether 
GDP or GTP is bound (Sprang, 1997). Gβ is composed of seven β-sheet repeats (WD40 repeats) 
that arrange in a propeller-like structure and interact with Gα, and of an α-helical amino-
terminus forming a coiled coil with the amino-terminal α-helix of Gγ at its entire length and 
thus explains the high affinity of Gβ and Gγ that lets them act as a dimer at all times (Fig. 1.4A; 
Wall et al., 1995; Sondek et al., 1996; Clapham and Neer, 1997). 
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Figure 1.4 Structure of the heterotrimeric G-protein and its binding to the G-protein coupled 
receptor. (A) The heterotrimeric G-protein consist of Gα and the Gβγ dimer. Gα is composed of an α-
helical domain (yellow) and a Ras-like GTPase domain (blue). The flexible switch regions (SI–III) of Gα are 
shown in green and bound GDP in magenta. The dimer is formed of Gβ (red) and Gγ (grey), whose 
prenylated carboxyl-terminus is depicted as a saw-tooth wave. Important residues of Gα and Gβ that 
interact at the switch region/Gβ contact site are indicated. (adapted from Johnston and Siderovski, 
2007) (B) The seven transmembrane G-protein coupled receptor is depicted in green with 
transmembrane segments 1, 5, 6 and 7 (light green) at the front and segments 2, 3 and 4 (dark green) at 
the back. The receptor couples to the G-protein via the second (brown) and third (orange) intracellular 
loops and the carboxyl-terminus (orange) that leads to the palmitoylation site (cyan). Lipid modifications 
on the G-protein are also depicted (cyan). Several regions (red) of the G-protein bind to the G-protein 
coupled receptor including the amino- and carboxyl-termini and the α4-β6 loop of Gα and the carboxyl-
terminus and the sixth β-sheet repeat of Gβ as well as the carboxyl-terminus of Gγ. (from Hamm, 1998) 
In contrast to their separate functions and signalling pathways in the active state, Gα and the 
Gβγ dimer form a complex, when G-proteins are inactive i.e. GDP-bound (Fig. 1.5). The 
association between Gα and Gβγ requires an intact Gα amino-terminus (Neer et al., 1988), 
whose residues are responsible for interaction with Gβ (Fig. 1.4A and Fig. 2.1; Wall et al., 1995; 
Lambright et al., 1996). Gβ also binds the switch II region of Gα and thus stabilizes the inactive 
G-protein preventing the release of GDP from Gα (Fig. 1.4A and Fig. 2.1; Wall et al., 1995; 
Lambright et al., 1996). In the case of Gs-, Gq- and G12-protein families the Gβγ dimer is also 
responsible for the plasma membrane targeting of Gα (Evanko et al., 2000 and 2001). G-
proteins attach to the plasma membrane by lipid modifications and the Gβγ dimer is anchored 
to the plasma membrane following prenylation at the carboxyl-terminus of Gγ (Fig. 1.4B; 
Simonds et al., 1991; Muntz et al., 1992). For Gα a two-signal model is proposed: firstly plasma 
membrane targeting either by myristoylation at the amino-terminus of α subunits of the Gi-
protein family or by Gβγ interaction of α subunits of the Gs/q/12-protein families and secondly 
stable attachment to the plasma membrane by palmitoylation at the amino-terminus of all α 
subunits (Fig. 1.4B and Fig. 2.1; Evanko et al., 2000; Chen and Manning, 2001). 
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Membrane attachment and complex formation of Gα and Gβγ are essential for the binding of 
G-proteins to GPCRs and their subsequent activation. The carboxyl-terminus as well as regions 
of the amino-terminus and the α4-β6 loop of Gα have been established as sites of contact with 
GPCRs (Fig. 1.4B; Hamm et al., 1988; Conklin and Bourne, 1993; Onrust et al., 1997; Oldham 
and Hamm, 2008; Hu et al., 2010), with the last amino acids of the carboxyl-terminus being 
critical for GPCR specificity (Martin et al., 1996; Kostenis et al., 1997). Gα primarily contacts the 
seven transmembrane GPCRs at the third intracellular loop that itself mediates the coupling to 
a specific Gα (Fig. 1.4B; Taylor et al., 1994; Kostenis et al., 1997; Bourne, 1997), but also at the 
second intracellular loop and at the intracellular carboxyl-terminus of GPCRs (Fig. 1.4B; Conklin 
and Bourne, 1993). Additionally, the carboxyl-terminus and the sixth β-sheet repeat of Gβ bind 
to the third intracellular loop and the carboxyl-terminus of the GPCR (Fig. 1.4B; Taylor et al., 
1994 and 1996; Bourne, 1997; Wu et al., 1998 and 2000; Hou et al., 2001; Mahon et al., 2006), 
while the carboxyl-terminus of Gγ contributes to GPCR binding (at the carboxyl-terminus) as 
well as to receptor specificity (Fig. 1.4B; Yasuda et al., 1996; Bourne, 1997; Hou et al., 2000). 
Furthermore, point mutations in Gβ at regions contacting the switch II region and the amino-
terminus of Gα prevent the exchange of GDP to GTP at Gα and thus show the importance of 
complex formation for G-protein activation (Ford et al., 1998). 
GPCR and G-protein interaction occurs rapidly (< 100 ms; Hein et al., 2005 and 2006), but 
whether G-protein coupling to GPCRs is established before ligand-binding to the receptor (pre-
coupled model) or requires an activated GPCR (collision model) is not fully characterised 
(Oldham and Hamm, 2008). Some studies have reported G-protein binding to inactive GPCRs 
(Nobles et al., 2005; Galés et al., 2005 and 2006). But others have shown that GPCR activation 
produces a conformational change in the receptor, in particular a rearrangement of the third 
and sixth transmembrane segments, which in turn reveals the binding domain for the carboxyl-
terminus of Gα (Gether et al., 1995; Farrens et al., 1996; Janz and Farrens, 2004; Park et al., 
2008; Scheerer et al., 2008). In either case, activated receptor-induced structural changes are 
relayed to the G-protein and cause the release of GDP by perturbing the receptor-bound 
carboxyl-terminus and α4-β6 loop of the Ras-like GTPase domain of Gα, which are both linked 
to the β6-α5 loop containing a conserved nucleotide-binding motif (TCAT) (Fig. 1.4A and Fig. 
2.1; Sprang, 1997; Kisselev et al., 1998; Oldham et al., 2006; Johnston and Siderovski, 2007; 
Oldham and Hamm, 2008). Mutations in this motif have been shown to considerably decrease 
GDP affinity (Thomas et al., 1993). The tight coupling of Gα and GDP slows the release of GDP 
upon receptor activation and constitutes the rate-limiting step in the signalling cascade of 
GPCRs (Ferguson et al., 1986). Rates for G-protein activation to be completed range from a few 
hundreds of milliseconds to seconds (Bünemann et al., 2003; Hein et al., 2006; Nikolaev et al., 
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2006; Adjobo-Hermans et al., 2011), which is substantially slower than GPCR activation and 
receptor association with the G-protein (Vilardaga et al., 2003; Lohse et al., 2008). Following 
GDP release, GTP, which is present in excess over GDP, binds to a conserved nucleotide-
binding motif (DVGGQ) in the Ras-like GTPase domain of Gα that partly overlaps with the 
switch II region (Fig. 2.1; Bourne et al., 1991; Sprang, 1997; Johnston and Siderovski, 2007). 
GTP binding causes the flexible switch regions of Gα to undergo a dramatic movement that 
separates the G-protein complex into Gα and Gβγ dimer and both dissociate from the GPCR 
(Fig. 1.5; Noel et al., 1993; Coleman et al., 1994; Lambright et al., 1994; Wall et al., 1995). 
Activated Gα and the now uninhibited Gβγ dimer engage in the regulation of their various 
effectors described above. The innate GTPase activity of Gα is responsible for the termination 
of Gα signalling by hydrolysing the γ phosphate of GTP, leaving Gα bound to GDP (Fig. 1.5; 
Hamm and Gilchrist, 1996). Three residues of the switch regions have been shown to be 
essential for GTP hydrolysis (R183, T186 and Q209 in Gαq; Noel et al., 1993; Coleman et al., 
1994; Sondek et al., 1994; Johnston and Siderovski, 2007). The reversal of the conformational 
changes caused by GTP binding restores the affinity of Gα for the Gβγ dimer and re-establishes 
the trimeric complex that G-protein adopt in their inactive state, thus completing the G-
protein cycle (Fig. 1.5). 
 
Figure 1.5 G-protein activation and deactivation cycle. The activated G-protein coupled receptor 
couples to the heterotrimeric G-protein consisting of Gα (blue), Gβ (brown) and Gγ (grey). The receptor 
acts as a guanine nucleotide exchange factor (orange) and facilitates GDP (yellow, the small circles 
depict the two phosphates) release from Gα. Subsequent GTP (green, the small circles depict the three 
phosphates) binding causes the G-protein to active and separate into Gα and the Gβγ dimer, which in 
turn signal to their downstream effectors. GTPase accelerating proteins such as regulators of G-protein 
signalling (magenta) accelerate the intrinsic GTPase activity of Gα that terminates Gα signalling and 
results in GDP-bound Gα. Guanine nucleotide dissociation inhibitors (purple) bind inactive Gα and 
hinder the release of GDP as well as re-assembly of Gα with the Gβγ dimer. (from Preininger and Hamm, 
2004) 
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The cycle of G-protein activation and deactivation is additionally controlled by various 
regulators that influence each step in the sequence. For example, GPCRs act as guanine 
nucleotide exchange factors (GEFs), since they facilitate the GDP/GTP exchange on Gα and 
thus catalyse G-protein activation (Fig. 1.5). Active GPCRs are themselves objects of regulation 
by GRKs, which phosphorylate the receptor causing its desensitization and enable the binding 
of β-arrestins that initiate GPCR internalization (Pitcher et al., 1998). The signalling of activated 
Gα is restricted by its intrinsic GTPase activity, whose rate of GTP hydrolysis is dramatically 
enhanced by GTPase accelerating proteins (GAPs) such as members of the regulator of G-
protein signalling (RGS) family (Fig. 1.5; Druey et al., 1996; Watson et al., 1996; Ross and 
Wilkie, 2000). RGS interact with activated Gα and catalyse its GTPase activity not by directly 
engaging in the GTP hydrolysis processes, but by stabilizing the switch regions of the GTP-
bound Gα (Berman et al., 1996; Tesmer et al., 1997). In the case of Gαq the GAP RGS4 
accelerated GTP hydrolysis to < 100 ms (Mukhopadhyay and Ross, 1999). With Gα returned to 
the GDP-bound state, guanine nucleotide dissociation inhibitors (GDIs) such as GoLoco motif-
containing proteins assert their effect by binding to inactive Gα and inhibiting the release of 
GDP (Willard et al., 2004). This renders Gα ineffective and presents a mechanism to control Gα 
signalling. Because their binding sites are overlapping, GDIs can also prevent the association of 
Gα with the Gβγ dimer (Fig. 1.5; Preininger and Hamm, 2004). Once the heterotrimeric G-
protein complex is restored, the Gβγ dimer also acts as a GDI given that it stabilizes the GDP-
bound Gα by sequestering its switch regions as described before. 
Gα becomes constitutively active by mutating residues in the switch regions that are essential 
for its intrinsic GTPase activity (Fig. 2.1; Noel et al., 1993; Coleman et al., 1994; Sondek et al., 
1994; Johnston and Siderovski, 2007). Mutating these key residues results in the inability of Gα 
to hydrolyse bound GTP and thus creates a Gα that remains in the active state and which in 
turn constitutively activates its effectors (Graziano and Gilman, 1989; Landis et al., 1989; Wong 
et al., 1991; Gupta et al., 1992). In the case of Gαq the mutation of residue arginine (R)183 to 
cystine (C) or glutamine (Q)209 to leucine (L) results in constitutively active Gαq (Fig. 2.1; 
Conklin et al., 1992; De Vivo et al., 1992; Kalinec et al., 1992; Wu et al., 1992; Qian et al., 1993). 
On the other hand, many GTP-binding proteins are rendered inactive by preventing the 
binding of GTP through a mutation of aspartate (D) into asparagine (N) in the conserved motif 
(NKXD; Fig. 2.1), which results in the binding of xanthine nucleotides instead of guanine 
nucleotides (Yu et al., 1997). However, in the case of Gα subunits this single mutation is 
insufficient and a double mutation is necessary to convey the xanthine nucleotide binding 
preference to Gα (Q209 to L and D277 to N in Gαq; Fig. 2.1; Yu et al., 1997; Yu and Simon, 
1998). Furthermore, Gαq has been studied using fluorescence microscopy techniques by 
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attaching fluorophores, such as green fluorescent protein (GFP) or enhanced cyan fluorescent 
protein (ECFP), to its carboxyl-terminus or in a loop of the α-helical domain (between residues 
124 and 125; Fig. 1.6 and Fig. 2.1) (Hughes et al., 2001; Witherow et al., 2003). 
 
Figure 1.6 Gα with fluorophore attachment. Green fluorescent protein (green) inserted in a loop 
of the α-helical domain of the Gα subunit. (from Hughes et al., 2001) 
1.4 Small GTPases  
Since sIAHP suppression by ACh and glutamate through the metabotropic receptors M3 and 
mGlu5 and the Gq-protein does not involve the classical signal transduction pathway of Gαq 
(section 1.2.3 and 1.3), the inhibitory effect of ACh and glutamate must be conveyed by other 
downstream effectors of Gαq. Small GTPases have emerged as mediators of GPCR signalling 
(van Biesen et al., 1996; Seasholtz et al., 1999; Sah et al., 2000; Marinissen and Gutkind, 2001; 
Bhattacharya et al., 2004). Due to their expression in the hippocampus (Olenik et al., 1997; 
O’Kane et al., 2003), reports of them being effectors of GPCRs coupled to G-proteins of the Gq 
family (Mitchell et al., 1998; Sagi et al., 2001; Booden et al., 2002; Chikumi et al., 2002; Dutt et 
al., 2002) and their ability to modulate ion channel activity (Wilk-Blaszczak et al., 1997; 
Cachero et al., 1998; Storey et al., 2002; Staruschenko et al., 2004; Yatani et al., 2005; 
Rossignol and Jones, 2006; Pochynyuk et al., 2007) small GTPases represent potential 
candidates in the signal transduction cascade leading to the suppression of sIAHP by ACh and 
glutamate.  
Small GTPases are monomeric G-proteins, with molecular weights of 20–40 kDa and their 
extensive superfamily comprises five subgroups: Ras, Rho, Rab, Sar1/Arf and Ran (Takai et al., 
2001). Like heterotrimeric G-proteins they act as molecular switches cycling between an 
inactive GDP-bound and an active GTP-bound state. Small GTPases signal to a multitude of 
effectors and regulate a variety of cellular processes including cell cycle progression, gene 
transcription, microtubule organization, intracellular vesicular and nucleocytoplasmic 
transport, regulation of cell growth and motility (Takai et al., 2001; Jaffe and Hall, 2005). 
Members of the Rho-GTPase subfamily are primarily known for their regulation of the actin 
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cytoskeleton (Machesky and Hall, 1996; Hall, 1998; Aspenström et al., 2004). For example, Rac 
causes the formation of the actin filament mesh found in membrane ruffles and lamellipodia 
and Cdc42 produces actin spikes known as filopodia, both associated with cell motility and 
process outgrowth, while Rho is responsible for the formation of focal adhesions and long 
actin filament bundles known as stress fibres and causes cell rounding and process retraction 
(Paterson et al., 1990; Ridley and Hall, 1992; Ridley et al., 1992; Kozma et al., 1995; Nobes and 
Hall, 1995; Katoh et al., 1998; Luo, 2000). In hippocampal pyramidal neurons Rho-GTPases are 
also associated with the outgrowth or retraction of dendritic spines (Nakayama et al., 2000). 
Cellular processes regulated by Rho-GTPases involve signalling pathways downstream of 
GPCRs (Buhl et al., 1995; Gohla et al., 1998; Katoh et al., 1998; Kjøller and Hall, 1999; Seasholtz 
et al., 1999). The signal transduction of activated GPCRs is mediated through the interaction of 
their associated G-protein α subunit (Gα) with GEFs, which serve as activators of small GTPases 
(Hart et al., 1998; Kozasa et al., 1998; Fukuhara et al., 1999 and 2000; Booden et al., 2002; Lutz 
et al., 2005). Downstream targets of the small GTPase RhoA include serine/threonine kinases 
like Rho-kinase (ROCK; Leung et al., 1995; Kimura et al., 1996; Matsui et al., 1996) and citron 
(Madaule et al., 1995) and protein kinase N (PKN; Amano et al., 1996; Watanabe et al., 1996), 
myosin-binding subunit of myosin light chain phosphatase (Kimura et al., 1998) as well as 
RhoA-binding proteins such as rhophilin (Watanabe et al., 1996), rhotekin (Reid et al., 1996) 
and mDia (Watanabe et al., 1997). 
Structurally, like all members of the superfamily of GTPases including the α subunit of 
heterotrimeric G-proteins, small GTPases contain a conserved domain consisting of α helices, β 
sheets and connecting loops (G1–5) that convey their guanine nucleotide-binding capacity as 
well as their GTPase activity (Bourne et al., 1991). Guanine nucleotide-binding occurs at 
conserved motifs of small GTPases with the guanine base being recognised by the (N/T)KXD 
motif in G4 and by the (T/G/C)(C/S)A motif in G5, while the β phosphate interacts with the 
GXXXXGK(S/T) motif in G1/P-loop (phosphate-binding loop; Sprang, 1997; Paduch et al., 2001; 
Vetter and Wittinghofer, 2001). Depending on whether small GTPases are bound to GDP or 
GTP, a conformational change mediated by the flexible switch regions I and II occurs (Fig. 1.7; 
Milburn et al., 1990; Wei et al., 1997; Ihara et al., 1998). The γ phosphate of GTP interacts with 
the conserved threonine in the XTX motif in G2/switch I and with the DXXG motif in G3/switch 
II of small GTPases and causes the structural change, which is reversed once GTP is hydrolysed 
(Sprang, 1997; Paduch et al., 2001; Vetter and Wittinghofer, 2001). The switch regions of small 
GTPases are critical for effector binding and the conformational change of switch I and II in the 
active GTP-bound state uncovers numerous binding sites, many of them overlapping (Corbett 
and Alber, 2001; Vetter and Wittinghofer, 2001; Biou and Cherfils, 2004). 
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Figure 1.7 Structure of small GTPases and conformational change of the switch regions upon 
GTP binding. Small GTPase bound to GTP is shown in green (α helices and β sheets), red (switch 
regions), blue (loops G1–5) and magenta (GTP). The structure of the small GTPase bound to GDP is 
displayed in grey. (from Wennerberg et al., 2005) 
The activated state is terminated by hydrolysis of the γ phosphate of the bound GTP and the 
small GTPase returns to its inactive GDP-bound state. The intrinsic GTPase activity of small 
GTPases, kcat 0.02 min
-1, is much lower than that of G-protein α subunits, kcat 3–5 min
-1 (Bourne 
et al., 1991). Akin to heterotrimeric G-protein α subunits, a conserved glutamine (Q63 in RhoA; 
equivalent to Q209 in Gαq) in G3/switch II plays a central role in the hydrolysis of GTP in small 
GTPases (Pai et al., 1990; Bourne et al., 1991; Sprang, 1997). Mutating this residue renders 
small GTPases deficient in their ability to hydrolyse GTP, which results in small GTPases that 
are constitutively active (Der et al., 1986). Furthermore, an arginine (R), which in Gα (R183 in 
Gαq) interacts with the γ phosphate of GTP and is essential in GTP hydrolysis (Noel et al., 
1993), is absent in small GTPases and contributes to the lower GTPase activity of small GTPases 
(Paduch et al., 2001). Small GTPases rely on GAPs (Fig. 1.8; Trahey and McCormick, 1987) to 
provide the missing arginine (also called the arginine finger; Ahmadian et al., 1997; Li et al., 
1997; Scheffzek et al., 1997; Nassar et al., 1998) and to catalyse GTP hydrolysis to kcat 32–
72 min-1 (Zhang et al., 1998). GAPs are subfamily-specific, but their mechanism to promote GTP 
hydrolysis is similar (Gamblin and Smerdon, 1998; Scheffzek et al., 1998). GAP binding 
stabilizes the switch regions of the small GTPase and ensures the proper alignment of the 
conserved glutamine (Q63 in RhoA) allowing it to perform its GTPase activity (Resat et al., 
2001; Moon and Zheng, 2003). Small GTPases in their inactive GDP-bound state can then be 
reactivated by the release of GDP and subsequent binding of GTP. 
38 
 
 
Figure 1.8 Small GTPase activation and deactivation cycle. Rho-GTPases (green) are molecular 
switches that cycle between an inactive GDP-bound state and an active GTP-bound state (GDP and GTP, 
blue circle with small purple circles depicting the phosphates). These two conditions are regulated by 
guanine nucleotide dissociation inhibitors (blue) that hinder GDP release and keep small GTPases 
inactive, by guanine nucleotide exchange factor (yellow) that promote the activation of small GTPases 
by accelerating exchange of GDP to GTP and by GTPase accelerating proteins (grey) that facilitate 
GTPase activity. Membrane association of Rho-GTPases is conveyed by a hydrophobic moiety (orange 
wavy line) at the carboxyl-terminus, which in the inactive state is shielded by GDI and thus ensures the 
cytosolic localisation of Rho-GTPase. Bound to their effectors (purple) Rho-GTPases are responsible for 
numerous cellular processes including the regulation of the actin cytoskeleton, cell-cycle progression 
and gene expression. (from Rossman et al., 2005) 
The activation and deactivation cycle of small GTPase is not only assisted by the 
aforementioned GAPs, but also by two other classes of regulators namely GEFs, which activate 
small GTPases by promoting the exchange of GDP to GTP, and GDIs, which keep small GTPases 
inactive by preventing GDP release (Fig. 1.8; Boguski and McCormick, 1993). In their inactive 
state small GTPases are bound to GDP and in the case of Rho- and Rab-GTPases this 
conformation is stabilized by subfamily-specific GDIs, which inhibit nucleotide exchange and 
thus the activation of these small GTPases (Vetter and Wittinghofer, 2001). Rho-GTPases are 
prenylated at the conserved CAAX motif of the carboxyl terminus and this lipid modification, 
mainly through geranylgeranylation, mediates their attachment to membranes (Adamson et 
al., 1992a; Wennerberg and Der, 2004). The linkage of a geranylgeranyl isopreniod group 
makes Rho-GTPases more hydrophobic than, for example, the farnesylated Ras-GTPases 
(Seabra, 1998). GDIs are able to extract Rho-GTPases from membranes and sequester them in 
the cytoplasm by shielding the prenyl group in a hydrophobic pocket of their carboxyl-
terminus and the amino-terminus of GDIs binds to the switch regions of the small GTPases 
hindering the association of GEFs and thereby the release of GDP (Gosser et al., 1997; Hoffman 
et al., 2000; Scheffzek et al., 2000). In the cell the concentration of Rho-GDI and Rho-GTPases 
is similar, suggesting that the majority of Rho-GTPases is associated with GDIs and therefore 
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inactive (Michaelson et al., 2001). The release of GDP presents the rate-limiting step of the 
signalling cascade of any small GTPase and its intrinsic rate is slow, kdiss 0.001–0.01 min
-1, 
however, GDP release is facilitated by GEFs that accelerate the activation of small GTPases up 
to 105-fold (Klebe et al., 1995; Lenzen et al., 1998; Hutchinson and Eccleston, 2000). GEF 
association causes a structural disturbance of the nucleotide-binding pocket of small GTPases 
and as a result GDP-binding becomes unstable (Renault et al., 2001; Hoffman and Cerione, 
2002). Small GTPase-interacting GEFs are subfamily specific, for example RasGEFs are 
characterised by a Cdc25 homology domain (Boguski and McCormick, 1993; Chardin et al., 
1993) and the majority of RhoGEFs contain a Dbl homology (DH) domain usually in 
combination with a pleckstrin homology (PH) domain (Cerione and Zheng, 1996; Schmidt and 
Hall, 2002; Rossman et al., 2005), while another group of RhoGEFs contain a Dock homology 
region (DHR) domain (Côté and Vuori, 2002). Following the release of GDP, the small GTPase, 
still in complex with a GEF, transiently exists in a nucleotide-free state, before GTP binding and 
the subsequent separation from the GEF allows the now active small GTPase to interact with 
its downstream targets (Vetter and Wittinghofer, 2001). 
Small GTPases become constitutively active through the mutation of residues involved in GTP 
hydrolysis (Barbacid, 1987). As described before a glutamine (Q63 in RhoA) of switch II is 
essential for GTPase activity and its mutation into leucine (L) results in the inability of small 
GTPases to hydrolyse GTP (Der et al., 1986). Furthermore, constitutively active small GTPases 
are also generated by mutating the P-loop residue glycine (G14 in RhoA) into valine (V) 
(Seeburg et al., 1984; Garrett et al., 1989). Since this residue of the P-loop is not affected by 
the conformational change following GTP binding, the inhibitory effect on GTPases activity of 
the valine substitution (V14 in RhoA) cannot be caused by a direct involvement in GTP 
hydrolysis (Krengel et al., 1990; Milburn et al., 1990). Instead, the valine side chain perturbs 
the space and thus the orientation of the glutamine (Q63 in RhoA) of switch II, which hinders 
its ability to hydrolyse GTP (Krengel et al., 1990; Milburn et al., 1990). On the other hand, 
inactive small GTPases show a reduced affinity for GTP and have initially been described for 
Ras-GTPases displaying a serine (S) to asparagine (N) mutation at residue 17 (Feig and Cooper, 
1988); the corresponding mutation in RhoA is a threonine (T) to asparagine (N) substitution at 
residue 19 (Qiu et al., 1995). These inactive mutants have an increased affinity for GEFs and 
this competitive binding prevents the interaction of GEFs with endogenous small GTPases 
(Feig, 1999). Inactive small GTPases are neither bound to GDP nor to GTP i.e. exist in a 
nucleotide-free state that in the normal cycle is only transitional, which prevents the 
interaction with downstream effectors and thus disrupts the signal transduction pathway 
(Feig, 1999; Strassheim et al., 2000). 
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Since small GTPases are able to mediate GPCR signalling, the potential participation of small 
GTPases in the transduction pathway used by ACh and glutamate to suppress sIAHP was 
investigated in the laboratory of one of my supervisors. Whole-cell patch clamp recordings of 
sIAHP in hippocampal pyramidal neurons in the presence of a RhoA inhibitory peptide showed a 
reduction in the cholinergic inhibition of sIAHP (P. Pedarzani, personal communication). 
Furthermore, the intracellular application of C3-exoenzyme, which inhibits RhoA by ADP-
ribosylation (Narumiya et al., 1988; Aktories and Hall, 1989; Sekine et al., 1989), reduces the 
inhibitory effect of cholinergic as well as glutamatergic agonist on sIAHP (P. Pedarzani, personal 
communication). This indicates that RhoA is part of the signalling pathway mediating the 
suppression of sIAHP by ACh and glutamate. 
1.5 Aims and Objectives 
The slow afterhyperpolarizing current (sIAHP), which is activated by Ca
2+ and follows a train of 
action potentials, contributes to the regulation of neuronal excitability and firing properties of 
hippocampal pyramidal neurons by being responsible for spike frequency adaptation i.e. the 
cessation of firing in response to a prolonged stimulus. sIAHP is suppressed by various 
neurotransmitters and thus presents a point of convergence allowing separate signalling 
pathways to influence neuronal excitability. While the signalling cascade of monoamine 
transmitters to suppress sIAHP is established, the pathway used by ACh and glutamate is not 
well characterised. The aim of this study was to investigate the nature of the signal 
transduction pathway mediating the suppression of sIAHP following the cholinergic activation of 
GPCRs. The mAChR M3 couples to the heterotrimeric Gq-protein and the participation of the 
Gq-protein α subunit (Gαq) in sIAHP suppression by cholinergic agonists has been shown (Krause 
et al., 2002). The involvement of the small GTPase RhoA in this signalling pathway and its role 
as a downstream effector of Gαq was to be investigated by the work undertaken in this study. 
The potential protein-protein interaction of Gαq and RhoA was studied by performing co-
immunoprecipitation and fluorescence resonance energy transfer (FRET) experiments in 
heterologous expression system. The ability of the small GTPase RhoA to associate with Gαq 
would indicate that both proteins could also be part of a common signal transduction pathway 
that is responsible for the inhibitory effect of ACh on sIAHP observed in hippocampal pyramidal 
neurons. In order to identify a RhoA involvement in the suppression of sIAHP, constitutively 
active or inactive RhoA mutants were introduced into hippocampal pyramidal neurons either 
by the intracellularly application of purified RhoA protein or by Sindbis virus infection and the 
effect of mutant RhoA on sIAHP was studied by whole-cell patch clamp electrophysiology.   
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2 Materials and Methods 
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2.1 Materials 
2.1.1 DNA constructs 
The following DNA constructs were used in this thesis and were either obtained from other 
researchers or constructed by myself (section 2.2.13). Plasmid DNA was prepared by 
transforming bacteria (section 2.2.12.7) followed by the growth of bacteria cultures and the 
isolation of plasmid DNA (section 2.2.12.8). The DNA was used to transfect cells (section 
2.2.2.1), which were subsequently used to prepare cell lysates for Western blotting (section 
2.2.3.1) or to perform microscopy experiments (section 2.2.11). The pGex plasmids were used 
to perform protein purifications (section 2.2.7). The pSinrep5 and Sindbis helper plasmids were 
used to produce Sindbis virus (section 2.2.10) that was used to infects cells and cultured 
hippocampal neurons (section 2.2.2.3). 
Construct name Plasmids Researcher 
Small GTPase RhoA 
RhoA pRK5-myc-RhoA J. Pitcher 
RhoA-V14 pRK5-myc-RhoA-G14V J. Pitcher 
RhoA-N19 pRK5-myc-RhoA-T19N J. Pitcher 
Venus-RhoA pRK5-myc-Venus-RhoA L.Gallasch 
VP16-RhoA-V14 pVP16-4-RhoA-G14V M. Stocker 
G-protein Gαq 
Gαq pcDNA3.1-EE-Gαq J. Pitcher 
Gαq -L209 pcDNA3.1-EE-Gαq-Q209L J. Pitcher 
Gαq -L209/N277 pcDNA3.1-EE-Gαq-Q209L-D277N J. Pitcher 
Gαq -ECFP pECFP-N1-Gαq (COOH-terminus tag) G. Willars 
Gαq-ECFP- Gαq pECFP-N1-Gαq (loop tag) G. Willars 
Gαq-ECFP-Gαq-C183 pcDNA1-ECFP-Gαq-R183C (loop tag) L. Scarlata 
Gαq-ECFP-Gαq-L209 pcDNA3.1-EE-ECFP-Gαq-Q209L (loop tag) L. Gallasch 
Protein purification 
GST-RhoA-V14 pGEX-6P-1-RhoA-G14V J. Pitcher 
GST-RhoA-N19 pGEX-6P-1-RhoA-T19N J. Pitcher 
GST pGEX-4T M. Stocker 
GST pGEX-6P-1 J. Pitcher 
Sindbis virus 
EGFP control pSinrep5-EGFP A. Jeromin 
RhoA-V14 pSinrep5-RhoA-G14V-EGFP L. Gallasch 
RhoA-N19 pSinrep5-RhoA-T19N-EGFP L. Gallasch 
Helper pHelper-DH-BB (tRNA/TE12) A. Jeromin 
Others 
CFP-YFP pECFP-N1-EYFP A. Tinker 
M3 pCD-HA-M3 J. Wess 
mRFP pRK7-mRFP R. Schoepfer 
Nav1.2 pRII-2A M. Stocker 
Raichu pCAGGS-Raichu1298X Y. Goda 
Rhophilin pRK5-myc-Rhophilin J. Pitcher 
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Figure 2.1 Amino acid sequence and secondary structure of Gαq. Conserved motifs such as 
nucleotide binding motifs (highlighted in red) and sites involved in GTP hydrolysis (highlighted in yellow) 
are indicated in the amino acid sequence. The mutation sites of the Gαq constructs used in this thesis 
are indicated (bold and underlined amino acids): the constitutively active mutations R183C or Q209L 
and the inactive double mutation Q209L/D277N. Attachment of Gαq to the plasma membrane is 
achieved through palmitoylation of two cysteine residues (C9 and C10, black bar) at the amino-terminus 
as well as through complex formation with Gβγ, with Gγ being prenylated at the carboxyl terminus. 
Contact sites of Gαq with Gβγ are indicated by black dots above the amino acid sequence. Features of 
the secondary structure of Gαq, α-helices (blue and magenta boxes) and β-sheets (green arrows), are 
shown below the amino acid sequence. (adapted from Johnston and Siderovski, 2007) The inset displays 
the secondary structure of Gαq distinguishing the α-helical domain and the Ras-like GTPase domain of 
Gαq. (adapted from Oldham and Hamm, 2008) 
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2.1.2 Buffers 
10x PBS 1.3 M NaCl 
 70 mM Na2HPO4 
 30 mM NaH2PO4 
   pH 7.3, autoclave 
10x TBS 1.4 M NaCl 
 200 mM Tris Base 
   pH 7.5, autoclave 
2x Laemmli Buffer 120 mM Tris-HCl pH 6.8 
 4 % SDS 
 20 % Glycerol 
 0.016 % Bromphenol Blue 
 5 % β-Mercaptoethanol 
6x Laemmli Buffer 300 mM Tris-HCl pH 6.8 
 12 % SDS 
 20 % Glycerol 
 0.6 % Bromphenol Blue 
 600 mM DTT 
2.1.3 Bacteria media, agar-plates and antibiotic stock solutions 
Miller’s Luria Broth (LB medium) 25 g/l Miller’s Luria Broth base 
   autoclave 
LB Plates 500 ml LB Medium 
 7.5 g Select Agar 
   autoclave 
LB-ampicillin/kanamycin Plates 500 ml LB Medium 
 7.5 g Select Agar 
   autoclave, cool to 50˚C and add 
 2.5 ml Ampicillin Stock Solution (CFinal 50 μg/ml) 
 or 5 ml Ampicillin Stock Solution (CFinal 100 μg/ml) 
 or 1.5 ml Kanamycin Stock Solution (CFinal 30 μg/ml) 
Antibiotics Stock Solutions 10 mg/ml Ampicillin 
 10 mg/ml Kanamycin 
 10 mg/ml Carbenicillin 
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2.1.4 Cell culture media 
BHK-21 Starvation Medium   MEM alpha 
 2 mM L-Glutamine 
 100 U/ml Penicillin 
 100 μg/ml Streptomycin 
BHK-21 Complete Medium 
 BHK-21 Starvation Medium supplemented with 5 % FBS 
BHK-21 Low Serum Medium 
 BHK-21 Starvation Medium supplemented with 1 % FBS 
BHK-21 Virus Production Medium   MEM alpha with Ultraglutamine and 
   nucleosides 
 5 % FBS 
 100 U/ml Penicillin 
 100 μg/ml Streptomycin 
HEK293 Complete Medium   DMEM/F-12 
 10 % FBS 
 2 mM L-Glutamine 
 100 U/ml Penicillin 
 100 μg/ml Streptomycin 
HEK293 FuGene 6 Transfection Medium DMEM/F-12 
 2 mM L-Glutamine 
Swiss-3T3 Starvation Medium   DMEM 
 2 mM L-Glutamine 
 100 U/ml Penicillin 
 100 μg/ml Streptomycin 
Swiss-3T3 Complete Medium 
 Swiss-3T3 Starvation Medium supplemented with 10 % FBS 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Coverslip preparation 
Glass coverslips, 10 mm Ø for primary cell culture and 22 x 22 mm for experiments with cell 
lines, were washed with 100 % IMS for 1 h, then rinsed three times with 75 % IMS and 
sterilized by baking at 200 °C for a minimum of 6 h. Before use coverslips were coated with 
poly-D-lysine (100 μg/ml); the 10 mm Ø coverslips were incubated at 37 °C for 3–24 h and the 
22 x 22 mm coverslips at 37 °C for 10 min–3 h. Poly-D-lysine treatment was followed by three 
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rinses (5 min each) with dH2O and coverslips were either used immediately or stored at 37 °C 
in water or medium. 
2.2.1.2 Maintenance and splitting of cell lines 
Human embryonic kidney (HEK293) and Swiss-3T3 cell lines were grown in their respective 
complete medium (section 2.1.4) in T25 flasks in the incubator at 37 °C and 5 % CO2. Cells were 
split when they reached 80–90 % confluency. The medium was aspirated and the cells were 
washed with 3 ml PBS (Gibco). 1 ml of 0.05 % Trypsin/EDTA solution was added to the flask 
and gently distributed to coat the cell layer. Surplus trypsin solution was removed and the cells 
were incubated 1–2 min at 37 °C. Detached cells were resuspended in 3 ml complete medium. 
To maintain cell lines 500 μl of this cell suspension plus 4.5 ml of complete medium was placed 
back into a flask and returned to the incubator. The remaining cells were plated for 
experiments such as lysate preparation for Western blotting and co-immunoprecipitation 
(section 3.1.1 and 3.1.6) and other binding assays (section 3.2.2), FRET experiments (section 
3.1.7) or stress fibre formation assessments (section 3.2.3). 
Baby hamster kidney (BHK-21) cells were maintained in BHK-21 complete medium (section 
2.1.4) in T75 flasks in the incubator (37 °C, 5 % CO2) and split when 80-90 % confluent. The 
medium was aspirated and cells were rinsed twice with 5 ml PBS (Gibco). 3 ml of 0.05 % 
Trypsin/EDTA solution was added to the flask, evenly distributed and then removed. Cells were 
incubated at 37 °C for 3 min and resuspended in 5 ml BHK-21 complete medium. To maintain 
the cell line 5 x 105 cells (counted in a Neubauer chamber) were placed into a T75 flask, 
complete medium was added to a total volume of 15 ml and the flask was returned to the 
incubator. The remaining cells were used for experiments during Sindbis virus production 
(section 3.3.1). 
2.2.1.3 Primary culture of hippocampal neurons 
All procedures were carried out according to regulations of the Home Office Animal (Scientific 
Procedures) Act of 1986. Three P0 (newborn) Sprague Dawley rats were sacrificed by 
decapitation and the brains dissected. Both brain hemispheres were transferred to a dish 
containing cold dissection medium, the meninges were removed and the hippocampus 
isolated. In a separate dish containing fresh dissection medium, the hippocampus was cut into 
small pieces and transferred to a 15 ml tube. The tissue was left to settle in the bottom of the 
tube and the dissection medium was replaced with 0.25 % trypsin (Gibco, 2.5 %) solution, 
diluted in 2 ml dissection medium. Digestion occurred at 37 °C for 10 min after which the 
tissue was transferred to a new tube, allowed to settle and the remaining trypsin solution was 
aspirated. The tissue pellet was rinsed twice with fresh dissection medium (~7 ml) and twice 
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with attachment medium (~7 ml) to completely remove the trypsin; the tissue was allowed to 
settle in the bottom of the tube between each wash. To obtain a homogeneous solution the 
tissue was dissociated mechanically by pipetting up and down with fire-polished glass Pasteur 
pipettes of decreasing tip. Briefly, after the last wash 3 ml of attachment medium was added 
and the tissue was triturated (~10x) with a wide-opening glass Pasteur pipette. Tissue that was 
not dissociated was allowed to settle and the supernatant was recovered and transferred to a 
new 15 ml tube. 2 ml attachment medium were added and trituration was repeated with a 
narrow-opening glass Pasteur pipette (10x). Remaining tissue was left to settle at the bottom 
of the tube and the supernatant was recovered and centrifuged (Heraeus) at 200 x g for 3 min. 
The cell pellet was resuspended in 3 ml attachment medium and a sample of the cell 
suspension was stained with 10 % Trypan Blue. Using a Neubauer chamber viable cell numbers 
were determined; on average 1.65 x 106 cells/ 3 P0 rats. Cells were plated on poly-D-lysine 
coated coverslips (4.5 x 104/well) in a total volume of 500 μl attachment medium, which was 
replaced with maintenance medium 6–24 h later. Cells were kept in the incubator (37 °C, 5 % 
CO2) and half of the maintenance medium was replaced with fresh maintenance medium every 
five days. The replaced medium (conditioned maintenance medium) was kept at 4 °C and used 
in subsequent experiments (section 2.2.2.3). Day in vitro (DIV) 1 corresponded to the day the 
culture was made. Primary cultured hippocampal neurons were used to perform whole-cell 
patch clamp recordings (section 3.3.2 and 3.3.3). 
Dissection Medium   1x HBSS 
 10 mM HEPES 
Attachment Medium   MEM 
 10 % Horse Serum 
 0.6 % Glucose 
 2 mM Glutamine 
 1 mM Sodium Pyruvate 
Maintenance Medium   Neurobasal 
 1 x B27 
 0.6 % Glucose 
 2 mM Glutamine 
 100 U/ml Penicillin 
 100 μg/ml Streptomycin 
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2.2.2 Expression 
2.2.2.1 Transient transfection 
Lipofectamine 2000 
HEK293 cells (1–1.3 x 106/3.5 cm Ø well and 3 x 106/6 cm Ø well) were plated 24 h before 
transfection in HEK293 complete medium (section 2.1.4). Cells were transfected with 
Lipofectamine 2000 when grown to 85–95 % confluency. At a ratio of 1:2.5, DNA and 
Lipofectamine 2000 (1.2–7 μg DNA:3–17.5 μl Lipofectamine 2000) were separately diluted in 
Opti-MEM (50–250 μl) and incubated at room temperature for 15 min. Diluted DNA and 
Lipofectamine 2000 were combined, mixed gently and incubated for another 15 min at room 
temperature. Cells were removed from the incubator and the medium was replaced with 
enough Opti-MEM to cover the cells (300–750 ul/3.5–6 cm Ø well). The transfection complex 
was added to the cells, mixed gently, and incubated at 37 °C for 3–5 h. After incubation, the 
transfection complex/Opti-MEM mix was removed and replaced with HEK293 complete 
medium without antibiotics (section 2.1.4). Cells were returned to the incubator for 24 h 
before being used for experiments such as cell lysate preparation for Western blotting and co-
immunoprecipitation (section 3.1.1 and 3.1.6) as well as other binding assays (section 3.2.2) or 
FRET experiments (section 3.1.7). 
Swiss-3T3 cells (0.5 x 104/3.5 cm Ø well) were plated on poly-D-lysine coverslips in Swiss-3T3 
complete medium (section 2.1.4) and allowed to grow for three days before being washed 
twice with 2 ml PBS (Gibco) and kept in Swiss-3T3 starvation medium (section 2.1.4) for two 
days before transfection. Transfections with Lipofectamine 2000 were performed as described 
above and cells were kept in Swiss-3T3 starvation medium without antibiotics (section 2.1.4) in 
the incubator for 24 h before being used in stress fibre formation assessments (section 3.2.3). 
FuGene 6  
HEK293 cells were plated 24–48 h before transfection in HEK293 complete medium (section 
2.1.4) in 10 cm Ø dishes. Transfections with FuGene 6 were carried out when cells reached 30–
50 % confluency. At a FuGene 6 to DNA ratio of 3:1, FuGene 6 was diluted in HEK293 FuGene 6 
transfection medium (section 2.1.4) and incubated at room temperature for 5 min. Diluted 
FuGene 6 was added to the DNA (2 μg RhoA, 5 μg Gαq) and incubated at room temperature for 
30 min. Cells were removed from incubator and the transfection complex was gently added. 
Cells were incubated at 37 °C for 48 h before cell lysates were prepared for Western blotting 
and co-immunoprecipitation experiments (section 3.1.1 and 3.1.6). 
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2.2.2.2 Microinjection 
Swiss-3T3 cells (6–9 x 104/3.5 cm Ø well) were plated on poly-D-lysine coated coverslips in 
Swiss-3T3 complete medium (section 2.1.4) and allowed to attach (min 6 h). Cells were rinsed 
twice with 2 ml PBS (Gibco) and Swiss-3T3 starvation medium (section 2.1.4) was added. Cells 
were starved for two to three days before microinjection took place. Microinjections were 
performed using a FemtoJet microinjector (Eppendorf) and a 5171 micromanipulator 
(Eppendorf). Long tapered needles were pulled on a horizontal P-97 Flaming/Brown puller 
(Sutter) from Borosilicate glass capillaries (Harvard). Before use, all solutions were filtered 
using VectaSpin Micro centrifuge filters (Eppendorf, 9,400 x g, 4 min). The dish containing the 
cells was removed from the incubator and placed on a microscope (Axiovert 135M, Zeiss, 
section A.1.3) stage enclosed in a Perspex chamber. The FemtoJet microinjector settings were 
adjusted to: injection pressure (pi) of 120 hPa, injection time (ti) of 0.3 s and compensation 
pressure (pc) of 60 hPa. Microinjections were carried out in semi-automatic mode with defined 
Z-plane limits and a set injection time or manually by touching the cell membrane with the tip 
of the needle and retracting the needle once a slight shiver and enlargement of the cell was 
observed. Manual injection was the method most often used as it gave fine control over the 
entire injection process. Experiments were performed with two concentrations of purified 
RhoA protein (0.15 μg/μl and 0.3 μg/μl, in adapted intracellular solution; section 2.2.7.2). 
Purified RhoA-V14 or RhoA-N19 protein was injected into the cytoplasm of the cells. To detect 
injected cells, tetramethylrhodamine isothiocyanate (TRITC; 5–12.5 mg/ml) was microinjected 
together with the purified protein at all times. As a control TRITC (8–10 mg/ml, in 
microinjection buffer) was also injected on its own. Microinjections lasted no longer than 
30 min after which the cells were returned to the incubator and allowed to recover (max 
1.5 h). Cells were fixed and prepared for microscopy (section 2.2.11.1) in order to asses stress 
fibre formation (section 3.2.3). 
Microinjection Buffer 154 mM NaCl 
 5 mM HEPES 
 2.5 mM KCl 
 0.5 mM MgCl2 
   pH 7.4 
2.2.2.3 Viral infection 
BHK-21 cells (2 x 105/3.5 cm Ø well) were plated on poly-D-lysine coated coverslips in BHK-21 
complete medium (section 2.1.4). The next day cells were rinsed twice with 2 ml PBS (Gibco) 
and BHK-21 starvation medium (section 2.1.4) was added. Infections with Sindbis virus took 
place 24 h later. The virus was diluted in BHK-21 starvation medium (EGFP control 1:5000, 
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RhoA-N19 1:1000 and RhoA-V14 1:100) and 100 μl of the diluted virus was added to the cells, 
which had been covered with 900 μl fresh BHK-21 starvation medium. After 4 h of incubation 
at 37 °C another 1 ml of BHK-21 starvation medium was added to the cells without removing 
the virus. Cells were left to incubate for 24 h before being fixed and stained (section 2.2.11.1) 
for stress fibre formation assessment (section 3.3.1.4). 
Cultured hippocampal neurons (DIV 9–16) were infected with Sindbis virus. The virus was 
diluted (EGFP control 1:5000; RhoA-N19 1:1000 or 1:2000; RhoA-V14 1:100 or 1:500) in 
conditioned maintenance medium (section 2.2.1.3). 100 μl of virus dilution was mixed with 
100 μl of medium from the wells and added to the neurons, from which the remaining medium 
had been removed. The removed medium was used to enrich fresh maintenance medium 
(50:50). After an incubation of 2 h at 37 °C the virus was removed from the neurons and 500 μl 
of enriched maintenance medium was added to each well. Neurons were returned to the 
incubator and used for whole-cell patch clamp experiments 24–48 h later (section 3.3.3). 
2.2.3 Lysis preparation 
2.2.3.1 Lysate preparation from HEK293 cells 
Transiently transfected (Lipofectamine 2000 or FuGene 6) HEK293 cells were lysed 24 h after 
transfection. Dishes containing the cells were removed from the incubator, placed on ice and 
cells were rinsed twice with ice-cold 1x PBS (section 2.1.2). GTPase lysis buffer was added to 
each dish (0.5–1 ml/6–10 cm Ø dish), cells were scraped off and transferred to a 1.5 ml tube. 
The lysate was sonicated using a SonoPuls sonicator (Bandelin) at 15 % intensity and 40 % 
pulse at 4 °C for 30 s and centrifuged (Eppendorf) at 16,100 x g and 4 °C for 5 min. The 
supernatant was transferred to a fresh 1.5 ml tube and an aliquot was taken for protein 
estimation (section 2.2.4) before samples were frozen at -20 °C. Cell lysates were used in 
Western blotting and co-immunoprecipitation experiments (section 3.1.1 and 3.1.6) and in 
other binding assays (section 3.2.2). 
GTPase Lysis Buffer 50 mM Tris-HCl pH 8.0 
 150 mM NaCl 
 10 % Glycerol 
 2 mM EDTA 
 1 % Triton X-100 
 1 mM Benzamidine 
 0.23 mM PMSF 
2.2.3.2 Lysate preparation from rat brain 
All procedures were carried out according to Schedule One of the 1986 Home Office Animal 
(Scientific Procedures) Act. P23 Sprague Dawley rats were sacrificed by dislocation of the neck 
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and the brains dissected. Working on ice, cortex and hippocampus were isolated and cut into 
small pieces. Tissue pieces were suspended in cold homogenisation buffer A at a tissue to 
medium ratio of 5–10 % (w/v) and homogenised with 15 strokes using a pre-chilled glass 
homogeniser (Glas-Col). The homogenate was transferred to a Greiner tube and centrifuged 
(Heraeus) at 1,400 x g and 4 °C for 10 min. The supernatant (S1) was collected and stored on 
ice, while the pellet was resuspended in homogenisation buffer A and centrifuged as before. 
The resulting pellet (P1) was resuspended in homogenisation buffer B and aliquoted. The 
supernatant (S1’) was combined with S1 (small aliquots were taken) and centrifuged 
(Beckman, JA-17) at 13,800 x g and 4 °C for 10 min. The supernatant (S2) was collected and 
aliquoted. The pellet (P2) was resuspended in homogenisation buffer B and aliquoted. All 
aliquots were snap-frozen in liquid nitrogen and stored at -80 °C. Before use Triton X-100, to a 
final concentration of 0.5 %, was added to the samples and small aliquots were taken to 
estimate the protein concentration. 20 mM DTT (final concentration) was added and samples 
were rotated at 4 °C for 30 min. Brain lysates were used in Western blotting and co-
immunoprecipitation experiments (section 3.1.4) and in other binding assays (section 3.2.2). 
Homogenisation Buffer A 320 mM Sucrose 
 10 mM Tris-HCl pH 8.0  
 0.1 mM EDTA 
 0.1 mM PMSF 
 1 μg/ul Aprotinin 
 1 μM Leupeptin 
 1 μM Pepstatin 
Homogenisation Buffer B 20 mM Tris-HCl pH 8.0 
 0.1 mM EDTA 
 0.1 mM PMSF 
 1 μg/ul Aprotinin 
 1 μM Leupeptin 
 1 μM Pepstatin 
2.2.4 Protein concentration estimation 
The protein concentration of HEK293 lysates was estimated using a Bradford assay.  Protein 
standards (0, 2, 4, 6 μg bovine serum albumin; BSA) were set up in 1.5 ml tubes, to which 2.5 μl 
of GTPase lysis buffer (section 2.2.3.1) had been added. 2.5 μl of each sample lysate was added 
to separate 1.5 ml tubes. The Bradford stock solution (BIO-RAD) was diluted 1:5 with water 
and 1 ml of diluted Bradford solution was added to every standard and sample tube. Vortexed 
briefly, all were transferred to disposable cuvettes and incubated at room temperature for 
5 min. Optical density (OD) values were read at 595 nm and protein concentrations were 
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estimated using a spectrophotometer (SmartSpec Plus, BIO-RAD). Protein concentrations of 
brain lysates were estimated in the same way as HEK293 lysates. Homogenisation buffer B 
(section 2.2.3.2) was used to set up the BSA protein standards. 
The Bradford assay was also used to estimate protein concentrations of cleaved purified 
proteins (section 2.2.7.3). The assay was scaled down and a Nanodrop 1000 
spectrophotometer (Labtech International) was used the read OD values and estimate the 
protein concentration of the samples. BSA protein standard dilutions (0, 0.1, 0.2, 0.4, 0.6 
μg/μl) were set up in adapted intracellular solution (section 2.2.7.2). 4 μl of these dilutions and 
of the purified protein samples were transferred to 1.5 ml tubes and 200 μl of Bradford 
working solution (1:5 dilution of Bradford stock solution) was added to each. After 5 min 
incubation at room temperature, OD values were read at 595 nm and protein concentrations 
estimated. 
2.2.5 Co-immunoprecipitation 
250 μg of lysate from HEK293 cells or rat brain (P2 fraction) was incubated with 1–2 μg of 
antibody (anti-myc, anti-RhoA or anti-Gαq/11 (Millipore and Santa Cruz)) and rotated at 4 °C for 
1 h. Protein A/G agarose (20–30 μl of 50 % slurry) was washed once with 1 ml cold GTPase lysis 
buffer (section 2.2.3.1). The samples were added to the washed beads and rotated at 4 °C for a 
further hour. Samples were centrifuged (Eppendorf) at 200 x g for 2 min and beads were 
rinsed three times with 1 ml cold GTPase lysis buffer. After the last wash beads were 
transferred to new 1.5 ml tubes, the GTPase lysis buffer was aspirated and 20 μl of 1x Laemmli 
buffer (diluted from 6x Laemmli buffer with 1x PBS, section 2.1.2) was added. The samples 
were denatured at 60 °C for 30 min before being analysed by Western blotting. 
2.2.6 SDS-PAGE and Western blotting 
2.2.6.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out using either a mini-PROTEAN II (BIO-RAD) or a SE600 (Hoefer) 
system. Discontinuous polyacrylamide gels consisting of a 3 or 4 % stacking gel and a 10–15 % 
separating gel were used to separate proteins. Gels were cast at room temperature between 
glass plates using the provided casting stands. Polyacrylamide (AA/BA) polymerisation was 
initiated by ammonium persulfate (APS) and catalysed by TEMED. 
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Mini-PROTEAN II (BIO-RAD) 
For 2 gels 10 % 12 % 15 % Stacking Gel, 3 % 
30 % AA/BA, ml 3.33 4.0 5 0.5 
Lower Tris, ml 2.5 2.5 2.5 - 
Upper Tris, ml - - - 1.25 
APS (10 %), ul 70 70 70 30 
TEMED, ul 10 10 10 10 
dH2O, ml 4.09 3.42 2.42 3.21 
Total, ml 10 10 10 5 
Table 2.1 Preparation of gels for SDS-PAGE, Mini-PROTEAN II (BIO-RAD). 
Upper Tris 0.4 % SDS 
 0.5 M Tris-HCl, pH 8.8 
Lower Tris 0.4 % SDS 
 1.5 M Tris-HCl, pH 6.8 
 
SE600 (Hoefer) 
For 2 gels 11 % 12.5 % Stacking Gel, 4 % 
30 % AA/BA, ml 13.75 15.625 2.6 
Tris-HCl, pH 8.8, 
ml 
18.75 18.75 - 
Tris-HCl, pH 6.8, 
ml 
- - 3.3 
SDS (10 %), ul 375 375 200 
APS (10 %), ml 2 2 1.4 
TEMED, ul 25 25 20 
dH2O, ml 2.6 0.725 12.5 
Total, ml 37.5 37.5 20 
Table 2.2 Preparation of gels for SDS-PAGE, SE600 (Hoefer). 
Indicated amounts of HEK293 and brain samples were prepared for SDS-PAGE by mixing the 
lysate with 1x PBS (section 2.1.2) and 6x Laemmli buffer (section 2.1.2; 1x final concentration) 
to a minimum final volume of 18 μl and denatured at 60 °C for 30 min for Gαq samples and at 
95 °C for 5 min for RhoA samples (section 3.1.6). Co-immunoprecipitation samples were 
denatured at 60 °C for 30 min, and protein purification samples at 95 °C for 10 min. Denaturing 
conditions for the various binding assay are specified in the individual sections in the results 
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chapter. To bring down condensation or to pellet beads, samples were centrifuged 
(Eppendorf) at 200 x g for up to 3 min before being loaded onto the gel. Protein markers (All 
Blue PrecisionPlus or Low Range, BIO-RAD or High-Range Rainbow, GE) were loaded alongside 
the samples. SDS-PAGE was carried out in 1x running buffer and gels were run at 80 V constant 
voltage through the stacking gel and 18 mA constant current through the separating gel (mini-
PROTEAN II , BIO-RAD) or at 300 V constant voltage (SE600 , Hoefer) until the Bromphenol Blue 
dye had run out of the gel.  
1x Running Buffer 192 mM Glycine 
 25 mM Tris 
 0.1 % SDS 
2.2.6.2 Transfer and immunodetection 
Following SDS-PAGE proteins were transferred onto nitrocellulose membranes (Protran BA83, 
Whatman or Hybond ECL, GE) either by tank (mini Trans-Blot, BIO-RAD) or semi-dry blotting 
(V20-SDB, Scie-Plas).  
For tank blotting, the gel was equilibrated in cold 1x tank transfer buffer for 5 min and the 
nitrocellulose membrane was pre-soaked in dH2O and 1x tank transfer buffer. The transfer 
cassette was assembled by placing the gel together with the nitrocellulose membrane in 
between two pieces of blotting paper and two fibre pads; all soaked in 1x tank transfer buffer. 
The transfer cassette was placed into the tank; the black/gel side of the cassette facing the 
cathode (negative, black) and the clear/membrane side of the cassette facing the anode 
(positive, red). An ice-pack and stirring bar were also placed into the tank and it was filled with 
cold 1x tank transfer buffer. In the cold-room (4 °C) the tank was placed on a magnetic stirrer 
and transfer was performed at 100 V constant voltage for 50 min. 
1x Tank Transfer Buffer 192 mM Glycine 
 25 mM Tris 
 20 % Methanol 
For semi-dry transfer, the gel and six pieces of blotting paper were soaked in 1x Semi-Dry 
transfer buffer and the transfer was assembled in the following order: three pieces of blotting 
paper were placed onto the anode (positive) plate, followed by the nitrocellulose membrane, 
the gel and three further pieces of blotting paper; the stack was then covered with the 
cathode (negative) plate. Transfer was performed at a constant current of 0.8 mA/cm2 for 1 h 
50 min. 
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1x Semi-Dry Transfer Buffer 40 mM Glycine 
 50 mM Tris 
 0.3 % SDS 
 20 % methanol 
The two systems, BIO-RAD and Hoefer/Scie-Plas, used gels and membranes that differed in size 
and thus volumes of solutions in the immunodetection experiments had to vary. Volumes in 
the text refer to experiments that used the BIO-RAD system; volumes in brackets were used 
with the Hoefer/Scie-Plas system. 
Blots were processed directly or stored overnight, in 1x TBS (section 2.1.2) at 4 °C or dried at 
room temperature. The dried membrane was soaked for 10 min in dH2O and 10 min in 1x TBS 
before use. Membranes were blocked at room temperature on an orbital shaker for 40 min–
1 h in 15 ml (50 ml) blocking solution. Primary antibodies were diluted in 1 ml (20 ml) blocking 
solution and membranes were incubated in primary antibody solutions in a plastic pouch (in a 
box) at room temperature for 3 h or at 4 °C overnight, continuously rotating or shaking. 
Membrane were washed three times with 12 ml blocking solution and three times with 12 ml 
TBST for 5 min each (6x with 50 ml TBST, 5 min each) and then incubated with horseradish 
peroxidase (HRP)-conjugated secondary antibodies, diluted in 10 ml (25 ml) blocking solution, 
at room temperature on an orbital shaker for 1 h. Washes in blocking solution and TBST were 
repeated as before. For each blot 1 ml SuperSignal West Pico (Pierce) (25 ml ECL, GE) detection 
reagent was used; the luminal and enhancer solutions were mixed in equal amounts. 
Detection solution was added to the blots, which were placed on a glass plate (in a box), and 
incubated for 5 min (1 min) at room temperature. Membranes were drained off excess 
detection solution, covered with an acetate sheet and placed into a developing cassette. 
Emitted signals were detected by exposing the blots to films (Hyperfilm ECL, GE or BioMax MR-
1, Kodak) for up to 30 min and developing the films in an automatic film processor (RG II, Fuji). 
At times signals were detected digitally using a CCD-camera based imager (ImageQuant 
LAS4000 mini, GE). In this case, blots were placed on a tray, covered in 1.5 ml SuperSignal 
West Pico detection solution, which remained on the blot during imaging, and placed inside 
the ImageQuant machine. Exposure conditions and times were set using the ImageQuant 
LAS4000 control software. 
At times membranes were stripped of antibody and re-probed. Membranes were submerged 
in stripping buffer and incubated at 60 °C for 30 min, after which they were extensively rinsed 
in TBST (~30 min). Membranes were incubated in blocking solution and probed with a different 
primary antibody following the procedure as described before. 
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Primary Antibodies 
RhoA  anti-mouse Santa Cruz 0.2 mg/ml 1:200-1:1000 
  anti-rabbit Santa Cruz 0.2 mg/ml 1:200 
Gαq/11  anti-rabbit Santa Cruz 0.2 mg/ml 1:200-1:1000 
Gαq  anti-rabbit Santa Cruz 0.2 mg/ml 1:1000 
Myc  anti-mouse Roche   0.4 mg/ml 1:400 
  anti-mouse Millipore 1 mg/ml 1:1000 
  anti-rabbit Santa Cruz 0.2 mg/ml 1:400-1:1000 
EE  anti-rabbit Abcam  0.2 mg/ml 1:500 
Secondary Antibodies 
Goat anti-mouse HRP   BioRad    1:5000 
Sheep anti-mouse HRP   GE    1:2500 
Goat anti-rabbit HRP   BioRad    1:5000 
Donkey anti-rabbit HRP  GE    1:2500 
 
Blocking Solution 1 x TBS 
 5 % Milk powder 
 5 % NGS 
 0.1 % Tween-20 
TBST 1 x TBS 
 0.1 % Tween-20 
Stripping Buffer 62.5 mM Tris-HCl pH 6.8 
 2 % SDS 
 100 mM β-Mercaptoethanol 
2.2.6.3 Coomassie staining of SDS-PAGE gels 
SDS-PAGE gels were stained with Coomassie Blue to document the stages of protein 
purification and to estimate purified protein concentrations (section 2.2.7 and 3.2.1) or to 
evaluate transfer efficiency during Western blotting experiments. Gels were stained with 
Coomassie solution at room temperature on an orbital shaker for 10–20 min. The Coomassie 
solution was removed and gels were rinsed with dH2O before being destained in Fast Destain 
solution for 15 min and Slow Destain solution at room temperature overnight. Gels were 
soaked in drying solution and dried between cellophane sheets (Novex). 
Coomassie Solution 0.2 % Coomassie Brilliant Blue R250 
 7.5 % Acetic Acid 
 50 % Methanol 
Fast Destain Solution 45 % Methanol 
 7.5 % Acetic Acid 
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Slow Destain Solution 10 % Methanol 
 7.5 % Acetic Acid 
Drying Solution 2 % Glycerol 
 0.01 % Na-Azide 
2.2.7 Glutathione-S-transferase (GST) fusion protein purification 
RhoA-V14 and RhoA-N19 were purified as recombinant GST fusion proteins. For binding assay 
experiments (section 3.2.2) purified GST-RhoA-V14 and GST-RhoA-N19 were used bound to 
glutathione agarose beads. In electrophysiological experiments (section 3.2.4) RhoA-V14 and 
RhoA-N19 cleaved off the GST fusion protein were added to the intracellular solution. 
2.2.7.1 Electroporation of BL21 (DE3) bacteria 
Electroporation cuvettes (1 mm, BTX model 610, Harvard Apparatus) were cooled on ice. 1 μg 
of DNA (pGEX-6P-1-RhoA-V14, pGEX-6P-1-RhoA-N19) was gently mixed with 25 μl 
electrocompetent BL21 (DE3) bacteria and then added to the cuvettes before being 
electroporated at 129 Ω, 50 uF, 1.5 kV (ECM 600, BTX). Bacteria were transferred to a Falcon 
tube with 1 ml of LB medium (section 2.1.3; 37 °C) and incubated at 37 °C and 120 rpm for 
40 min. Bacteria were harvested by centrifugation (Heraeus, 2,000 x g, 1 min), resuspended in 
100 μl LB medium and spread on LB-ampicillin plates (section 2.1.3; 100 μg/ml). Plates were 
incubated at 37 °C overnight. 
2.2.7.2 Purification of GST fusion proteins 
This description of the purification of GST fusion proteins is also illustrated by a flow diagram 
(Fig. 3.14A) in the results section. As a starter culture, 20 ml LB medium (section 2.1.3; 
100 μg/ml Ampicillin) was inoculated with a single colony picked from the LB-ampicillin plate 
and incubated, shaking at 200 rpm, at 37 °C overnight. 5 ml starter culture was diluted (1:50) in 
250 ml LB medium (100 μg/ml Ampicillin) and grown at 200 rpm until an OD600 of 0.4–0.5 was 
reached; incubation took place at 37 °C for ~1 h before the culture was cooled down to 22 °C. 
An aliquot (pre-induction) of the culture was taken, the bacteria pelleted (Eppendorf, 
13,500 x g, 5 min) and resuspended in 2x Laemmli buffer (section 2.1.2); so as not to overload 
the gel 2x Laemmli buffer was added in proportion to the OD600 according to the following 
formula: (ml of culture taken x OD600 / 0.035) x 10. Protein expression was induced by adding 
0.05 mM isopropyl β-D-thiogalactopyranoside (IPTG), which causes transcription of the cloned 
genes controlled by the lac operon, to the culture and the culture was incubated at 200 rpm, 
at 22 °C for 3 h. An aliquot (post-induction) was taken, centrifuged and resuspended as 
described for the pre-induction aliquot. Bacteria were harvested by centrifugation (Beckman, 
JA-14 rotor, 3,100 x g, 4 °C, 10 min). On ice, the pellet was washed with 10 ml cold GST fusion 
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protein lysis buffer (without DTT and PMSF) and transferred to a 15 ml tube. After 
centrifugation (Heraeus) at 3,200 x g and 4 °C for 10 min the pellet was resuspended in 5 ml 
cold GST fusion protein lysis buffer (without DTT and PMSF). 0.5 mg/ml lysozyme was added 
and incubated on ice for 15 min. PMSF and DTT were added to a final concentration of 1 mM 
and the lysate was sonicated (Bandelin, 25 % intensity, continuous, 1min, on ice). To 
precipitate DNA, 0.5 ml of a 30 % streptomycin sulphate solution was added and rotated at 
4 °C for 10 min. The lysate was centrifuged (Beckman, JA-17 rotor) in polycarbonate tubes at 
27,000 x g and 4 °C for 15 min. An aliquot of the supernatant was taken and 2x Laemmli buffer 
was added according to the following formula: μl of supernatant taken x OD600 (post 
induction) / 0.35. Glutathione agarose beads (Sigma, 100 μl of 25 % slurry i.e. 25 μl of packed 
beads/250 ml culture) were prepared by three washes with 150 μl GST fusion protein lysis 
buffer (without DTT and PMSF) and were transferred to a 15 ml tube. The supernatant was 
added to the prepared glutathione agarose beads and rotated at 4 °C for 1 h. After incubation 
beads were pelleted (Hereaus, 98 x g, 4 °C, 10 min), transferred to a 1.5 ml tube and 
centrifuged (Eppendorf) at 200 x g and 4 °C for 3 min. Depending on use, beads were then 
washed three times with 250 μl GST fusion protein lysis buffer (without PMSF, for binding 
assay experiments) or in 250 μl adapted intracellular solution (for electrophysiology). Beads 
were resuspended in their corresponding buffers to a total volume of 100 μl (25 % slurry). An 
aliquot (2 μl) was taken and 10 μl of 2x Laemmli buffer was added. For binding assay 
experiments GST-RhoA-V14 and GST-RhoA-N19 bound glutathione agarose beads were 
aliquoted, snap-frozen and stored in liquid nitrogen. For electrophysiology purified RhoA-V14 
and RhoA-N19 proteins were cleaved off the GST fusion protein (section 2.2.7.3). The aliquots 
taken at various stages of the purification process were denatured at 95 °C for 10 min and 
subjected to SDS-PAGE as described before (section 2.2.6.1). A 1 μg BSA sample was loaded 
onto the gel alongside the samples and used to estimate the concentration of purified GST-
RhoA-V14 and GST-RhoA-N19 protein bound to the glutathione agarose beads by Coomassie 
staining of the gel (section 2.2.6.3). GST, expressed from pGEX-6P-1, was purified as described 
for RhoA and used as a control for direct binding assays (section 2.2.9.2). 
GST Fusion Protein Lysis Buffer 50 mM Tris-HCl pH 7.5 
 50 mM NaCl 
 5 mM MgCl2 
 1 mM DTT 
 1 mM PMSF 
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Adapted Intracellular Solution 135 mM KGluc 
 10 mM KCl 
 10 mM HEPES 
 1 mM MgCl2 
 1 mM DTT 
   pH 7.2–7.3 
   osmolarity 270–290 
2.2.7.3 PreScission protease cleaving 
For electrophysiological experiments (section 3.2.4) purified RhoA-V14 and RhoA-N19 were 
cleaved off their GST-fusion part with PreScission protease (GE) to ensure the intracellular 
application of only the protein of interest and to limit the size of the protein having to be 
introduced to the neuron through the patch pipette. The process of PreScission protease 
cleaving is also illustrated by a flow diagram (Fig. 3.15A) in the results section. 1 U of 
PreScission protease was added to the GST-RhoA-V14 or GST-RhoA-N19 glutathione agarose 
beads (resuspended in adapted intracellular solution, section 2.2.7.2) and rotated at 4 °C for 
2 h. Beads were pelleted by centrifugation (Eppendorf, 200 x g, 4 °C, 3 min), the supernatant 
was saved and the beads were resuspended to a total volume of 100 μl with GST fusion 
protein lysis buffer (section 2.2.7.2). Aliquots (2 μl) of the supernatant and beads were taken 
and 10 μl of 2x Laemmli buffer (section 2.1.2) was added to each. Any excess PreScission 
protease, a GST-fusion protein itself, was removed from the supernatant by adding the 
supernatant to a fresh set of glutathione agarose beads (100 μl of 25% slurry, washed three 
times with 150 μl adapted intracellular solution) and rotating at 4 °C for 30 min. Beads were 
pelleted as before and the supernatant was aliquoted. The supernatant was either used 
directly or snap-frozen and stored in liquid nitrogen. The protein concentration of the cleaved 
purified protein was estimated using a Bradford assay as described before (section 2.2.4). The 
aliquots taken at various stages of the purification and cleaving process were denatured at 
95 °C for 10 min and subjected to SDS-PAGE and stained with Coomassie (section 2.2.6). As a 
control for electrophysiology recordings GST, expressed from pGEX-4T, was mock purified and 
cleaved in the same way. 
2.2.8 Binding assays with purified protein 
Purified GST-RhoA-V14 and GST-RhoA-N19 bound to glutathione agarose beads (section 
2.2.7.2) were incubated with HEK293 lysates or brain lysates. As a control, GST protein (25 μg) 
was bound to glutathione agarose beads (20 μl of 25 % slurry), which had been washed three 
times with 150 μl GTPase lysis buffer (without PMSF and Benzamidine; section 2.2.3.1), by 
rotating at 4 °C for 1 h in 100 μl GTPase lysis buffer. After incubation GST bound beads were 
rinsed three times with 150 μl GTPase lysis buffer and resuspended in a total volume of 20 μl 
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with GTPase lysis buffer. The amount of purified GST-RhoA-V14 and GST-RhoA-N19 bound to 
glutathione agarose beads was estimated as described (section 2.2.7.2) and the binding assay 
experiments were performed using 40 μg purified GST-RhoA protein. GST bound control 
beads, GST-RhoA-V14 and GST-RhoA-N19 bound beads were incubated with Gαq HEK293 
lysate (50 μg) or brain lysate (250–1500 μg), and as control with rhophilin HEK293 lysate 
(25 μg). Beads, lysates and 100 μl of cold GTPase lysis buffer (+5 mM MgCl2) were mixed in a 
1.5 ml tube and rotated at 4 °C for 1 h. Beads were pelleted (Eppendorf) at 200 x g and 4˚C for 
3 min, rinsed three times with cold 500 μl GTPase lysis buffer and transferred to a new 1.5 ml 
tube. 20 μl of 1x Laemmli buffer (diluted from 6x Laemmli buffer with 1x PBS, section 2.1.2) 
was added and the samples were denatured at 95 °C for 10 min or at 60 °C for 20 min. Samples 
were analysed by SDS-PAGE and Western blotting (section 2.2.6). 
2.2.9 In vitro translation and direct binding assays 
2.2.9.1 In vitro translation 
The TNT coupled transcription/translation system (Promega) was used to in vitro translate 
rhophilin and Gαq-L209. In vitro translation reactions were performed according to 
manufacturer’s instructions. Briefly, 1 μg of sample DNA was mixed with 25 μl of TNT rabbit 
reticulocyte lysate, 2 μl TNT reaction buffer, 1 μl TNT RNA polymerase, 1 μl amino acid mixture 
(without methionine) and 1 μl RNasin Ribonuclease inhibitor or with 40 μl of TNT quick master 
mix. 2 μl [35S] methionine was added and the reaction brought to a total volume of 50 μl with 
nuclease-free water before being incubated at 30 °C for 90 min. Synthesised proteins were 
analysed by running 1–2 μl of the radioactive translation products on SDS-PAGE and exposing 
the dried gel to films as described below (section 2.2.9.2). In vitro translation reactions in the 
absence of DNA were carried out and served as controls in direct binding assays (section 
3.1.8). 
2.2.9.2 Direct binding assays with purified RhoA-V14 
20 μl of in vitro [35S] translation product (rhophilin, Gαq-L209 or control) was added to 10 μg 
purified GST-RhoA-V14 or GST protein bound to glutathione agarose beads (section 2.2.7.2). 
200 μl of NP-40 buffer was added and samples were rotated at 4 °C for 1 h. Beads were 
washed three times with 1 ml NP-40 buffer and transferred into a new 1.5 ml tube. Beads were 
resuspended in 25 μl 1x Laemmli buffer (diluted from 6x Laemmli buffer with 1x PBS, section 
2.1.2) and denatured at 70 °C for 5 min. Samples were analysed by electrophoresis as 
described (section 2.2.6.1). Gels were fixed in fixation solution for 15 min, rinsed with dH2O 
and soaked in Autofluor enhancer solution (National Diagnostics) at room temperature for 1 h. 
Gels were dried on a gel dryer (BIO-RAD) at 80 °C for 2 h and exposed to films (BioMax MR-1, 
Kodak) at -80 °C for 48 h. Films were developed using an automatic film processor (RG II, Fuji). 
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NP-40 Buffer 50 mM Tris-HCl pH 7.5 
 100 mM NaCl 
 10 mM MgCl2 
 0.5 % NP-40 
Fixation Solution 7 % Methanol 
 7 % Acetic Acid 
2.2.10 Sindbis virus production 
2.2.10.1 RNA synthesis 
RhoA-V14 and RhoA-N19 were cloned into pSinRep5-EGFP (section 2.2.13) generously 
provided by A. Jeromin (Jeromin et al., 2003). The Sindbis plasmid contained the nonstructural 
protein (nsP) 2 mutation (P726S) that has been described (Dryga et al., 1997) and expressed 
enhanced green fluorescent protein (EGFP) under control of a second genomic promoter. 
Plasmid DNA (pSinrep5-EGFP, pSinrep5-RhoA-V14-EGFP, pSinrep5-RhoA-N19-EGFP and 
pHelper-DH-BB (tRNA/TE12)) was linearized by digesting 3 μg of DNA with the appropriate 
amount of restriction enzyme and its respective buffer (Roche or NEB) in a total reaction 
volume of 40 μl at 37 °C for 1–4 h. pSIN vectors were digested with PacI for 4 h and the helper 
plasmid with XhoI for 1 h. 1 μl aliquots of the digests were taken for analysis. Linearized 
plasmids were purified by phenol/chloroform extraction. Briefly, digests were taken up to 
100 μl with diethyl pyrocarbonate (DEPC)-dH2O and 100 μl phenol (pH 7.5) and 50 μl 
chloroform were added. Samples were vortexed for 10 s and centrifuged (Eppendorf) at 
16,100 x g and 4 °C for 5 min. The upper phase was transferred to a new 1.5 ml tube and 
1 volume chloroform was added; samples were vortexed and centrifuged as before. The upper 
phase was transferred into a new 1.5 ml tube and 300 mM NaAc (pH 5.2) and 2.5 volumes 
100 % EtOH added; DNA was precipitated at -20 °C overnight. The DNA was pelleted 
(Eppendorf) at 16,100 x g and 4 °C for 15 min and washed with 500 μl 80 % EtOH. The sample 
was centrifuged again under the same conditions for 5 min and the supernatant was aspirated. 
The pellet was air-dried for 35 min and dissolved in 5 μl DEPC-dH2O. A 0.5 μl aliquot was 1:20 
diluted in DEPC-dH2O, of which 3 μl was analysed on a DNA agarose gel (section 2.2.12.3) 
alongside the corresponding samples taken before purification. 
RNA was synthesised using the mMessage mMachine SP6 kit (Ambion). The reaction was 
performed according to manufacturer’s instructions. In 20 μl total volume, 2.5–4.5 μl of 
linearized DNA (0.5–1 μg) was combined with 5 mM of each ATP, CTP and UTP, 1–2 mM GTP, 
4 mM CAP analog (m7G(5’)ppp(5’)G), 1x reaction buffer and 1x enzyme mix (including RNase 
inhibitor). The amount of GTP added to the reaction depended on the length of the 
synthesised transcripts; for larger transcripts (pSIN-EGFP, 9 kb; pSIN-RhoA-V14-EGFP and pSIN-
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RhoA-N19-EGFP, 9.5 kb) 2 mM GTP was added. Additional GTP will decrease the amount of 
capped RNA, but is necessary to synthesise full-length transcripts. According to the mMessage 
mMachine manual a ratio of 4:1 (CAP:GTP) results in 80 % of the synthesised transcripts being 
capped, while the 2:1 ratio used for larger transcripts produces transcripts of which 67 % are 
capped. Transcription was performed at 37 °C for 2 h and was followed by DNase treatment. 
2 U TURBO DNase (provided with the mMessage mMachine SP6 kit) was added to the reaction 
and incubated at 37 °C for 15 min. 0.5 μl aliquots were taken for analysis and the remaining 
RNA was stored at -20 °C before being used in the Sindbis virus production (section 3.3.1). 
RNA samples, alongside a sample of isolated RNA from HEK293 cells (1 μg), were analysed by 
formaldehyde agarose gel electrophoresis. 0.5 μl of RNA sample was combined with 2.5 μl 
DEPC-dH2O and 5 volumes of RNA loading buffer, and incubated at 65 °C for 15 min. 1 μl of 
ethidium bromide (1mg/ml) was added and the samples were loaded onto a 1 % formaldehyde 
agarose gel (pre-run at 50 V constant voltage at 4 °C for 30 min). Electrophoresis was 
performed at 50 V constant voltage at 4 °C for 2 h. The RNA was visualized under UV light and 
the gels documented as prints. 
10x MOPS/EDTA 200 mM MOPS 
 50 mM NaAC 
 10 mM EDTA 
   pH 7.0 
Formaldehyde Agarose Gel 1 % SeaKem LE agarose 
 1 x MOPS/EDTA 
 0.63 M Formaldehyde 
1x RNA Gel Running Buffer 1 x MOPS/EDTA 
 0.63 M Formaldehyde 
RNA Loading Buffer 750 ul Formamid 
 150 ul 10x MOPS/EDTA 
 240 ul 37 % Formaldehyde 
 100 ul Glycerol 
 60 ul H2O 
 20 ul Bromphenol Blue stock 
 20 ul Xylene Cyanol stock 
2.2.10.2 Transfection of BHK-21 cells and harvesting of virus particles 
BHK-21 cells were transfected with the synthesised RNA by electroporation. BHK-21 cells were 
harvested by trypsinisation as described (section 2.2.1.2). Trypsinised cells were resuspended 
in 5 ml BHK-21 complete medium (section 2.1.4) and pipetted up and down to obtain a single 
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cell suspension. After centrifugation (Heraeus) at 200 x g for 5 min, cells were rinsed with 
10 ml ice-cold PBS (Gibco, without cations) and counted in a Neubauer chamber. Cells were 
centrifuged (Heraeus, 200 x g, 5 min) and resuspended in ice-cold PBS at 1 x 107cells/ml. For 
each electroporation 5 x 106 cells (500 μl) were transferred to a pre-cooled electroporation 
cuvette (4 mm, BTX model 640, Harvard Apparatus, cooled on ice for ~40 min). 7.5 μl (3.75–
10 μg RNA) each of synthesised Sindbis (SIN-RhoA-V14-EGFP, SIN-RhoA-N19-EGFP or SIN-EGFP) 
and helper RNA were mixed with the cells. Electroporation was performed on a GenePulser 
XCell electroporator (BIO-RAD) using the time constant protocol to deliver an exponential 
pulse with a specified pulse length of 7 ms and voltage of 500 V. Capacitor and resistor settings 
were selected automatically to produce the requested pulse. Pulses were delivered to the cells 
twice. Following electroporation cells were allowed to recover on ice for 5 min. They were 
then transferred to 15 ml tubes containing 9.5 ml BHK-21 virus production medium (with 
nucleosides; section 2.1.4) and the cuvettes were rinsed several times to collect all cells. Cells 
were plated in 10 cm Ø dishes and returned to the incubator for 24 h. The medium containing 
the virus particles was collected and centrifuged (Eppendorf, 2,000 x g, 10 min) to remove any 
detached cells. The supernatant was aliquoted and stored at -80 °C and subsequently used for 
the infection of BHK-21 cells (section 3.3.1) and primary cultured hippocampal neurons 
(section 3.3.3). 
2.2.10.3 Determining the potency of the virus stock 
The potency of the harvested virus stock and the optimal amounts of virus needed for 
infection were determined empirically by infecting BHK-21 cells with various dilutions of the 
virus stock and using EGFP expression as an indicator for the number of virions (section 
3.3.1.3). BHK-21 cells (2 x 105/3.5 cm Ø well) were plated 24 h prior to infection in BHK-21 
complete medium (section 2.1.4). Dilutions of the virus (1:10, 1:100, 1:500, 1: 1000, 1:2500 
and 1:5000) were prepared in BHK-21 low serum medium (1 % FBS; section 2.1.4). Cells were 
removed from the incubator and the medium aspirated. 100 μl of the dilutions was mixed with 
300 μl of BHK-21 low serum medium and added to the cells. Cells were incubated at 4 °C for 
1 h, during which the dishes were tilted every 15 min to make sure the cells remained covered 
in solution. 2 ml of BHK-21 low serum medium was added and cells were placed in the 
incubator for 24 h. Cells were rinsed twice with 2 ml PBS (Gibco) and 2 ml of fresh BHK-21 low 
serum medium was added. Cells were examined using an inverted microscope (DM IBR, Leica, 
section A.1.3) equipped with a 20x objective and an eyepiece grid micrometer (10 x 10 grid, 
0.25 mm2 with 20x objective). EGFP-positive (infected) cells were counted in the 10 x 10 grid in 
several areas of the dish and used to calculate the potency of the virus stock; on average 108–
109 virions/ml. 
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Virions/ml = Average number of infected cells in 10x10 grid x 3,520 x dilution factor 
volume of viral dilution used (ml) 
3,520 = 3.5 cm Ø dish (880 mm2) / 10 x 10 grid (0.25 mm2) 
1 infected cell = 1 virion 
2.2.11 Microscopy 
2.2.11.1 Preparation of cells for microscopy 
Transiently transfected, microinjected and infected cells were prepared for microscopy by 
fixation with paraformaldehyde followed in some cases by immunocytochemistry or cell 
staining. Transfected cells (HEK293 or Swiss-3T3) were fixed in 4 % PFA/PBS. For microinjected 
(Swiss-3T3) and infected (BHK-21) cells the 4 % PFA/PBS fixation solution also contained 10 % 
sucrose. HEK293 cells, transfected with Lipofectamine 2000 in 3.5 cm Ø dishes, were split onto 
poly-D-lysine coated 22 x 22 mm coverslips (8 x 104-1 x 105 cells/well) 24 h before fixation. 
Swiss-3T3 and BHK-21 cells were plated on poly-D-lysine coverslips from the start of an 
experiment. 
Transiently transfected HEK293 and Swiss-3T3 cells were removed from the incubator, the 
medium was aspirated and the cells were rinsed three times with 2 ml 1x PBS (section 2.1.2). 
Cells were fixed in 1 ml 4 % PFA/PBS at room temperature for 10 min and then washed twice 
with 2 ml 1x PBS. For FRET experiments, HEK293 cells were mounted onto glass slides (BDH) 
with Mowiol mounting medium. Microinjected Swiss-3T3 cells and infected BHK-21 cells were 
fixed by adding 300 μl of 4 % PFA/PBS (also containing 10 % sucrose) to the medium and 
incubating at room temperature for 30 min. Cells were then rinsed twice with 2 ml 1x PBS. For 
immunocytochemistry and cell staining, fixed HEK293, Swiss-3T3 and BHK-21 cells were 
permeabilized in 750 μl 0.2 % Triton X-100 for 2 min and rinsed four times 5 min with 2 ml 
1x PBS. Coverslips were transferred into a humidified chamber and 200 μl of blocking solution 
was added to each coverslip. The humidified chamber was placed into an incubator (37 °C) for 
30 min. For cell staining experiments of Swiss-3T3 and BHK-21 cells, the blocking solution was 
replaced with Alexa Fluor 488 or 594 phalloidin conjugate (0.25 U) diluted in 200 μl blocking 
solution and incubated in the humidified chamber at 37 °C for 30 min. After incubation the 
solution was drained off the coverslips and coverslips were rinsed by dipping them 5x in a 
beaker filled with 30 ml 1x PBS and then by washing them three times 5 min with 10 ml 1x PBS. 
Coverslips were mounted onto glass slides using ProLong Antifade (Molecular Probes) 
mounting medium. For immunocytochemistry experiments of HEK293 cells, the blocking 
solution was removed and 200 μl of primary antibody dilution (anti-HA 1:100, in blocking 
solution) was added to the coverslips. Incubation was performed in the humidified chamber at 
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37 °C for 1h and coverslips were then washed with 1x PBS as described for cell staining 
experiments. Cells were incubated with secondary antibodies (anti-mouse Cy5 conjugated 
1:600, in 200 μl of blocking solution) in the humidified chamber at 37 °C for 30 min. Coverslips 
were washed as before and mounted onto glass slides with ProLong Antifade mounting 
medium. Protected from light, slides were kept at room temperature overnight to allow the 
mounting medium to harden. Coverslips were fixed firmly to the slides by sealing the edges 
with nail polish. Slides were examined and images acquired with an Axiophot (Zeiss) 
microscope and Micropublisher CCD camera (QImaging) or with a TCS SP5 confocal (Leica) 
microscope and corresponding LAS AF software (Leica) (section A.1.3). Images were analysed 
and processed with ImageJ (version 1.44p, Java 1.6.0_20) and Adobe Photoshop CS. 
4 % PFA/PBS 1 x PBS 
 4 % PFA 
   pH 7.3 
0.2 % Triton X-100 1 x PBS pH 7.3 
 0.2 % Triton X-100 
Blocking Solution 1 x PBS 
 10 % FBS 
 2 % BSA 
Mowiol Mounting Medium 100 mM Tris-HCl pH 8.5 
 10 % Mowiol 4-88 
 25 % Glycerol 
2.2.11.2 Fluorescence resonance energy transfer (FRET) 
M3 muscarinic acetylcholine receptor stimulation 
Muscarinic acetylcholine receptor M3 transfected HEK293 cells for FRET experiments (section 
3.1.7) were stimulated with CCh (10 μM) before fixation. Cells were removed from the 
incubator and washed once with 2 ml 1x PBS (section 2.1.2). The dilution of CCh was prepared 
in 1x PBS and added to the cells for 3 min at room temperature. Cells were fixed in 4 % 
PFA/PBS containing CCh (10 μM) for 10 min. Cells were washes four times with 2 ml 1x PBS 
before being mounted onto glass slides (BDH) with Mowiol mounting medium. 
Confocal microscopy 
FRET experiments (section 3.1.7) were performed on a TCS SP5 Leica confocal microscope 
fitted with a 63x/1.4 NA oil-immersion objective (section A.1.3). Confocal images were 
acquired at 8 bit intensity resolution over 512 x 512 pixels and with a scan speed of 100 Hz of 
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the 100 mW Argon laser (set to 20%). Cyan fluorescent protein (CFP) and its derivatives were 
excited using the 458 nm laser line (at 20–30% intensity) and detected at 462–500 nm, and 
yellow fluorescent protein (YFP) and its derivatives were excited with the 514 nm laser line (at 
20–30% intensity) and detected at 520–600 nm. No cross talk was observed under these 
conditions. FRET was assessed by acceptor photobleaching and was performed using Leica’s 
LAS AF software acceptor photobleaching wizard. Bleaching experiments were performed as 
follows: first sequential scans of the donor and acceptor were acquired, secondly a defined 
region of interest (ROI) of the acceptor was bleached by increasing the intensity of the 514 nm 
laser line (to 50 %) to destroy the YFP fluorophores, and thirdly the sequential scan of the 
donor and acceptor was repeated. 
FRET analysis 
The ImageJ plug-in AccPbFRET (Roszik et al., 2008) was used. Following the subtraction of the 
background fluorescence of a cell-free area from the overall fluorescence intensity and the 
registration of before and after photobleaching images, FRET image analysis was performed.  
The mean fluorescence intensities of ROIs at the membrane (for cells expressing Gαq-ECFP-
Gαq) or in the cytoplasm (for cells expressing CFP-YFP, Gαq-ECFP, Gαq-ECFP-Gαq-L209 or Gαq-
ECFP-Gαq-C183) were measured in before and after bleaching donor images and used to 
calculate FRET efficiency (E) according to the following formula: 
E = 1 – (IDA/ID) 
IDA describes the normalized fluorescence intensity of the donor in presence of the acceptor 
(i.e. before acceptor photobleaching) and ID the normalized fluorescence intensity of the donor 
after acceptor photobleaching. The average of three ROI FRET efficiency measurements was 
taken to determine a cell’s overall FRET efficiency. 
Mean acceptor fluorescence after bleaching was calculated as percentage left (with 100% 
corresponding to the acceptor fluorescence intensity before photobleaching) by measuring 
YFP fluorescence intensity of three ROIs in before and after photobleaching images. 
2.2.11.3 Analysis of stress fibre formation in microinjected or infected cells 
Mean fluorescence intensity was used as a measure to impartially assess the level of stress 
fibre formation in control, RhoA-V14 and RhoA-N19 microinjected and infected cells (section 
3.2.3 and 3.3.1.4). Cells injected with TRITC alone were used as control in microinjection 
experiments, while the effect of RhoA-V14 and RhoA-N19 infections was compared to EGFP 
infected cells. TRITC and EGFP also served to identify microinjected and infected cells. Actin 
was stained with Alexa Fluor 488 phalloidin conjugate or Alexa Fluor 594 phalloidin conjugate 
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and its image was analysed together with its reporter image (TRITC or EGFP) in ImageJ. The 
reporter image was enhanced and the threshold (Image -> Adjust -> Threshold -> select 
over/under) adjusted in a way that only the injected/infected cell was spared from being 
masked in blue. Using the wand tool the cell was selected and its outline displayed by a yellow 
line. This cell outline was saved as a ROI in the ROI manager (Analyse -> Tools -> ROI Manager) 
and used to select the same area in the corresponding actin stain image. The mean 
fluorescence intensity of the actin stained cell was measured using the ROI manager. This 
procedure was repeated for all control, RhoA-V14 or RhoA-N19 injected. Results are shown as 
mean ± SEM and statistical analysis was performed in GraphPad Prism 4.0 (GraphPad 
software). For statistical comparison one-way ANOVA (including a post-hoc Bonferroni’s 
multiple comparison test) was used and significance was defined as P<0.05. 
2.2.11.4 Co-localisation analysis 
Co-localisation between ECFP-tagged Gαq and Venus-RhoA (section 3.1.5) was analysed using 
the ImageJ plug-ins: Just Another Co-localisation plug-in (JACoP; plug-in authors S. Bolte and F. 
Cordelieres; Bolte and Cordelières, 2006) and the intensity correlation analysis plug-in (plug-in 
authors T. Collins and E. Stanley; Li et al., 2004). The Pearson’s coefficient, overlap coefficient 
and Manders’ co-localisation coefficients were calculated using the JACoP plug-in and the 
intensity correlation quotient (ICQ) was calculated using the intensity correlation analysis plug-
in. Confocal images were aligned and background subtracted before co-localisation analysis. 
For the analysis of the plasma membrane region, a membrane-only ROI was drawn in ImageJ 
with the Gαq-ECFP-Gαq image as a template. The equal number of objects in each channel is a 
requirement for the overlap coefficient, so ratios between channel A (ECFP-tagged Gαq) and 
channel B (Venus-RhoA) were determined using the intensity correlation analysis plug-in. The 
normalized intensity scatter plots were drawn using the ECFP-tagged Gαq and Venus-RhoA 
intensity value pairs obtain with the intensity correlation analysis plug-in. For the intensity 
correlation analysis graphs the product of the difference of the mean (PDM) values were 
plotted against the normalized fluorescence intensity of ECFP-tagged Gαq or Venus-RhoA 
intensity; all values were obtained using the intensity correlation analysis plug-in. Whether the 
calculated ICQ was significantly different from zero, was assessed by performing a sign test 
using Excel.  
The following formulas refer to the pixel intensity values of channel A (ECFP-tagged Gαq) as Ai 
and of channel B (Venus-RhoA) as Bi, corresponding mean intensity values are represented as a 
and b. N+ve PDM is defined as the number of positive PDM values obtained and Ntotal refers to the 
total number of pixel pairs tested.  
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2.2.12 Molecular biology techniques 
2.2.12.1 Digestion of DNA with restriction enzymes 
DNA was mixed with the appropriate amount of restriction enzymes, their corresponding 
buffer (Roche, GE or NEB) and dH20 in 1.5 ml tubes and digested at 37 °C for 1–4 h. Analytical 
digests were performed in a total volume of 15 μl containing 40–1000 ng DNA. For preparative 
digests and digestions of vectors 1–3.6 μg DNA was digested in a volume of 40 μl. 5x DNA 
sample buffer was added to the digests to stop the reaction. Samples were analysed on an 
agarose gel. 
5x DNA Sample Buffer 20 % Ficoll 400 
 100 mM EDTA 
 0.25 % Bromphenol Blue 
 0.25 % Xylene Cyanol 
2.2.12.2 Dephosphorylation of vectors 
After linearization by restriction enzyme digestion, vectors were treated with alkaline 
phosphatase to prevent self-ligation. 2 U of alkaline phosphatase (Roche) and corresponding 
10x dephosphorylation buffer was added to the digestion reaction and incubated at 37 °C for 
1 h. Reactions were stopped with the addition of 5x DNA sample buffer (section 2.2.12.1). 
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2.2.12.3 Agarose gel electrophoresis 
DNA fragments were separated by horizontal agarose gel electrophoresis. Depending on 
fragment size separation was performed on 0.5 %, 0.7 %, 1.0 % or 1.3 % agarose gels. TAE 
(National Diagnostics) buffer was used for preparative gels; TBE buffer was used for analytical 
gels. The necessary amount of agarose was added to 1x TAE or 1x TBE buffer in 40 ml or 70 ml 
and dissolved by heating in the microwave. After cooling ethidium bromide was added to a 
final concentration of 0.4 μg/ml, which was identical to the amount of ethidium bromide in the 
1x TAE or 1x TBE running buffer, and the gel was poured. Samples were loaded alongside DNA 
molecular weight markers (100 bp and 1 kb DNA ladders, Invitrogen) and electrophoresis was 
performed at 50–100 V for 30 min–2 h. The DNA was visualized under UV light (365 nm for 
preparative gels, 254 nm for analytical gels) and the gels documented as prints. 
5x TBE 445 mM Tris Base 
 445 mM Boric Acid 
 10 mM EDTA 
2.2.12.4 Gel extraction of DNA 
DNA was extracted from gels with the Nucleobond Extract kit (Macherey-Nagel) according to 
manufacturer’s instructions. The required DNA fragment was excised from the gel with a 
scalpel and the gel slice was dissolved in NT1 buffer (300 μl buffer/100 mg gel) at 65 °C for 5–
10 min. The DNA was isolated by loading the sample onto a DNA binding column (silica 
membrane adsorption), followed by two washes with NT3 buffer (600 μl and 200 μl) and 
elution with 30 μl NE buffer. To increase the yield the elution was run over the column a 
second time. 
2.2.12.5 Ligation 
Dephosphorylated vector was mixed with 3 molar excess of DNA insert, 1 U T4 ligase and 
5x ligation buffer and dH2O to a final volume of 20 μl. Ligation reactions were carried out in a 
water bath at 14 °C for 2 h. 10 μl of the ligation mix was used to transform DH5α bacteria 
(section 2.2.12.7). The remaining reaction was continued to be incubated overnight and used 
in case the transformation of the 2 h ligation product did not result in sufficient numbers of 
colonies. 
5x Ligation Buffer 100 mM Tris-HCl pH 7.5 
 50 mM MgCl2 
 50  mM DTT 
 5 mM ATP 
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2.2.12.6 Competent DH5α bacteria 
DH5α bacteria were made competent for transformation using the Okayama method (Inoue et 
al, 1990). DH5α bacteria were spread onto LB plates (section 2.1.3) and incubated at 37 °C 
overnight. A single colony was picked the next morning, inoculated in 25 ml of SOB medium 
and incubated at 37 °C and 220 rpm for 6-8 h. Of this starter culture 8 ml, 6 ml and 3 ml were 
used to start three cultures of 125 ml SOB medium each. Incubation was carried out at 18 °C 
and 150 rpm overnight. Once one of the cultures reached an OD600 of 0.55 it was transferred to 
an ice water bath for 10 min; the other two cultures were discarded. Bacteria were harvested 
by centrifugation (Beckman, JA-14 rotor) at 2,500 x g and 4 °C for 10 min, resuspended in 38 ml 
ice-cold TB buffer and incubated in the ice water bath for 10 min. Bacteria were pelleted 
(Beckman, JA-14 rotor, 2,500 x g, 4 °C, 10 min) and resuspended in 10 ml ice-cold TB buffer. 
Keeping the bacteria suspension in the ice water bath and swirling it gently 750 μl of DMSO 
was added drop-wise. Bacteria were incubated in the ice water bath for 10 min before being 
aliquoted (~110 ul/ aliquot) and immediately snap-frozen in liquid nitrogen. Competent DH5α 
bacteria were stored at -80 °C and had a transformation efficiency of ≥ 3 x 107. 
SOB Medium 20 g/l Tryptone 
 5 g/l Yeast Extract 
 10 mM NaCl 
 5 mM KCl 
   pH 7.0, autoclave 
 10 mM MgCl2, sterile-filtered 
 10 mM MgSO4, sterile-filtered 
TB Buffer 10 mM MOPS 
 15 mM CaCl2 
 250 mM KCl 
   pH 6.7 
 55 mM MnCl2 
   sterilized by filtration 
2.2.12.7 Transformation of DH5α Bacteria 
Transformation of DH5α bacteria with DNA was performed according to one of the following 
protocols. 
In the short protocol, 100 μl of competent bacteria were added to plasmid DNA, which had 
been diluted in 10 μl dH2O, and mixed gently. Depending on selection criterion, transformed 
bacteria were spread either on LB-ampicillin plates (section 2.1.3; 100 μg/ml) or on 
LB-kanamycin plates (section 2.1.3; 30 μg/ml) and incubated at 37 °C overnight to allow 
colonies to grow.  
71 
 
The standard protocol was mainly used following ligations. 10 μl of the ligation product was 
mixed with 100 μl bacteria and incubated on ice for 15 min.  The bacteria were heat-shocked 
by placing them on a heat block at 37 °C for 5 min. 110 μl of pre-warmed LB medium (section 
2.1.3) was added to the bacteria, mixed gently, and the bacteria were further incubated at 
37 °C for 15 min. Transformed bacteria were plated on LB-ampicillin plates (100 μg/ml) and 
incubated at 37 °C overnight. 
The gentle protocol was used to transform DH5α bacteria with Sindbis plasmid DNA (pSIN-
EGFP, pSIN-RhoA-V14-EGFP and pSIN-RhoA-N19-EGFP) and its helper pHelper-DH-BB 
(tRNA/TE12). Bacteria were thawed on ice, mixed with DNA (diluted in 10 μl dH2O) or 5 μl of 
ligation product in pre-cooled 1.5 ml tubes and incubated on ice for 30 min. The heat-shock 
was performed by transferring bacteria to a heat block at 37 °C for 5 min. 1 ml pre-warmed 
SOC medium was added and bacteria were incubated at 37 °C and 120 rpm for 45 min. 
Bacteria were harvested by centrifugation (Eppendorf) at 2,500 x g for 6 min and resuspended 
in 110 μl SOC medium. Transformed bacteria were spread on LB-ampicillin plates (50 μg/ml) 
and incubated at 37 °C overnight. 
SOC Medium 20 g/l Tryptone  
 5 g/l Yeast Extract 
 10 mM NaCl 
 2.5 mM KCl 
   pH 7.0, autoclave 
 20 mM Glucose, sterile-filtered 
 10 mM MgCl2, sterile-filtered 
 10 mM MgSO4, sterile-filtered 
2.2.12.8 Isolating DNA from bacteria 
Isolation of plasmid DNA from small cultures 
A single colony was picked from a LB-ampicillin or LB-kanamycin plate and used to inoculate 
4.5 ml LB medium (section 2.1.3) containing the appropriate antibiotic (75–100 μg/ml 
ampicillin or 20 μg/ml kanamycin). The culture was incubated in 14 ml Falcon tubes with snap-
caps at 37 °C and 200 rpm overnight. Plasmid DNA was isolated using the NucleoSpin Plasmid 
kit (Macherey-Nagel) according to manufacturer’s instruction. Bacteria were harvested by 
centrifugation (Heraeus) at 3,200 x g for 5 min and the pellet was resuspended in 250 μl A1 
buffer and transferred to a 1.5 ml tube. 250 μl of A2 lysis buffer was added and gently mixed 
by inverting. 300 μl of A3 neutralization buffer was added, mixed and the lysate was clarified 
by centrifugation (Eppendorf) at 16,100 x g for 5 min. The DNA was bound by loading the 
supernatant onto the NucleoSpin Plasmid column (silica membrane adsorption) (Eppendorf, 
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11,000 x g, 1 min) and washed by adding 600 μl A4 wash buffer (Eppendorf, 11,000 x g, 1 min). 
The column membrane was dried by centrifugation (Eppendorf) at 11,000 x g for 2 min. The 
DNA was eluted by addition of 50 μl pre-warmed AE elution buffer (70 °C), incubation for 1 min 
and centrifugation (Eppendorf) at 11,000 x g for 1 min. 
Isolation of plasmid DNA from medium and large cultures 
Plasmid DNA was isolated using the NucleoBond PC100 or PC500 kits (Macherey-Nagel) 
according to manufacturer’s instructions. Midi-preparations (PC100) were prepared from 
40 ml cultures (high-copy plasmid protocol) or 70 ml cultures (adapted low-copy plasmid 
protocol) bacterial cultures; maxi-preparations (PC500) from 120 ml cultures (high-copy 
plasmid protocol) or 210 ml cultures (adapted low-copy plasmid protocol). 
40 ml of LB medium (section 2.1.3) containing the appropriate antibiotic (100 μg/ml ampicillin 
or 20 μg/ml kanamycin) was inoculated with a single colony picked from a LB-ampicillin or LB-
kanamycin plate and incubated at 37 °C and 200 rpm overnight. Bacteria were harvested by 
centrifugation (Hereaus) at 3,200 x g and 4 °C for 10 min and resuspended in 4 ml cold 
S1 buffer. Cells were lysed by adding 4 ml of S2 buffer and the suspension was gently mixed by 
inverting. 4 ml S3 buffer was added, gently mixed and incubated on ice for 5 min. The lysate 
was clarified by centrifugation (Heraeus, 3,200 x g, 4 °C, 5 min) and filtration of the 
supernatant through a paper filter. The supernatant was loaded onto an AX100 column (anion-
exchange chromatography), which had been pre-equilibrated with 2.5 ml N2 buffer. The 
cartridge was washed twice with 5 ml N3 buffer and the DNA was eluted with 5 ml N5 buffer. 
The eluted DNA was precipitated by adding 3.5 ml isopropanol and centrifuging (Beckman, JA-
17 rotor) at 12,000 x g and 4 °C for 30 min. The pelleted DNA was washed with 2 ml 
75 % ethanol and centrifuged (Beckman, JA-17 rotor, 12,000 x g, 4 °C, 15 min) before being air-
dried and dissolved in dH2O at a final concentration of 1 μg/μl. DNA purity and concentration 
was determined using a spectrophotometer (SmartSpec Plus, BIO-RAD or NanoDrop 1000, 
Labtech International). 
Sindbis plasmids (pSIN-EGFP, pSIN-RhoA-V14-EGFP and pSIN-RhoA-N19-EGFP) were purified 
from 70 ml bacterial cultures. LB medium containing 75 μg/ml carbenicillin was inoculated 
with a single colony or with 5 μl of a starter-culture (a single colony grown in 5 ml LB medium 
(75 μg/ml carbenicillin) at 37 °C and 200 rpm for 7 h) and grown at 37 °C and 200 rpm 
overnight. Bacteria were harvested (Heraeus, 3,200 x g, 4 °C, 10 min), resuspended in 8 ml S1 
buffer containing 2 mg/ml lysozyme and incubated on ice for 10 min. Purification was 
continued as described above, using 8 ml of S2 and S3 buffers. Column-bound DNA was 
washed three times with 4 ml N3 wash buffer and elution of DNA was carried out using 5 ml 
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pre-warmed N5 (50 °C). DNA was precipitated, washed and dissolved following the above 
protocol exactly. 
For DNA purifications using the NucleoBond PC500 kit (Macherey-Nagel) and the high-copy 
plasmid protocol, 120 ml of LB medium (100 μg/ml ampicillin) was inoculated with a single 
colony picked from a LB-ampicillin plate and grown at 37 °C and 200 rpm overnight. DNA 
purification was performed as described for 40 ml bacterial culture preparations. It differed 
only in the use of larger amounts of buffers (12 ml of S1, S2 and S3) and the removal of cell 
debris by a centrifugation of 15 min (Heraeus, 3,200 x g, 4 °C) instead of 5 min. An AX500 
column, equilibrated with 6 ml N2 buffer, was used to bind the DNA and bound DNA was 
washed twice with 16 ml N3 buffer. 15 ml of N5 buffer was used to elute DNA, which was 
precipitated by addition of 11 ml of isopropanol and centrifugation (Beckman, JA-17 rotor, 
12,000 x g, 4 °C, 30 min). DNA pellets were washed and dissolved as described above. 
Maxi-preparations of the Sindbis helper plasmid (pHelper-DH-BB (tRNA/TE12)) were 
performed using the adapted low-copy plasmid protocol described above for 70 ml cultures. 
Briefly, a 5 ml starter culture (LB medium, 75 μg/ml carbenicillin) was inoculated with a single 
colony and grown at 37 °C and 200 rpm for 7 h. 5 μl of the starter culture was used to 
inoculate 210 ml LB medium (75 μg/ml carbenicillin) and grown at 37 °C and 200 rpm 
overnight. Bacteria were harvested (Beckman, JA-14) at 3,200 x g and 4 °C for 10 min and the 
pellet was resuspended in 24 ml S1 buffer containing 2 mg/ml lysozyme and incubated on ice 
for 10 min. Purification was continued as described for 120 ml high-copy plasmid purifications, 
using 24 ml of S2 and S3 buffers. DNA bound to the AX500 column was washed twice with 
18 ml N3 buffer. Elution and precipitation of DNA was performed as described for maxi-
preparations and the DNA was dissolved in dH2O. 
Reuse of AX columns 
At times AX100 and AX500 columns were reused. Cross contamination was avoided by always 
using a cartridge for only one plasmid DNA. For direct reuse the cartridge was re-equilibrated 
with the appropriate amount of N2 buffer (2.5 ml for AX100 and 6 ml for AX500). For long term 
storage the cartridge was washed twice with dH2O and then once with 50 % ethanol; the 
cartridge was filled all the way to the top and allowed to completely run out. The cartridge was 
carefully wrapped in Parafilm and stored in its original plastic packaging at 4 °C. The cartridge 
was prepared for reuse by one rinse with dH2O and equilibration with N2 buffer as described 
above. 
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2.2.12.9 Amplification of DNA by polymerase chain reaction (PCR) 
DNA modifications 
DNA was amplified by PCR with KOD hot start polymerase (Novagen). In 0.2 ml PCR tubes, DNA 
was mixed with 1 pmol/μl of each of the two primers, 0.2 mM dNTPs, 1.5 mM MgSO4, 1x KOD 
hot start buffer and 1 U KOD hot start polymerase in a total volume of 50 μl. In a thermal 
cycler (2720, Applied Biosystems) the PCR was performed as follows: an initial denaturing step 
at 94 °C for 5 min was followed by 15 cycles of denaturing at 94 °C for 30 s, annealing at 45 °C 
for 30 s and elongation at 72 °C for 1 min, and concluded by an elongation at 72 °C for 10 min. 
The reaction was kept in the thermal cycler at 4 °C until use. 
 
 
Figure 2.2 KOD polymerase PCR. Schematic representation of the reaction conditions used to 
perform DNA modifications.  
PCR products were separated by agarose gel electrophoresis and extracted from the gel 
(section 2.2.12.3 and 2.2.12.4). Amplified DNA products were digested with appropriate 
restriction enzymes (section 2.2.12.1) and prepared for ligation by agarose electrophoresis and 
gel extraction as before. 
Single colony PCR 
Following ligations of RhoA-V14 or RhoA-N19 into pSIN-EGFP single colony PCR was performed 
to screen for recombinant plasmids. Single colonies were picked from LB-ampicillin plates and 
dissolved in 10 μl dH2O. In 0.2 ml PCR tubes, 5 μl of the dissolved colony was mixed with 
1 pmol/μl primers (P2137 and P2222), 0.2 mM dNTPs, 1.5 mM MgCl2, 1x Taq buffer and 
0.15 U Taq polymerase (Invitrogen) in a total volume of 15 μl. PCR was performed with the 
following settings: an initial denaturing step at 95 °C for 10 min was followed by 25 cycles of 
denaturing at 94 °C for 30 s, annealing at 65 °C for 30 s and elongation at 72 °C for 1 min, and 
was completed by an elongation at 70 °C for 7 min. Reactions were kept at 4 °C in the thermal 
cycler until use. PCR products were analysed by agarose gel electrophoresis (section 2.2.12.3). 
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Figure 2.3 Single colony PCR. Schematic representation of the reaction conditions used to carry 
out single colony PCR. 
2.2.12.10  Sequencing 
For sequencing reactions, 400 ng of DNA was mixed with 4 μl BigDye terminator v2.0 (Applied 
Biosystems) and 3.5 pmol of the sequencing primer and brought to a total volume of 20 μl with 
dH20. The PCR was run with the following settings in a 2720 thermal cycler (Applied 
Biosystems): an initial denaturing step at 94 °C for 30 s was followed by 25 cycles of denaturing 
at 94 °C for 30 s, annealing at 50 °C for 15 s and elongation at 60 °C for 4 min; reactions were 
then kept at 4 °C in the thermal cycler or at -20 °C until processed. 
 
Figure 2.4 Sequencing PCR. Schematic representation illustrating the reaction settings used to 
sequence DNA. 
Sequencing PCR products were precipitated with the addition of 2 μl NaAc (pH 4.6, 3 M) mixed 
with 50 μl EtOH absolute and incubation on ice for 10 min. Precipitated DNA was collected by 
centrifugation (Eppendorf) at 14,000 x g and 4 °C for 15 min, the supernatant was aspirated 
and the pellet was washed with 250 μl EtOH (75 %) and centrifuged as before. All liquid was 
aspirated and the pellet air-dried before being sent for sequencing (3100-Avant, Applied 
Biosystems). Analysis was performed with DNAstar Software (Lasergene). 
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2.2.13 Cloning strategies 
2.2.13.1 pRK5-myc-Venus-RhoA  
The fluorescent fusion protein Venus-RhoA, used for FRET experiments (section 3.1.7), was 
constructed by inserting the YFP derivative Venus into pRK5-myc-RhoA using the Bam HI site. 
Employing this cloning strategy leaves the carboxyl-terminus of RhoA, which contains a CAAX 
motif essential for plasma membrane attachment, intact. 
 
 
Figure 2.5 Cloning strategy of pRK5-myc-Venus-RhoA. The fluorophore Venus, a YFP derivative, 
was inserted between the Myc-tag and the amino-terminus of RhoA. 
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2.2.13.2 pcDNA3.1-EE-ECFP-Gαq-Q209L  
The fluorescent fusion protein Gαq-ECFP-Gαq-L209, used for FRET experiments (section 3.1.7), 
was constructed by inserting a section of Gαq that was tagged with the fluorophore ECFP 
between residues 124 and 125 into pcDNA3.1-EE-Gαq-Q209L using the Hind III and Nde I sites. 
The strategy to insert ECFP into an internal loop of Gαq was chosen to leave the amino-
terminus of Gαq intact, because these residues are essential for palmitoylation and Gβγ 
binding (Evanko et al., 2000; Chen and Manning, 2001), and are required so as to prevent 
cytosolic localization of a carboxyl-terminal tagged Gαq (Witherow et al., 2003).  
 
 
Figure 2.6 Cloning strategy of pcDNA3.1-EE-ECFP-Gαq-Q209L. Construction of constitutively 
active Gαq-ECFP-Gαq-L209 with ECFP placed between residues 124 and 125 of Gαq. 
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2.2.13.3 pSinrep5-RhoA-G14V-EGFP 
RhoA-V14 Sindbis virus, used to infect cultured hippocampal pyramidal neurons (section 3.3.3), 
was constructed by inserting constitutively active RhoA-V14 into pSinrep5-EGFP using the Xba I 
site. 
 
 
Figure 2.7 Cloning strategy of pSinrep5-RhoA-G14V-EGFP. Constitutively active RhoA-V14 was 
cloned into the Sindbis virus expression vector. nsP, nonstructural protein; PSG, subgenomic promoter 
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2.2.13.4 pSinrep5-RhoA-T19N-EGFP 
RhoA-N19 Sindbis virus, used to infect cultured hippocampal pyramidal neurons (section 
3.3.3), was constructed by inserting inactive RhoA-N19 into pSinrep5-EGFP using the Xba I site. 
 
Figure 2.8 Cloning strategy of pSinrep5-RhoA-T19N-EGFP. Inactive RhoA-N19 was cloned into 
the Sindbis virus expression vector. nsP, nonstructural protein; PSG, subgenomic promoter 
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2.2.13.5 Restriction enzyme abbreviations 
Apa I Ap 
Asp 718 K 
Bam HI B 
Cla I C 
Eco RI E 
Eco RV EV 
Hind III HIII 
Ksp I SII 
Nde I Nd 
Nhe I Nh 
Not I N 
Pst I P 
Sal I L 
Sma I M 
Sst I SI 
Xba I X 
Xho I O 
 
 
2.2.14 Electrophysiology 
2.2.14.1 Recordings in primary culture of hippocampal neurons 
3.8–5.0 MΩ borosilicate glass pipettes were pulled with a L/M-3P-A vertical puller (List 
Medical) and filled with a potassium methylsulphate (KMeSO4)-based intracellular solution. 
Whole-cell gigaseal recordings (Hamill et al., 1981) were obtained from pyramidal neurons in 
hippocampal cultures (DIV 9–16; section 3.3.2 and 3.3.3) prepared as described above (section 
2.2.1.3). Using an EPC10 patch clamp amplifier (HEKA Elektronik) and the Pulse v8.8 software 
(HEKA Elektronik) recordings were performed under visual control (Axiovert 200, Zeiss, section 
A.1.3) and pyramidal neurons were identified by their morphology. Cells, infected with RhoA-
V14 or RhoA-N19 Sindbis virus, were identified by their EGFP expression. Recordings from 
uninfected neurons served as control. Recordings were carried out at room temperature and 
cells were constantly superfused with extracellular solution (1 ml/min). In these recordings the 
liquid junction potential was 9.5 mV and not corrected. D-(-)-2-amino-5-phosphonopentanoic 
acid (APV, 25 μM), blocking NMDA receptors, and 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f) 
quinoxaline-7-sulfonamide (NBQX, 5 μM), blocking AMPA receptors, were added to the 
extracellular solution at all times to suppress excitatory network activity of the neurons. 
Intracellular Solution 135 mM KMeSO4 
 10 mM KCl 
 10 mM HEPES 
 1 mM MgCl2 
 2 mM ATP-Na 
 0.4 mM GTP-Na 
   pH 7.25–7.3 
   osmolarity 290–300 
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Extracellular Solution 140 mM NaCl 
 3.5 mM KCl 
 10 mM HEPES 
 16 mM Glucose 
 2 mM CaCl2 
 1.5 mM MgCl2 
   pH 7.4 
   osmolarity 305–310 
Ca2+-free Extracellular Solution 140 mM NaCl 
 3.5 mM KCl 
 10 mM HEPES 
 16 mM Glucose 
 5 mM MgCl2 
   pH 7.4 
   osmolarity 305–310 
Once whole-cell configuration was established, the membrane resting potential of a cell was 
read off immediately by switching to current clamp mode (without injecting any current). Only 
cells with a membrane resting potential of Vrest ≤ -50 mV were included in the analysis. In 
current clamp mode the firing activity of a cell was examined by delivering current injections in 
50 pA steps (starting with 50 pA) that lasted 1 s (Fig. 2.9). Current injections were delivered 
every 10 s and acquired traces were filtered at 2.8 kHz. 
 
Figure 2.9 Assessing the firing activity of a cell. The firing behaviour of a cell (top) was examined 
using a stimulation protocol (bottom) that delivered increasing current injections, in 50 pA steps, every 
10 s with each injecting of current lasting 1 s. In this example of a recording, only current injections of 
50 pA and 100 pA were delivered. 
The cell was then switched to voltage clamp mode and held at a holding potential of -50 mV. In 
whole-cell configuration the current will flow through a series of resistors. The resistances 
(series resistance, Rs and membrane resistance, Rin) present were calculated from the current 
response of the cell to a 5 mV hyperpolarizing step from the holding potential of -50 mV that 
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lasted 100 ms (Fig. 2.10). Traces were acquired at intervals of 4 s and were filtered at 5 kHz. 
Only cells with a series resistance of Rs < 30 MΩ and a membrane resistance of Rin > 100 MΩ 
were included in the analysis. 
 
Figure 2.10 Measuring passive membrane property of a cell. (A) The hyperpolarizing voltage step 
from -50 mV to -55 mV (Vcommand, bottom) resulted in the current trace shown (top). (B) This current 
response was used to calculate the series resistance (RS) and the membrane resistance (Rin) using Ohm’s 
law. RS was calculated by dividing the Vcommand step by the amplitude of the capacitive transient, I1. 
For Rin the Vcommand step was divided by the amplitude of the current (after reaching steady state), I2. 
2.2.14.2 sIAHP recordings in cultured hippocampal neurons 
Cells were voltage-clamped at -50 mV and sIAHP was activated by applying a depolarizing step 
to +30 mV that lasted 200 ms (Fig. 2.11A). This caused a rise in intracellular Ca2+, which was 
elicited by the opening of voltage-gated Ca2+ channels (CaV). Changes to the series resistance 
were monitored throughout by delivering a 100 ms long 5 mV hyperpolarizing step to the cell 
at the beginning of each protocol (Fig. 2.11A). This stimulating protocol was delivered at 30 s 
intervals and traces were filtered at 250 Hz. Ca2+ influx into the cells was maximized by adding 
the voltage-gated Na+ channel blocker tedrodotoxin (TTX, 0.5 μM) and the voltage-gated K+ 
channel blocker TEA (1 mM) to the bath solution. The addition of dTC (50–100 μM) to the 
extracellular solution isolated sIAHP by blocking KCa2 channels that underlie IAHP. sIAHP was 
suppressed by the application of the cyclic AMP analogue 8CPT-cAMP (100 μM, in bath 
solution) or the cholinergic agonist CCh (2.5 μM, in bath solution). 
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Figure 2.11 Example of a sIAHP recording and details of the corresponding stimulation protocol 
and current measurements. (A) Current trace (top) recorded upon delivery of the voltage clamp 
protocol shown (bottom). The protocol commenced with a hyperpolarizing step (to -55 mV for 100 ms) 
that was used to monitor series resistance (Rs), while the depolarizing step (to +30 mV for 200 ms) 
caused an influx of Ca2+ through CaV channels and activated Ca
2+-dependent sIAHP. (B) Enlarged sIAHP 
current trace indicating the measurements that were taken: amplitude (amp, mean amplitude value at 
the peak of sIAHP) and charge transfer (Q, area under the curve measured from the peak to the end of 
the trace). The dashed grey line indicates zero current. The recording was performed in the presence of 
25 μM D-(-)-2-amino-5-phosphonopentanoic acid, 5 μM 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f) 
quinoxaline-7-sulfonamide, 0.5 μM tedrodotoxin, 1 mM tetraethylammonium and 50 μM d-
Tubocurarine. 
After reaching a stable baseline, recorded sIAHP current traces were analysed by taking the 
following measurements: amplitude (amp; Fig. 2.11B, mean current value measured at the 
peak of the sIAHP trace (0.7–1.0 s after the end of the depolarisation step)) and charge transfer 
(Q; Fig. 2.11B, area under curve measured from the peak to the end of the sIAHP current trace). 
Occasionally IAHP current traces were analysed (Fig. 3.26) and mean IAHP amplitude values were 
measured ~0.1 s after termination of the depolarisation step. Stock solution of 8CPT-cAMP 
(50 mM), APV (50 mM), CCh (10 mM), dTC (20 mM), NBQX (5 mM), TEA (1 M) and TTX 
(0.2 mM) were prepared in dH2O. TEA and TTX stock solutions were stored at +4 °C and all 
other stock solutions at -20 °C. 
2.2.14.3 Data analysis and statistics 
Electrophysiological data were analysed using Igor Pro 6.2 (WaveMetrics) and statistical 
analysis was performed in GraphPad Prism 4.0 (GraphPad software). Results are shown as 
mean ± SEM. For statistical comparison paired and unpaired two-tailed Student’s t-tests and 
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one-way ANOVA (including a post-hoc Bonferroni’s multiple comparison test) were used and 
significance was defined as P<0.05. 
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3 Results 
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3.1 Investigating the interaction between the G-Protein α subunit Gαq and 
the small GTPase RhoA 
The signalling pathway mediating the suppression of sIAHP by cholinergic and glutamatergic 
agonists has been shown to involve the G-protein α subunit Gαq (Krause et al., 2002), but not 
via the classical pathway involving activation of PLCβ and Ca2+ release from IP3-sensitive stores 
or activation of PKC (Krause and Pedarzani, 2000; Sim et al., 1992). Thus this thesis examined 
whether sIAHP suppression was conveyed by other downstream effectors of Gαq, for example 
through members of the family of small GTPases (section 1.4). It focuses on the involvement of 
the small GTPase RhoA in the signalling pathway responsible for the inhibition of sIAHP by 
cholinergic and glutamatergic agonists and its association with Gαq.  
3.1.1 The G-Protein α subunit Gαq interacts with the small GTPase RhoA 
The hypothesized interaction of the G-protein α subunit Gαq and the small GTPase RhoA was 
assessed by conducting co-immunoprecipitation experiments. G-proteins and small GTPases 
cycle between GTP-bound (active) and GDP-bound (inactive) states and co-
immunoprecipitations were performed using active and inactive mutants as well as native Gαq 
and RhoA (section 2.1.1 and Fig. 2.1). Native Gαq, constitutively active Gαq-L209 and inactive 
Gαq-L209/N277 were transiently transfected into HEK293 or COS7 cells together with native 
RhoA, constitutively active RhoA-V14 or inactive RhoA-N19, all three were Myc-tagged at the 
amino terminus (section 2.1.1). Gαq, Gαq-L209, Gαq-L209/N277, RhoA, RhoA-V14 and RhoA-
N19 transfected on their own served as controls as did untransfected HEK293 cells. Protein 
expression was assessed by Western blotting using anti-Gαq/11, anti-Gaq and anti-Myc 
antibodies and the detected bands at ~40 kDa for Gαq and at ~23 kDa for Myc-tagged RhoA 
matched their predicted molecular weights (Fig. 3.1A and B, middle and lower panels 
(lysates)). 
 
 Figure 3.1 G-Protein α subunit Gαq and constitutively active Gαq-L209 interact with the small 
GTPase RhoA, constitutively active RhoA-V14 and inactive RhoA-N19. HEK293 cells (A) and COS7 cells 
(B) were transiently transfected with the various RhoA and Gαq constructs as indicated (section 2.1.1 for 
construct details). Untransfected HEK293 cells were used as control (A, lane 1). Protein expression was 
analysed by Western blotting (lysates (15 μg), middle and lower panels (A and B)) using anti-Gαq/11, anti-
Gαq and anti-Myc (targeting Myc-tagged RhoA) antibodies at a dilution of 1:1000. For co-
immunoprecipitations (A and B, upper panels), 250 μg of the lysates were incubated with 1–2 μg anti-
Myc antibody (Millipore (A) or Santa Cruz (B)) and RhoA was immunoprecipitated (IP). Proteins were 
separated on 12.5 % polyacrylamide gels, transferred to nitrocellulose membranes and immunoblotting 
(IB) was performed using anti-Gαq/11 (A, upper panel) or anti-Gαq (B, upper panel) antibodies at a 
dilution of 1:1000. (A) Representative result, n=6. The vertical grey lines show where the digital image of 
the blot was cut into sections in order to present the data of this experiment in two different figures. (B) 
Experiments were performed by J. Pitcher and a different antibody (anti-Gαq, Santa Cruz) and molecular 
weight marker was used. The anti-Gαq antibody generally resulted in high background signals and 
because the two antibodies (anti-Myc and anti-Gαq, both Santa Cruz) were raised in the same species, 
antibody chain bands (~50 kDa, upper panel) were detected. The star in the upper panels indicate co-
immunoprecipitated Gαq. 
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The small GTPase RhoA was immunoprecipitated using an anti-Myc antibody and co-
immunoprecipitation of Gαq was tested by probing with anti-Gαq/11 or anti-Gαq antibody (Fig. 
3.1A and B, upper panels). Two different Gαq antibodies (anti-Gαq/11 and anti-Gαq; section 
A.1.6) were tested in the co-immunoprecipitation experiments presented in this thesis. The 
anti-Gαq antibody resulted in high background signals and thus the anti-Gαq/11 antibody was 
preferentially used. Co-immunoprecipitations of untransfected HEK293 cell lysates and lysates 
transfected with the various constructs of RhoA or Gαq on their own did not result in the 
detection of bands when probed with anti-Gαq/11 antibody (Fig. 3.1A, upper panel, lanes 1–5) 
or anti-Gαq antibody (Fig. 3.1B, upper panel, lanes 1–5). In lysates expressing both proteins, 
Gαq and constitutively active Gαq-L209 were able to associate with RhoA and constitutively 
active RhoA-V14 as seen by the detection of bands at ~40 kDa (Fig. 3.1A, upper panel, lane 6–
9). Gαq and constitutively active Gαq-L209 also interacted with inactive RhoA-N19 (Fig. 3.1B, 
upper panel, lanes 9 and 11). Inactive Gαq-L209/N227 failed to associate with constitutively 
active RhoA-V14 as well as with inactive RhoA-N19 (Fig. 3.1B, upper panel, lanes 7 and 10). It 
was thus shown that, in a heterologous expression system, the G-protein α subunit Gαq 
interacts with the small GTPase RhoA and that this interaction relies on Gαq being active. 
                         
RhoA 
active            
RhoA-V14 
inactive        
RhoA-N19 
Gαq 
 
✓ ✓ ✓ 
active Gαq-L209 
 
✓ ✓ ✓ 
inactive Gαq-L209/N277 
 
 ✗ ✗ 
Table 3.1 Summary of Gαq and RhoA co-immunoprecipitations experiments. Co-
immunoprecipitations of the G-Protein α subunit Gαq and the small GTPase RhoA have shown that Gαq 
and constitutively active Gαq-L209 interact with RhoA, constitutively active RhoA-V14 and inactive RhoA-
N19, while inactive Gαq-L209/N277 binds neither constitutively active RhoA-V14 nor inactive RhoA-N19. 
3.1.2 Constitutively active Gαq-L209 specifically binds constitutively active RhoA-
V14, but not other small GTPases 
To test whether the interaction of the G-Protein α subunit Gαq with the small GTPase RhoA 
was specific, co-immunoprecipitations of constitutively active Gαq-L209 with other small 
GTPases were performed. COS7 cells were transiently transfected with constitutively active 
Gαq-L209 on its own or together with RhoA-V14, Rac-V12, Cdc42-V12, RalA-L61 or Arf6-L67, all 
of which were constitutively active mutants and Myc-tagged at the amino-terminus. Protein 
expression was tested by Western blotting using anti-Gαq/11 and anti-Myc antibodies and 
bands were detected at ~40 kDa for Gαq-L209 and ~21 kDa for the small GTPases (Fig. 3.2, 
middle and lower panels (lysates)). Small GTPases were immunoprecipitated using an anti-Myc 
antibody and co-immunoprecipitation of Gαq-L209 was assessed by probing with an anti-Gαq/11 
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antibody. Gαq-L209 associated specifically with RhoA-V14 and bound none of the other small 
GTPases tested (Fig. 3.2, upper panel, lane 3). 
 
Figure 3.2 Constitutively active Gαq-L209 specifically interacts with constitutively active RhoA-
V14. COS7 cells were transiently transfected with constitutively active Gαq-L209 and constitutively active 
small GTPases as indicated. 15 μg of the lysates were used to test for protein expression by Western 
blotting with anti-Gαq/11 (middle panel) and anti-Myc (lower panel) antibodies at a dilution of 1:1000. To 
immunoprecipitate (IP) Myc-tagged small GTPases 250 μg of the lysates were incubated with 1 μg anti-
Myc antibody (Santa Cruz), before being probed (IB) for associated Gαq-L209 using the anti-Gαq/11 
antibody (upper panel) at a dilution of 1:1000. Proteins were separated on 12.5 % polyacrylamide gels. 
Antibody chain bands (~50 kDa, upper panel) were detected, as the two antibodies (anti-Myc and anti-
Gαq, both Santa Cruz) used in this co-immunoprecipitation experiment were raised in the same species. 
The star indicates co-immunoprecipitated Gαq. Experiments were performed by J. Pitcher. 
3.1.3 Constitutively active RhoA-V14 specifically interacts with constitutively active 
Gαq-L209 and constitutively active Gα14-L205 
Gαq has been shown to specifically bind RhoA and this interaction led to the investigation of 
whether RhoA can also associate with other Gα subunits. To perform these co-
immunoprecipitations COS7 cells were transiently transfected with constitutively active RhoA-
V14 and constitutively active, Glu Glu (EE) epitope-tagged Gαq-L209 (Fig. 2.1), Gα11-L209, Gα14-
L205, Gα15-L212, Gα12-L231 or Gα13-L226. Expression of the proteins was assessed by Western 
blotting using anti-Myc and anti-EE antibodies and bands of the expected molecular weights 
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were detected (Fig. 3.3, middle and lower panels (lysates)). Constitutively active RhoA-V14 was 
immunoprecipitated with anti-Myc antibody and its interaction with constitutively active 
Gαq-L209 as well as constitutively active Gα14-L205 was determined after probing with an anti-
EE antibody (Fig. 3.3, upper panel, lane 3 and 7). 
 
Figure 3.3 Constitutively active RhoA-V14 interacts with constitutively active Gαq-L209 and 
constitutively active Gα14-L205. COS7 cells were transiently transfected with RhoA-V14 and Gα subunits 
as indicated and Western blotting using anti-Myc and anti-EE antibodies at a dilution of 1:1000 assessed 
the expression of the proteins (lysates (15 μg), middle and lower panels). To immunoprecipitate (IP) 
Myc-tagged RhoA-V14 250 μg of the lysates were incubated with 1 μg anti-Myc antibody (Santa Cruz). 
Associated Gα subunits were detected by probing (IB) with an anti-EE antibody at a dilution of 1:1000 
(upper panel). Proteins were separated on 12.5 % polyacrylamide gels. Antibody chain bands (~50 kDa, 
upper panel) were detected, as the two antibodies (anti-Myc and anti-Gαq, both Santa Cruz) used in this 
co-immunoprecipitation experiment were raised in the same species. The star indicates co-
immunoprecipitated Gαq and the arrow the correct molecular weight of Gα subunits (40 kDa). 
Experiments were performed by J. Pitcher. 
3.1.4 Investigating the interaction between G-protein α subunit Gαq and small 
GTPase RhoA in rat brain lysates 
Following the successful co-immunoprecipitation of G-Protein α subunit Gαq with the small 
GTPase RhoA in a heterologous expression system, their interaction was studied in native 
tissue. Lysates of rat brain were prepared and the presence of endogenous proteins was 
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assessed by Western blotting. Western blots of brain lysate were probed with anti-Gαq/11 
antibody and showed a band at ~40 kDa being similar to the band of Gαq-L209 expressed in 
HEK293 cells and the known molecular weight of Gαq (Fig. 3.4A). The anti-RhoA antibody was 
shown to detect RhoA expressed in HEK293 cells just like the anti-Myc antibody did (compare 
Fig. 3.4B, right panel to Fig. 3.1A). When it was used to probe for endogenous RhoA in brain 
lysates it detected a band at ~21 kDa corresponding with the molecular weight of RhoA (Fig. 
3.4B, left panel). But, while endogenous Gαq was readily detected by the anti-Gαq/11 antibody, 
the detection of RhoA with anti-RhoA antibody required the use of far greater amounts of 
brain lysate (Fig. 3.4). 
 
Figure 3.4 Western blots of brain and HEK293 cell lysates using anti-Gαq/11 and anti-RhoA 
antibodies. Cell lysates were separated on 12 % polyacrylamide gels, transferred to nitrocellulose 
membranes and probed with either anti-Gαq/11 (A) or anti-RhoA antibodies (B). (A) 30 μg of brain lysate 
and 15 μg of HEK293 cell lysate expressing Gαq-L209 were separated by SDS-PAGE and immunoblotting 
was performed using anti-Gαq/11 antibody at a dilution of 1:500. (B) Western blots of RhoA used 110 μg 
of brain lysate and 15 μg of HEK293 cell lysate expressing RhoA and were probed using anti-RhoA 
antibody at a dilution of 1:200. Western blots are representative of at least three separate experiments. 
Co-immunoprecipitations of endogenous Gαq and RhoA were performed by incubating brain 
lysate with anti-RhoA antibody before probing for Gαq using the anti-Gαq/11 antibody. No bands 
were detected at ~40 kDa, indicating that Gαq was probably not associated with RhoA (data 
not shown). Co-immunoprecipitations were repeated using anti-Gαq/11 antibody to precipitate 
Gαq and probing for bound RhoA with anti-RhoA antibody, but no band was detected at the 
expected molecular weight of RhoA at ~21 kDa (data not shown). To test the effectiveness of 
the anti-RhoA antibody in co-immunoprecipitation experiments, both versions of co-
immunoprecipitations described above for brain lysates were also performed with HEK293 cell 
lysates co-expressing Gαq and RhoA. Once more, no bands were detected at the expected 
molecular weights in either experiment (data not shown). To test whether RhoA was 
precipitated in the first place, immunoprecipitations of RhoA were probed with anti-RhoA 
antibody and the absence of bands established that the anti-RhoA antibody could not 
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immunoprecipitate RhoA (data not shown). Thus, due to the unavailability of an anti-RhoA 
antibody with sufficient avidity, the interaction of the G-protein α subunit Gαq and the small 
GTPase RhoA shown in heterologous expression systems could not be verified in native tissue. 
3.1.5 Expression and co-localisation of ECFP-tagged Gαq and Venus-tagged RhoA in 
HEK293 cells 
To study the interaction of the G-Protein α subunit Gαq and the small GTPase RhoA by FRET, 
fluorescent fusion proteins were constructed. The choice for the generation of fluorescent 
fusion proteins was based on our experience with CFP/YFP tags in FRET experiments 
(Kerschensteiner et al., 2005) and on the fact that the anti-RhoA antibody was found to be too 
insensitive in previous experiments. Gαq and RhoA were tagged with GFP variants and in the 
case of Gαq several ECFP-tagged fusion proteins were constructed. The ECFP-tag was placed 
either at the carboxyl-terminus of Gαq (Witherow et al., 2003) or between residues 124 and 
125 in a loop of the α-helical domain (Fig. 1.6 and Fig. 2.1) (Hughes et al., 2001; Witherow et 
al., 2003). The reason to insert ECFP into an internal loop of Gαq was due to reports of a 
cytosolic localisation of the carboxyl-terminal tagged Gαq (Witherow et al., 2003). In addition 
to the native Gαq fusion proteins, two constitutively active Gαq constructs containing the ECFP-
tag between residues 124 and 125 were constructed (Gαq-ECFP-Gαq-L209; section 2.2.13 and 
Gαq-ECFP-Gαq-C183; Dowal et al., 2006).  
RhoA contains a CAAX motif at the carboxyl-terminus, which is prenylated and the lipid 
modification allows the small GTPase to anchor to the plasma membranes (Wennerberg and 
Der, 2004). Given the importance of an intact carboxyl-terminus for the plasma membrane 
localisation of RhoA (Adamson et al., 1992b; Robertson et al., 1995), the RhoA fusion protein 
was constructed by inserting the fluorophore Venus, a YFP-derivative, between the Myc-tag 
and the amino-terminus of RhoA (section 2.2.13). A constitutively active Venus-tagged RhoA 
construct was not constructed, since the over-expression of active RhoA was expected to lead 
to gross morphological changes like cell rounding and blebbing (Paterson et al., 1990). 
To assess their expression and localisation the constructed Gαq and RhoA fusion-proteins were 
transiently transfected into HEK293 cells. In addition to the confocal image, panels A–E of 
Fig. 3.5 show a graph underneath plotting the fluorescence intensity along the line indicated in 
the image. Carboxyl-terminal tagged Gα-ECFP was evenly distributed throughout the 
cytoplasm of HEK293 cells, which can also be seen in the line plot (Fig. 3.5A). This cytosolic 
localisation of Gαq-ECFP resembles the distribution previously reported (Witherow et al., 
2003). Loop-tagged Gαq-ECFP-Gαq was localised almost exclusively at the cell membrane with 
only limited expression in the cytoplasm, as clearly illustrated by the distribution plot 
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(Fig. 3.5B). In contrast, the constitutively active Gαq-ECFP-Gαq-L209 and Gαq-ECFP-Gαq-C183 
were localised throughout the cytoplasm, even though they were both loop-tagged (Fig. 3.5C 
and D). Thus the position of the ECFP-tag was not the only factor influencing the localisation of 
Gαq. Any potential membrane signal in cells expressing Gαq-ECFP-Gαq-L209 or Gαq-ECFP-Gαq-
C183 was not distinguishable from the expression in the cytoplasm. HEK293 cells expressing 
Gαq-ECFP-Gαq-C183 displayed clusters of higher fluorescence intensity (Fig. 3.5D) that were 
not observed in Gαq-ECFP-Gαq-L209 expressing cells (Fig. 3.5C). There was hardly any signal 
above background noise in the nucleus in any of the ECFP-tagged Gαq transfected cells.  
 
Figure 3.5 Localisation of ECFP-tagged Gαq and Venus-tagged RhoA in HEK293 cells. HEK293 
cells were transfected with ECFP-tagged Gαq or Venus RhoA as indicated. Confocal images and line scans 
of representative cells are shown. Carboxyl-terminal tagged Gαq-ECFP was distributed throughout the 
cytoplasm (A), while the loop-tagged Gαq-ECFP-Gαq was localised at the cell membrane (B). Both 
constitutively active and loop-tagged Gαq, Gαq-ECFP-Gαq-L209 (C) and Gαq-ECFP-Gαq-C183 (D), were 
localised in the cytoplasm with no distinguishable membrane signal. Venus-RhoA was distributed 
throughout the cytoplasm (E). The fluorescence intensity plots below the images represent line scans 
through the cells along the indicated bars; the x-axis corresponds to 10 μm and the y-axis represents 
fluorescence intensity. Scale bars 10 μm.  
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HEK293 cells expressing Venus-RhoA showed a distribution throughout the cytoplasm with no 
distinguishable signal at the cell membrane or expression in the nucleus, which is supported by 
the line plot (Fig. 3.5E). This predominantly cytosolic expression of RhoA was reported 
previously (Adamson et al., 1992b; Michaelson et al., 2001) and demonstrates that a Venus tag 
at the amino-terminus does not interfere with the localisation of RhoA. 
Confocal images of Gαq and RhoA expressing HEK293 cells were also used to study the co-
distribution of their signals by performing co-localisation analysis. Co-localisation of ECFP-
tagged Gαq and Venus-RhoA was assessed in HEK293 cells transiently transfected with Gαq-
ECFP, Gαq-ECFP-Gαq, Gαq-ECFP-Gαq-L209 or Gαq-ECFP-Gαq-C183 in combination with Venus-
RhoA. The distribution of the expressed fusion proteins was not influenced by the co-
transfection. Gαq-ECFP was distributed throughout the cytoplasm (Fig. 3.6A) and Gαq-ECFP-Gαq 
displayed membrane localisation (Fig. 3.6D), while constitutively active Gαq-ECFP-Gαq-L209 
(Fig. 3.6G) and Gαq-ECFP-Gαq-C183 (Fig. 3.6J) localised in the cytoplasm. Expression of Venus-
RhoA was observed throughout the cytoplasm (Fig. 3.6B, E, H and K). Co-localisation of Gαq 
and RhoA was analysed using the Just Another Co-localisation Plug-in (JACoP) and the intensity 
correlation analysis plug-in in ImageJ. Co-localisation was quantified by calculating the 
Pearson’s coefficient (Manders et al., 1992), the overlap coefficient and Manders’ M1 and M2 
coefficients (Manders et al., 1993) and the more recently developed ICQ (Li et al., 2004) (Table 
3.2). Scatter plots (Fig. 3.6C, F, I and L) were used to study co-localisation graphically by 
plotting the intensity value of a pixel in one channel against the intensity of the corresponding 
pixel in the other channel. A pixel’s x-coordinate corresponds to its intensity value in channel A 
(ECFP-tagged Gαq), while its intensity value in channel B (Venus-RhoA) is used as the y-
coordinate. Complete co-localisation would be represented by a diagonal line, while exclusion 
would result in a scatter plot displaying two distinct dot clouds along the x- and y-axes. Thus 
while scatter plots can give some insight into the degree of co-localisation of two proteins, 
only the use of co-localisation coefficients allow its quantification. 
The Pearson’s coefficient uses the intensity values of the pixels in a dual-colour image, as 
displayed in the scatter plot, to estimate the strength of their association. It ranges from -1 to 
1, with -1 being complete negative correlation, 0 indicating absence of correlation and 1 
complete positive correlation, while conclusions from mid-range values (-0.5 – 0.5) cannot be 
drawn. The scatter plots of Gαq-ECFP and Gαq-ECFP-Gαq-L209 with Venus-RhoA show dot 
clouds that display a good percentage of co-localised pixels along the diagonal (Fig. 3.6C and I). 
This observation was substantiated by a Pearson’s coefficient of 0.791 for Gαq-ECFP and 
Venus-RhoA (Fig. 3.6A, B) and 0.725 for Gαq-ECFP-Gαq-L209 and Venus-RhoA (Fig. 3.6G, H) 
indicating strong correlation. The scatter plot of Gαq-ECFP-Gαq-C183 with Venus-RhoA 
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(Fig. 3.6L) implied a weaker correlation, which was confirmed by a Pearson’s coefficient of 
0.578 (Fig. 3.6J, K). In cells expressing Gαq-ECFP-Gαq with Venus-RhoA (Fig. 3.6D, E) the 
cytosolic signal of Venus-RhoA led to a dot cloud along the y-axis of the scatter plot (Fig. 3.6F) 
and a weak Pearson’s coefficient of 0.470. Therefore analysis of these cells was restricted to a 
membrane-only region, for which a ROI (membrane-only) was created in ImageJ using the Gαq-
ECFP-Gαq image as a template. In the scatter plot of the membrane region (Fig. 3.6f) the 
deflection towards the y-axis was reduced displaying more co-localised pixels along the 
diagonal and a Pearson’s coefficient of 0.778 indicated strong correlation (Fig. 3.6d, e).  
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Figure 3.6 Co-localisation analysis of ECFP-tagged Gαq and Venus-tagged RhoA in HEK293 cells. 
Representative confocal images of HEK293 cells co-transfected with Gαq-ECFP and Venus-RhoA (A, B), 
Gαq-ECFP-Gαq and Venus-RhoA (D, E), Gαq-ECFP-Gαq-L209 and Venus-RhoA (G, H) or Gαq-ECFP-Gαq-C183 
and Venus-RhoA (J, K) are shown. Cells expressing Gαq-ECFP-Gαq and Venus-RhoA the membrane-only 
region was analysed separately (d, e). Normalized scatter plots displaying the pixel intensity values of 
both channels plotted against one another (C, F, I and L), representing a method of visualising the 
degree of correlation between two proteins, in which a diagonal line would represent complete co-
localisation. Scale bars 10 μm. 
97 
 
The Pearson’s coefficient provides information about the correlation of intensity values but 
the degree of overlapping signals is more reliably described by the overlap coefficient. It is 
based on Pearson’s coefficient but the mean intensities are removed from the equation 
(section 2.2.11.4). The overlap coefficient ranges from 0 (no overlap) to 1 (complete co-
localisation) and therefore gives the percentage of overlapping pixels. However, results from 
the overlap coefficient only provide valuable information when the number of objects in each 
channel is equal (i.e. a channel A (ECFP-tagged Gαq):channel B (Venus-RhoA) ratio of one). The 
overlap coefficient of Gαq-ECFP with Venus-RhoA (Fig. 3.6A, B) was 0.814 indicating co-
localisation of the two proteins, in agreement with the results obtained from the Pearson’s 
coefficient. However, the channel A:channel B ratio of 0.775 limited the validity of the 
calculated overlap coefficient. The same was observed with other Gαq and RhoA combinations: 
the overlap coefficient of Gαq-ECFP-Gαq with Venus-RhoA was 0.521 (Fig. 3.6D, E; channel 
A:channel B ratio of 0.739), of Gαq-ECFP-Gαq-L209  with Venus-RhoA 0.752 (Fig. 3.6G, H; ratio 
0.662) and of Gαq-ECFP-Gαq-C183 with Venus-RhoA 0.634 (Fig. 3.6J, K; ratio 0.801). Only the 
analysis of the membrane-only ROI for Gαq-ECFP-Gαq with Venus-RhoA resulted in an equal 
channel A:channel B ratio (Fig. 3.6d, e; 0.938) and therefore allowed the use of the overlap 
coefficient, which was 0.781 and supported the co-localisation indicated by Pearson’s 
coefficient. 
Manders’ coefficients M1 and M2, ranging from 0 (no overlap) to 1 (complete co-localisation), 
quantify the proportion of signals in one channel that coincide with above zero intensity 
signals in the second channel. Manders’ coefficients M1 and M2 are thus suitable for 
quantifying co-localisation in images displaying unequal number of particles in the two 
channels. The analysis of Gαq-ECFP with Venus-RhoA (Fig. 3.6A, B) resulted in M1 (the amount 
of Gαq overlapping RhoA) and M2 (the amount of RhoA overlapping Gαq) coefficients of 0.919 
and 0.933 and thus indicated co-localisation of the two proteins. A similarly strong correlation 
was observed for Gαq-ECFP-Gαq-L209 with Venus-RhoA (Fig. 3.6G, H) with M1 and M2 
coefficients of 0.895. On the other hand, the weaker correlation between Gαq-ECFP-Gαq-C183 
and Venus-RhoA (Fig. 3.6J, K) was indicated by M1 and M2 coefficients of 0.718 and 0.662. M1 
and M2 coefficients calculated for Gαq-ECFP-Gαq with Venus-RhoA (Fig. 3.6D, E) were 0.790 
and 0.704, while the analysis of its membrane-only ROI (Fig. 3.6d, e) produced M1 and M2 
coefficients of 0.996 and 0.948 indicating almost complete co-localisation of both proteins at 
the membrane. 
The intensity correlation analysis is based on the assumption that if two proteins co-localise 
their signal intensities would deviate from the mean intensity in synchrony, but would change 
in opposite directions if they do not. In a dual-channel image the signal intensity of each pixel 
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pair is tested for its deviation from the mean and the ICQ is calculated by dividing the number 
of pairs, whose PDM was positive, by the total number of pixel pairs (section 2.2.11.4; Li et al., 
2004). 0.5 is subtracted from this value to produce an ICQ ranging from -0.5 to 0.5, with -0.5 
corresponding to exclusion and 0.5 to co-localisation. Plotting the normalized channels’ 
intensity against the PDM produces a graph that allows the identification of co-localisation 
(Fig. 3.7). Dots on the right side (x > 0) of the graph represent co-localisation, while pixels on 
the left (x < 0) indicate exclusion (Fig. 3.7A). The ICQ of Gαq-ECFP with Venus-RhoA was 0.364 
(Psign test< 0.001; the sign test was used to assess if PDM values were significantly different from 
zero (Li et al., 2004)) and that of Gαq-ECFP-Gαq-L209 with Venus-RhoA was 0.302 (Psign 
test< 0.001), which corresponded with the strong correlation determined by the other co-
localisation coefficients and was also seen in the intensity correlation analysis graphs (Fig. 3.7B 
and D). An ICQ of 0.265 (Psign test< 0.001) was calculated for Gαq-ECFP-Gαq-C183 with Venus-
RhoA (Fig. 3.7E), which still indicates a strong covariance of the channels’ signal intensities and 
thus co-localisation. Co-localisation was also determined in the case of Gαq-ECFP-Gαq with 
Venus-RhoA (the calculated ICQ was 0.256 (Psign test< 0.001); Fig. 3.7C), while the analysis of its 
membrane-only ROI produced an ICQ of 0.090 (Psign test< 0.001; Fig. 3.7c) indicating only 
moderate covariance (Khanna et al., 2006). 
 
 Figure 3.7 Co-localisation analysis of ECFP-tagged Gαq and Venus-tagged RhoA in HEK293 cells 
using intensity correlation analysis. (A) The graph was adapted from Bolte and Cordelieres, 2006 and 
gives details on how to interpret results obtained with the intensity correlation analysis. A dot cloud on 
the positive side of the x-axis (x>0) signifies co-localisation, while pixels on the negative side (x<0) stand 
for exclusion. The representations of (B) Gαq-ECFP with Venus-RhoA, (D) Gαq-ECFP-Gαq-L209 with 
Venus-RhoA and (E) Gαq-ECFP-Gαq-C183 with Venus-RhoA display the majority of pixels on the right side 
of the x=0 line indicating the co-localisation of Gαq and RhoA. (C) Due to the localisation of the two 
proteins (see Fig. 3.6D and E) the case of Gαq-ECFP-Gαq with Venus-RhoA is more complex. The pixel 
cloud representing Gαq-ECFP-Gαq is situated mainly on the positive side of the x-axis, while the Venus-
RhoA cloud also displayed dots on the left side of the graph representing pixels that are not co-localised. 
(c) The analysis of the membrane-only Gαq-ECFP-Gαq with Venus-RhoA resulted in dot clouds being 
concentrated around the centre of the graph with some deflection towards the positive side of the x-
axis. 
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A summary of the co-localisation analysis is displayed in Table 3.2. 
 Pearson’s 
Coefficient 
Manders’ 
Overlap 
Coefficient 
Channel A: 
Channel B 
ratio 
Manders’ 
M1 
Coefficient - 
ECFP 
Manders’  
M2 
Coefficient - 
Venus 
Intensity 
Correlation 
Quotient 
(ICQ) 
Gαq-ECFP  
+ Venus-RhoA 
0.791 
± 0.025 
0.814 
± 0.025 
0.775 
± 0.084 
0.919 
± 0.016 
0.933 
± 0.020 
0.364 
± 0.024 
Gαq-ECFP-Gαq 
+ Venus-RhoA 
0.470 
± 0.060 
0.521 
± 0.045 
0.739 
± 0.078 
0.790 
± 0.056 
0.704 
± 0.082 
0.256 
± 0.028 
Gαq-ECFP-Gαq 
+ Venus-RhoA 
(membrane-only) 
0.778 
± 0.032 
0.781 
± 0.031 
0.938 
± 0.023 
0.996 
± 0.003 
0.948 
± 0.023 
0.090 
± 0.015 
Gαq-ECFP-Gαq- 
L209 
+ Venus-RhoA 
0.725 
± 0.028 
0.752 
± 0.026 
0.662 
± 0.078 
0.895 
± 0.047 
0.895 
± 0.023 
0.302 
± 0.026 
Gαq-ECFP-Gαq-
C183 
+ Venus-RhoA 
0.578 
± 0.044 
0.634 
± 0.030 
0.801 
± 0.046 
0.718 
± 0.035 
0.662 
± 0.021 
0.265 
± 0.017 
Table 3.2 Quantitative analysis of the co-localisation of the G-protein α subunit Gαq and the 
small GTPase RhoA in HEK293 cells. The expression of each ECFP-tagged Gαq in combination with 
Venus-RhoA was analysed for co-localisation by calculating the Pearson’s -, overlap -, Manders’ M1 and 
M2 coefficients and the intensity correlation quotient using the JACoP and intensity correlation analysis 
plug-ins in ImageJ (section 2.2.11.4). For cells expressing Gαq-ECFP-Gαq and Venus-RhoA a 
membrane-only ROI was also analysed. Results from the overlap coefficient analysis are reported, 
however, only Gαq-ECFP-Gαq and Venus-RhoA (membrane-only) displayed an equal number of particles 
in both channels, while the ratio in all other cases was ≤0.800. Mean values ± SEM are presented, n=5 
(number of cells analysed from multiple transfections). 
3.1.6 ECFP-tagged Gαq interacts with Venus-tagged RhoA 
Whether the fusion proteins ECFP-tagged Gαq and Venus-tagged RhoA retained their ability to 
interact was tested by co-immunoprecipitations. HEK293 cells were transiently transfected 
with Gαq-ECFP-Gαq or constitutively active Gαq-ECFP-Gαq-L209 in combination with Venus-
RhoA, which was also Myc-tagged (section 2.1.1). Gαq-ECFP-Gαq, Gαq-ECFP-Gαq-L209 and 
Venus-RhoA transfected on their own served as controls. Protein expression was assessed by 
Western blotting using anti-Gαq/11 and anti-Myc antibodies, which detected bands at the 
expected molecular weights of ~67 kDa for Gαq-ECFP-Gαq and Gαq-ECFP-Gαq-L209 (Fig. 3.8, 
middle panel (lysates), lanes 3–6) and of ~49 kDa for Venus-RhoA (Fig. 3.8, lower panel 
(lysates), lanes 2, 5 and 6). The detection of multiple bands in lysates expressing Venus-RhoA 
(Fig. 3.8, lower panel (lysates), lanes 2, 5 and 6) was reduced by denaturing the protein at 95 °C 
for 5 min (instead of 60 °C for 30 min), but continued to be observed especially in lysates co-
expressing Venus-RhoA and Gαq-ECFP-Gαq-L209. Multiple bands were also detected in Gαq-
ECFP-Gαq-L209 lysate and to a lesser extent in Gαq-ECFP-Gαq (Fig. 3.8, middle panel (lysates), 
lanes 3–6), but were independent of denaturing conditions. Co-immunoprecipitations were 
performed using an anti-Myc antibody to immunoprecipitate Venus-RhoA and Western blots 
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were probed with anti-Gαq/11 antibody. As expected, no bands were detected in 
immunoprecipitations of lysates of untransfected HEK293 cells or lysates expressing Venus-
RhoA, Gαq-ECFP-Gαq or Gαq-ECFP-Gαq-L209 on their own (Fig. 3.8, upper panel, lanes 1–4). 
Immunoprecipitations of lysates co-expressing both proteins showed that Gαq-ECFP-Gαq and 
Gαq-ECFP-Gαq-L209 were co-immunoprecipitated with Venus-RhoA (Fig. 3.8, upper panel, 
lanes 5 and 6). This shows that the interaction between the G-Protein α subunit Gαq and the 
small GTPase RhoA was not hindered by tagging the proteins with GFP variants. 
 
Figure 3.8 Gαq-ECFP-Gαq and constitutively active Gαq-ECFP-Gαq-L209 interact with Venus-
RhoA. HEK293 cells were transiently transfected with Venus-tagged RhoA and ECFP-tagged Gαq as 
indicated (see section 2.1.1 for construct details). Untransfected HEK293 cells were used as control (lane 
1). Protein expression was analysed by Western blotting (lysates (15 μg), middle and lower panels) using 
anti-Gαq/11 and anti-Myc (targeting Myc-tagged RhoA) antibodies at a dilution of 1:1000. For co-
immunoprecipitations (upper panel), 250 μg of the lysates were incubated with 1–2 μg anti-Myc 
antibody (Millipore (this presented experiment) or Santa Cruz) and Venus-RhoA was 
immunoprecipitated (IP). Proteins were separated on 12.5 % polyacrylamide gels, transferred to 
nitrocellulose membranes and immunoblotting (IB) was performed using anti-Gαq/11 antibody at a 
dilution of 1:1000. The vertical grey lines show where the digital image of the blot was cut into sections 
in order to present the data of this experiment in two different figures. The star indicates co-
immunoprecipitated Gαq and the arrows specify the correct molecular weights of Gαq-ECFP-Gαq, Gαq-
ECFP-Gαq-L209, and Venus-RhoA. Representative result, n=6. 
102 
 
3.1.7 Assessment of the interaction between ECFP-tagged Gαq and Venus-RhoA in 
HEK293 cells using FRET 
Results from the co-localisation studies and co-immunoprecipitation experiments indicate an 
interaction between the small GTPase RhoA and the G-protein α subunit Gαq, potentially 
involving them in a common signalling pathway leading to the suppression of sIAHP. In order to 
obtain an additional line of evidence to support this interaction, FRET experiments were 
performed. FRET occurs only when donor and acceptor fluorophores are located in close 
proximity (<10 nm), thus operating over a distance the size of proteins. The detection of a FRET 
signal is considered equivalent to direct protein interaction. FRET is the non-radiative transfer 
of energy from a donor fluorophore to an acceptor fluorophore such that excitation of a donor 
fluorophore leads to the emission of acceptor fluorescence. For FRET to occur certain 
requirements must be met. First the emission spectrum of the donor must overlap with the 
absorption spectrum of the acceptor, secondly the fluorophore dipoles have to be orientated 
parallel to one another and thirdly donor and acceptor must be no more than 10 nm apart 
(Vogel et al., 2006). Acceptor photobleaching is a widely accepted method to measure FRET, 
and examines the donor fluorescence before and after bleaching of the acceptor using 
conventional confocal microscopy without the need for additional equipment (fluorescence 
lifetime imaging microscopy (FLIM)-FRET) or extensive controls to account for potential cross-
talk and image processing (Sensitized Emission). In acceptor photobleaching FRET is present 
when the donor fluorophore shows an increase in fluorescence upon the destruction of the 
acceptor fluorophore (de-quenching), since the donor-acceptor energy transfer can no longer 
take place.  
First the acquisition settings of the confocal microscope were established to ensure that ECFP-
tagged Gαq and Venus-RhoA were properly visible and to prevent potential cross-talk between 
the two channels. HEK293 cells were either transfected with Gαq-ECFP-Gαq (Fig. 3.9A and B) or 
Venus-RhoA on their own (Fig. 3.9C and D) or together (Fig. 3.9E and F) and images were 
acquired using the same laser levels and photomultiplier tube (PMT) settings used during FRET 
experiments. In the CFP channel, CFP was excited with the 458 nm laser line and the PMT set 
to collect CFP emission between 462–500 nm, while the YFP channel uses the 514 nm laser line 
to excite of YFP/Venus with the PMT being set to 520–600 nm (section 2.2.11.2 and A.1.3). 
With these settings the chance of cross-talk was minimized, because the slight excitation of 
Venus/YFP by the 458 nm laser line (< 10 % of peak excitation efficiency) is minimally collected 
(< 5 %) by the CFP PMT and the excitation of CFP by the 514 nm laser line is low (< 1 %) in the 
first place (Karpova et al., 2003). Cells expressing Gαq-ECFP-Gαq alone were visible in the CFP 
channel (Fig. 3.9A), but not in the YFP channel (Fig. 3.9B). On the other hand Venus-RhoA was 
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only detected in the YFP channel, but not in the CFP channel (Fig. 3.9C and D). HEK293 cells 
expressing both proteins were clearly visible in both channels (Fig. 3.9E and F). 
 
Figure 3.9 Confocal imaging configurations used for FRET experiments prevent cross-talk 
between Gαq-ECFP-Gαq and Venus-RhoA. HEK293 cells were transfected with Gαq-ECFP-Gαq (A and B), 
with Venus-RhoA (C and D) or were co-transfected with both constructs (E and F). Confocal images were 
acquired using the same settings and protocol as for FRET experiments. Cells expressing only Gαq-ECFP-
Gαq are visible in the CFP channel (A) without any cross-talk in the YFP channel (B). The same was true 
for Venus-RhoA expressing cells, which were visible in the YFP channel (D), but not in the CFP channel 
(C). Cells expressing Gαq-ECFP-Gαq as well as Venus-RhoA were detected in both channels (E and F). 
Scale bars 10 μm. 
Control FRET experiments were performed in HEK293 cells transfected with a CFP-YFP dimer 
(section 2.1.1). The dimer was constructed by inserting enhanced YFP (EYFP) into pECFP-N1 
using the XhoI and BamHI sites of the multiple cloning site, yielding a CFP-YFP fusion protein 
(Benians et al., 2005). FRET experiments were carried out using Leica’s LAS AF software 
acceptor photobleaching wizard (section 2.2.11.2). Sequential scans of CFP (donor) and YFP 
(acceptor) were acquired before the acceptor was bleached by repeated scans with increased 
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laser power at 514 nm. The bleaching phase was followed by a second sequential scan of CFP 
and YFP. Confocal images of a HEK293 cell expressing the CFP-YFP dimer are presented before 
and after photobleaching (Fig. 3.10A). Acceptor photobleaching was performed in the area 
indicated by the square (Fig. 3.10A, upper right panel) and the destruction of the YFP 
fluorophore was demonstrated by plotting YFP fluorescence intensity against bleaching steps 
(Fig. 3.10B). YFP fluorescence intensity was plotted as percentage left with 100 % 
corresponding to the intensity measured at the first bleaching step. Mean acceptor 
fluorescence after photobleaching was 9.8 ± 1.1 %. To calculate FRET efficiencies CFP 
fluorescence intensities in before and after photobleaching images were measured in three 
cytosolic ROIs in each cell; the average of which accounted for a cell’s overall FRET efficiency. 
The detected FRET of the CFP-YFP fusion protein expressed in HEK293 cells amounted to 
E = 21.0 ± 1.4 %, n=20 (Fig. 3.10C).  
 
Figure 3.10 FRET in CFP-YFP dimer expressing HEK293 cells. As control, HEK293 cells were 
transfected with CFP-YFP and FRET was assessed by performing acceptor photobleaching experiments. 
(A) Confocal images of a representative cell expressing YFP (upper panels) and CFP (lower panels) before 
and after photobleaching. Acceptor photobleaching was carried out in the area of the cell indicated by 
the square. Scale bar 10 μm. (B) Bleaching of the acceptor was achieved by repeatedly scanning the 
defined area with high laser power at 514 nm. Plotting the YFP fluorescence intensity of this area against 
the bleaching steps illustrates the destruction of the YFP fluorophores. (C) FRET efficiency (E) was 
calculated using the CFP fluorescence intensities, measured in three cytosolic regions of interest in each 
cell, before (IDA) and after (ID) acceptor photobleaching according to the following formula: E = 1- (IDA/ID) 
(section 2.2.11.2). FRET detected with the CFP-YFP dimer was E = 21.0 ± 1.4 %, n=20 (number of cells 
analysed from multiple transfections). Mean values ± SEM are presented. 
Interaction between ECFP-tagged Gαq and Venus-RhoA was examined using the FRET acceptor 
photobleaching method tested on the CFP-YFP dimer control. HEK293 cells were transfected 
with Gαq-ECFP, constitutively active Gαq-ECFP-Gαq-L209 or constitutively active Gαq-ECFP-Gαq-
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C183 in combination with Venus-RhoA. Confocal images of ECFP-tagged Gαq and Venus-RhoA 
before and after photobleaching were acquired (Fig. 3.11A, C and E) and the indicated area of 
the cells was repeatedly scanned to bleach the acceptor fluorophore Venus (Fig. 3.11B, D and 
F). The application used to perform acceptor photobleaching experiments did not allow for any 
intervention during the acquisition process and therefore the number of bleaching steps had 
to be estimated at the start of an experiment. Bleaching iterations varied from 7–20 and mean 
acceptor fluorescence after bleaching amounted to 10.7 ± 2.6 % for cells co-expressing Gαq-
ECFP and Venus-RhoA (Fig. 3.11A), 27.0 ± 6.0 % for Gαq-ECFP-Gαq-L209 with Venus-RhoA (Fig. 
3.11C) and 11.6 ± 4.8 % for Gαq-ECFP-Gαq-C183 with Venus RhoA (Fig. 3.11E). FRET efficiencies 
were calculated from the ECFP fluorescence intensities measured from three cytosolic ROIs per 
cell in the before and after photobleaching images. In HEK293 cells expressing Gαq-ECFP with 
Venus-RhoA a FRET efficiency of E = 8.2 ± 1.2 %, n=14 was calculated (Fig. 3.11G). Cells 
expressing the constitutively active Gαq-ECFP-Gαq-L209 with Venus-RhoA had a FRET efficiency 
of E = 4.0 ± 2.2 %, n=5 (Fig. 3.11G). The FRET efficiency determined for the constitutively active 
Gαq-ECFP-Gαq-C183 with Venus-RhoA was E = 9.2 ± 3.0 %, n=5 (Fig. 3.11G).  
FRET experiments with ECFP-tagged Gαq variants and Venus-RhoA repeatedly resulted in 
negative FRET efficiencies (36 % of Gαq-ECFP, 55 % of Gαq-ECFP-Gαq-L209 and 62 % of Gαq-
ECFP-Gαq-C183 in combination with Venus-RhoA transfected cells) and were excluded from 
the analysis. Negative FRET efficiencies occur when the donor’s fluorescence intensity before 
acceptor photobleaching is greater than after, which could be caused by the bleaching of the 
donor itself during image acquisition or by the cross-excitation of ECFP with the 514 nm laser 
line (Karpova et al., 2003). What exactly caused this CFP bleaching effect could not be 
determined and was also observed in cells expressing Gαq-ECFP-Gαq alone (donor only; 
E = -6.0 ± 3.2%, n=3). Acceptor photobleaching experiments performed under the same 
conditions and on the same day could produce positive (53 % of cells) as well as negative (47 % 
of cells) FRET efficiencies. Furthermore, a potential effect of the number of bleaching 
iterations on FRET efficiency was rejected, since there was overall no correlation between 
these and the occurrence of negative FRET efficiencies (r2=0.16). It was therefore assumed that 
CFP bleaching was possible in any experiment and the introduced error to the FRET efficiency 
calculation was similar. 
 
 Figure 3.11 FRET between ECFP-tagged Gαq variants and Venus-RhoA. HEK293 cells were co-
transfected with Gαq-ECFP and Venus-RhoA (A), constitutively active Gαq-ECFP-Gαq-L209 and Venus-
RhoA (C) or constitutively active Gαq-ECFP-Gαq-C183 and Venus-RhoA (E) and acceptor photobleaching 
experiments were performed to determine FRET. (A, C and E) Confocal images of representative cells 
display Venus-RhoA (upper panels) and ECFP-tagged Gαq (lower panels) before and after acceptor 
photobleaching. The area of the cell that was bleached is indicated by the square in the Venus-RhoA 
after photobleaching images (A, C and E, upper right panels). Scale bars 10 μm. (B, D and F) For the cells 
shown in A, C and E the destruction of the acceptor fluorophores by bleaching was documented by 
plotting Venus fluorescence intensities against the bleaching iterations. (G) ECFP fluorescence intensities 
in before and after photobleaching images were measured in three cytosolic regions of interest in each 
cell and used to calculate FRET efficiency (E) (section 2.2.11.2). In cells expressing Gαq-ECFP and Venus-
RhoA the calculated FRET efficiency was E = 8.2 ± 1.2 %, n=14, in Gαq-ECFP-Gαq-L209 and Venus-RhoA 
expressing cells it amounted to E = 4.0 ± 2.2 %, n=5 and in Gαq-ECFP-Gαq-C183 and Venus-RhoA 
expressing cells to E = 9.2 ± 3.0 %, n=5. Only cells that displayed positive FRET efficiency values were 
included in the analysis. n numbers refer to the number of cells analysed from multiple transfections 
and mean values ± SEM are presented. 
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The FRET results so far indicate that there is an interaction between the G-protein α subunit 
Gαq and small GTPase RhoA, although the efficiency values obtained were considerably lower 
than the ones determined for the optimised CFP-YFP control. In order to assess the effect of 
Gαq localisation on FRET efficiencies, the acceptor photobleaching experiments were repeated 
with HEK293 cells expressing Gαq-ECFP-Gαq and Venus-RhoA (Fig. 3.12A), which were shown to 
co-localise at the membrane. Repeated scans using the 514 nm laser line destroyed the Venus 
fluorophores (Fig. 3.12A and B; mean acceptor fluorescence after photobleaching was 
8.4 ± 1.5 %) and the FRET efficiency detected was E = 7.1 ± 1.2 %, n=18 (Fig. 3.12E; excluding 
44 % of the cells because of negative FRET efficiency values). This FRET value was in a similar 
range as those observed with the previous ECFP-tagged Gαq constructs. In a separate set of 
experiments, co-expression of mAChR M3 with Gαq-ECFP-Gαq and Venus-RhoA (Fig. 3.12C) and 
CCh application (10 μM) to activate the Gαq signalling cascade, led to a comparable FRET 
efficiency of E = 10.1 ± 2.4 %, n=5 (Fig. 3.12E; excluding 38 % of the cells). CCh was applied to 
the cells to stimulate the M3 receptor and thereby activating Gαq before cells were prepared 
for microscopy and acceptor photobleaching experiments carried out as described (Fig. 3.12C 
and D, mean acceptor fluorescence after photobleaching was 5.5 ± 1.0 %). 
Immunocytochemistry experiments using an anti-HA antibody showed that the M3 receptor 
was predominantly located at the membrane with only limited expression in the cytoplasm, 
which can also be seen in the distribution plot (Fig. 3.12F). Expression of Venus-RhoA and Gαq-
ECFP-Gαq was not influenced by the co-transfection of the M3 receptor (compare Fig. 3.12C to 
Fig. 3.12A).  
The FRET efficiency values determined between the different ECFP-tagged Gαq and Venus-
RhoA indicated an interaction of the two proteins, which supports the observations made in 
co-localisation and co-immunoprecipitation experiments. 
 
 Figure 3.12 FRET between Gαq-ECFP-Gαq and Venus-RhoA without and with the stimulation of 
the mAChR M3. HEK293 cells were co-transfected with Gαq-ECFP-Gαq and Venus-RhoA (A) or with Gαq-
ECFP-Gαq, Venus-RhoA and M3 receptor (C). FRET acceptor photobleaching experiments were 
performed and confocal images of Venus-RhoA (A and C, upper panels) and Gαq-ECFP-Gαq (A and C, 
lower panels) before and after photobleaching were acquired. (B and D) The process of acceptor 
bleaching of the area indicated in the cells shown in A and C was document by plotting Venus 
fluorophore intensity against the bleaching steps. (E) ECFP fluorescence intensities measurements in 
three membrane regions of interest in each cell were taken in before and after photobleaching images 
and used to calculate FRET efficiency (E) (section 2.2.11.2). Only cells, which displayed positive FRET 
efficiencies, were included in the analysis. FRET detected in cells expressing Gαq-ECFP-Gαq with Venus-
RhoA was E = 7.1 ± 1.2 %, n=18. In cells that also expressed the mAChR M3 and which were stimulated 
with CCh (10 μM) FRET between Gαq-ECFP-Gαq and Venus-RhoA was E = 10.1 ± 2.4 %, n=5. These 
efficiencies were not significantly different (P=0.39, unpaired t-test). n numbers refer to the number of 
cells analysed from multiple transfections and mean values ± SEM are presented. (F) Expression of M3 
was studied by immunocytochemistry using an anti-HA antibody (1:100) and a Cy5 secondary antibody 
(1:600). It was predominantly expressed at the membrane showing only limited expression in the 
cytoplasm. The plot below the image represents fluorescence intensity along the indicated line with the 
x-axis representing 10 μm and the y-axis fluorescence intensity. Scale bars 10 μm. 
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3.1.8 Binding assays between in vitro translated constitutively active Gαq-L209 and 
purified constitutively active GST-RhoA-V14 
The co-immunoprecipitation experiments indicate the formation of a complex between two or 
more proteins. However, a potential direct interaction between the G-protein α subunit Gαq 
and the small GTPase RhoA can be investigated with a binding assay, in which only the proteins 
of interest are present. In vitro translated constitutively active Gαq-L209 (section 2.2.9.1) was 
used in pull-down experiments together with purified constitutively active GST-RhoA-V14 
(section 2.2.7). The fusion protein GST-RhoA-V14 purified from bacterial lysate was incubated 
with [35S] methionine-labelled Gαq-L209. In vitro translated Gαq-L209 was pulled down by GST-
RhoA-V14 (Fig. 3.13A, ~40 kDa), suggesting a direct interaction of the two proteins. Rhophilin, 
a known binding partner of RhoA (Watanabe et al., 1996), was used as a positive control and 
was also pulled down by GST-RhoA-V14 (Fig. 3.13B, ~76 kDa), whereas no bands were 
observed in the absence of in vitro translated product (Fig. 3.13C). In all cases unspecific 
binding was tested by incubating GST beads with in vitro translated product. Input lanes of in 
vitro translated Gαq-L209 and rhophilin showed bands of the expected molecular weights, 
~40 kDa and ~76 kDa (Fig. 3.13A and B, input) and no bands were detected in the input lane of 
the control (no DNA) sample (Fig. 3.13C). 
 
Figure 3.13 In vitro translated rhophilin and constitutively active Gαq-L209 bind directly to 
purified constitutively active GST-RhoA-V14. GST and GST-RhoA-V14 were purified and used to perform 
pull-down assays with in vitro translated [35S] methionine-labelled control (no DNA), rhophilin and Gαq-
L209. 10 μg of GST and GST-Rho-V14 beads were incubated with 20 μl of in vitro translated product. 
Binding assay samples and 1 μl of each in vitro translated product (input) were separated on an 11 % 
polyacrylamide gel, which was dried before autoradiography. (A) Gαq was in vitro translated (~40 kDa, 
input) and pulled down by GST-Rho-V14 but not by GST. Under these conditions the binding assay was 
performed once. (B) In vitro translated rhophilin, band at ~76 kDa (input) was pulled-down by GST-
RhoA-V14 and also slightly by GST. The second band, at ~38 kDa, visible in the input as well as GST-
RhoA-V14 binding assay lane was repeatedly observed. Rhophilin, but not Gαq-L209, pull-downs with 
GST-RhoA-V14 were also observed in two other experiments, in which conditions varied as to the type 
of buffer and to the amount of in vitro translated product and beads used. (C) Assays performed in the 
absence of in vitro translated product did not show any bands in pull-down assay with GST-RhoA-V14 
beads; a faint unspecific band at ~38 kDa was visible with GST. 
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3.1.9 Summary 
The results of co-localisation, co-immunoprecipitation, FRET and binding assays have shown 
that the small GTPase RhoA is a binding partner of the G-protein α subunit Gαq and could 
therefore be part of a common signalling pathway that mediates the suppression of sIAHP upon 
stimulation of GPCRs by cholinergic and glutamatergic agonists. In a heterologous expression 
system RhoA, the constitutively active RhoA-V14 and the inactive RhoA-N19 were co-
immunoprecipitated with Gαq and constitutively active Gαq. This co-immunoprecipitation of 
Gαq and RhoA was not hindered by the attachment of the fluorophore tags, ECFP and Venus. 
An interaction of endogenous Gαq and RhoA in co-immunoprecipitation experiments using 
brain lysate could not be shown. A strong correlation between Venus-RhoA and the carboxyl-
terminal tagged Gαq-ECFP, the constitutively active, loop-tagged Gαq-ECFP-Gαq-L209 and, at 
membrane level, also for Gαq-ECFP-Gαq was shown by co-localisation analysis. Complex 
formation of the G-Protein α subunit Gαq and the small GTPase RhoA was also shown by FRET 
and binding assays.  
  
111 
 
3.2 Purification of mutant RhoA proteins and their intracellular application 
into hippocampal neurons 
The involvement of the small GTPase RhoA in the signalling pathways mediating the 
cholinergic and glutamatergic suppression of sIAHP has been hypothesized from experiments 
showing the reduced inhibitory effect of the agonists CCh and DHPG following the intracellular 
application of RhoA inhibitors (section 1.4). The ability to purify RhoA proteins allows for the 
introduction of RhoA mutants, constitutively active RhoA-V14 and inactive RhoA-N19, directly 
into the neuron via a patch pipette. Electrophysiological recordings of sIAHP can therefore be 
performed under the influence of intracellularly applied mutant RhoA proteins. This approach 
has been used before for small GTPases in heterologous expression system (Storey et al., 2002) 
and should, in case of Rho-N19 being introduced into the neuron, lead to a reduced 
suppression of sIAHP by cholinergic and glutamatergic agonists. In contrast, the introduction of 
RhoA-V14 should lead to the inhibition of sIAHP without the application of cholinergic and 
glutamatergic agonists.  
3.2.1 Purification of the fusion proteins GST-RhoA-V14 and GST-RhoA-N19 and the 
protolytic release of the small GTPases 
The RhoA mutants, constitutively active RhoA-V14 and inactive RhoA-N19, were purified from 
bacterial lysates as recombinant GST fusion proteins using glutathione agarose beads (Fig. 
3.14A and section 2.2.7). Expression of GST-RhoA-V14 and GST-RhoA-N19 proteins was visible 
by the additional band at ~47 kDa in the post-induction lanes compared to pre-induction lanes 
(Fig. 3.14B, indicated by black arrow head). Bacteria were harvested, lysed and the 
supernatants containing the GST fusion proteins (Fig. 3.14B) were incubated with glutathione 
agarose beads. Beads were pelleted and the amount of bound GST-RhoA-V14 or GST-RhoA-
N19 protein was estimated by comparison with a BSA standard on a polyacrylamide gel (Fig. 
3.14B). In addition GST was bound to glutathione beads and used as control in subsequent 
binding assays (section 2.2.8). Bound GST protein was detected in the Coomassie stained 
polyacrylamide gel (Fig. 3.14C). 
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Figure 3.14 Purification of GST-RhoA-V14 and GST-RhoA-N19 fusion proteins. (A) Flow diagram of 
the steps leading to the purification of GST-RhoA-V14 and GST-RhoA-N19 proteins and details of the 
construct. (B) Samples taken at the various stages of the purification process were separated by SDS-
PAGE and the gels were analysed by Coomassie staining. 10 μl of pre-induction, post-induction and 
supernatant samples and 2 μl of GST-RhoA-V14 and GST-RhoA-N19 beads samples alongside a BSA 
standard (1 μg) were separated on a 15 % polyacrylamide gel. Expressed GST-RhoA-V14 and GST-RhoA-
N19 proteins, at ~47 kDa, are indicated by the black arrow head. The Coomassie stained gel 
documenting the protein purification process is a representative and was run for every purification 
batch. (C) GST protein was bound to glutathione agarose beads and used as control in the binding assay 
experiments. 10 μl of GST beads sample was separated on a 12 % polyacrylamide gel and stained with 
Coomassie. Control GST beads were examined by Coomassie stain once. 
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For use in electrophysiological experiments, the purified RhoA proteins were cleaved off the 
glutathione agarose beads. This was achieved by incubating GST-RhoA-V14 and GST-RhoA-N19 
beads with PreScission protease, which cleaves the RhoA proteins at its recognition site leaving 
the GST-tag bound to the glutathione agarose beads (Fig. 3.15A). Cleaved RhoA protein was 
observed at ~25 kDa (Fig. 3.15B, indicated by the black arrow). A sample of the beads after 
cleaving was also analysed and three bands were detected: the ~47 kDa band corresponding to 
uncleaved GST-RhoA-V14 beads (Fig. 3.15B, indicated by the black arrow head), the middle 
band at ~30 kDa represents GST protein (Fig. 3.15B, indicated by the grey arrow) and the 
~25 kDa band matching cleaved RhoA-V14 protein (Fig. 3.15B, indicated by the black arrow). 
Purified and cleaved RhoA protein was also examined by Western blotting using anti-RhoA 
antibody and the detected band demonstrated that RhoA was purified (Fig. 3.15C).  
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Figure 3.15 Purification and protolytic release of RhoA-V14 and RhoA-N19 proteins. (A) Flow 
diagram illustrating the cleaving of purified RhoA off the beads using PreScission protease. (B) Samples 
taken at the various stages of the purification process were separated by SDS-PAGE and the gels were 
analysed by Coomassie staining. 10 μl of pre-induction, post-induction and supernatant samples, 2 μl of 
GST-RhoA-V14 beads sample, 2 μl cleaved RhoA-V14 and 2 μl of beads after cleaving samples were 
separated on a 15 % polyacrylamide gel, which was stained with Coomassie. GST-RhoA-V14 is indicated 
by the black arrow head. Cleaved RhoA-V14 is indicated by the black arrow, while the band 
corresponding to GST protein in the beads after cleaving lane is indicated by the grey arrow. Coomassie 
stained gel documenting the protein purification and cleaving process is a representative and was run 
for every purification batch. The same procedure was performed for RhoA-N19. (C) 0.6 μg of cleaved 
RhoA-V14 protein was run on a 15 % polyacrylamide gel and Western blotting was performed using anti-
RhoA antibody at a dilution of 1:500. Western blotting of cleaved RhoA-V14 was performed once. 
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3.2.2 Purified mutant GST-RhoA fusion proteins bind to rhophilin and constitutively 
active Gαq-L209 
Whether purified mutant RhoA proteins retained their binding ability was tested by 
performing pull-down assays with the known RhoA binding partner rhophilin and also with 
constitutively active Gαq-L209. Binding assays of purified mutant RhoA with Gαq would also 
verify results obtained in co-immunoprecipitation experiments. Purified mutant GST-RhoA 
protein used for the pull-down assays was firstly examined by Western blotting and a band at 
~47 kDa was detected matching the expected molecular weight of the GST-RhoA fusion 
protein (Fig. 3.16C). Pull-down experiments were performed by incubating purified GST-RhoA-
V14 and GST-RhoA-N19 bound to glutathione agarose beads as well as control GST beads with 
HEK293 lysate expressing Myc-rhophilin or the constitutively active Gαq-L209. The detected 
bands at ~76 kDa showed that GST-RhoA-V14 as well as GST-RhoA-N19 pulled-down Myc-
rhophilin (Fig. 3.16A). Pull-down assays were also performed with Gαq, and GST-RhoA-V14 as 
well as GST-RhoA-N19 were able to bind Gαq-L209 as shown by the bands at ~40 kDa (Fig. 
3.16B). These results are consistent with the co-immunoprecipitation experiments that 
reported the ability of constitutively active Gαq-L209 to bind RhoA-V14 as well as with RhoA-
N19 (Fig. 3.1).  
 
Figure 3.16 Purified GST-RhoA-V14 and GST-RhoA-N19 bind rhophilin and Gαq-L209. GST-RhoA-
V14, GST-RhoA-N19 and control GST beads were incubated with HEK293 lysate expressing Myc-rhophilin 
or Gαq-L209. Samples were subjected to SDS-PAGE, transferred to nitrocellulose membranes and 
analysed by Western blotting. (A) 25 μg Myc-rhophilin lysate was incubated with 40 μg GST-RhoA-V14 
and GST-RhoA-N19 beads as well as with 25 μg control GST beads. The pull-down assay samples 
alongside a 10 μg Myc-rhophilin lysate control were separated on 10 % polyacrylamide gels. Western 
blotting was performed using anti-myc antibody at a dilution of 1:400. (B) 50 μg Gαq-L209 lysate were 
incubated with 40 μg GST-RhoA-V14 and GST-RhoA-N19 beads as well as with 25 μg control GST beads 
and the samples, alongside a 2.5 μg Gαq lysate control, were separated on 10 % polyacrylamide gels. 
Western blotting was performed using anti-Gαq/11 antibody at a dilution of 1:500. (C) GST-RhoA-V14 was 
examined by reprobing the membrane of a pull-down experiment, like (A) or (B), using anti-RhoA 
antibody at a dilution of 1:1000. The grey line indicates a discontinuity of the blot, because for this 
figure lanes were left out. Western blots of pull-down assays are representative of at least three 
separate experiments. Western blotting of GST-RhoA-V14 was performed once. 
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Having shown the ability of purified GST-RhoA-V14 and GST-RhoA-N19 to bind to Gαq-L209 
expressed in HEK293 lysates, pull-down assays were repeated using endogenous Gαq from 
brain lysates. Membranes were probed with anti-Gαq/11 antibody to detect any associated Gαq. 
Gαq bands at ~40 kDa were detected in both GST-RhoA-V14 and GST-RhoA-N19 binding assays 
(Fig. 3.17, indicated by the black arrow). However, the detected bands were very faint and 
experiments using more lysate (up to 1500 μg) did not result in stronger signals. Although 
detection in these pull-down experiments was weak, purified mutant GST-RhoA proteins seem 
to be able to interact with endogenous Gαq. 
 
Figure 3.17 Pull-down experiments of endogenous Gαq using purified GST-RhoA-V14 and GST-
RhoA-N19 protein. 25 μg control GST beads and 40 μg GST-RhoA-V14 and GST-RhoA-N19 were 
incubated with 700 μg brain lysate (P2 fraction). Samples, alongside 100 μg brain lysate and 25 μg Gαq-
L209 HEK293 cell lysate controls, were separated on a 12 % polyacrylamide gel, transferred to 
nitrocellulose membrane and analysed by Western blotting using anti-Gαq/11 antibody at a dilution of 
1:500. Under this condition (700 μg brain lysate) the binding assay was performed only once, but was 
repeated using different amounts of brain lysates (250–1500 μg), which also resulted in very faint bands. 
3.2.3 Purified constitutively active RhoA-V14, but not inactive RhoA-N19, causes 
stress fibre formation in Swiss-3T3 cells 
Before being used in electrophysiology studies, the biological activity of the purified and 
cleaved mutant RhoA proteins, constitutively active RhoA-V14 and inactive RhoA-N19, was 
tested by assessing their ability to affect the actin cytoskeleton structure within the cell. RhoA, 
together with other small GTPases like Rac and Cdc42, is known to be a regulator of the actin 
cytoskeleton (section 1.4) and microinjection of constitutively active RhoA-V14 has been 
shown to stimulate the formation of stress fibres in serum-starved Swiss-3T3 cells (Ridley and 
Hall, 1992). Thus this system was used to test the purified mutant RhoA proteins; RhoA-V14 
injected cells should show an increase in stress fibres, whereas RhoA-N19 injected cells should 
not differ from control cells. The concept of stress fibre formation induced by RhoA-V14 was 
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first tested by transfecting RhoA-V14 into Swiss-3T3 cells, which were serum-starved since 
they contain stress fibres in the presence of serum. Monomeric red fluorescent protein (mRFP) 
was co-transfected with RhoA-V14 to be able to identify transfected cells. Alexa Fluor 488 
phalloidin was used to label actin and transfected cells displayed abundant stress fibres 
compared to untransfected cells (Fig. 3.18A). Like untransfected cells, serum-starved Swiss-3T3 
cells that underwent mock transfection did not show the formation of stress fibres (compare 
Fig. 3.18A and Fig. 3.18B). 
 
Figure 3.18 Transfection of constitutively active RhoA-V14 induces stress fibre formation in 
Swiss-3T3 cells. (A) Representative images of serum-starved Swiss-3T3 cells, which were co-transfected 
with RhoA-V14 and monomeric red fluorescent protein. Actin was visualized by labelling the cells with 
Alexa Fluor 488 phalloidin (0.25 U) and monomeric red fluorescent protein was used to identify 
transfected cells. (B) Mock transfected serum-starved Swiss-3T3 cells were labelled with Alexa Fluor 488 
phalloidin (0.25 U). Scale bars 20 μm. 
Transfecting constitutively active RhoA-V14 successfully induced stress fibre assembly in Swiss-
3T3 cells, an effect that was subsequently assessed by the microinjection of purified and 
cleaved constitutively active RhoA-V14 or inactive RhoA-N19 protein into serum-starved Swiss-
3T3 cells. To identify microinjected cells TRITC was injected together with the RhoA proteins, 
while TRITC microinjected on its own served as control. Purified RhoA proteins were 
microinjected (section 2.2.2.2) in two concentrations, 0.15 μg/μl and 0.3 μg/μl, and in both 
cases constitutively active RhoA-V14 induced the formation of stress fibres, while inactive 
RhoA-N19 injected cells did not differ from control cells (Fig. 3.19). Actin was stained with 
Alexa Fluor 488 phalloidin and control (Fig. 3.19A and D) and RhoA-N19 (Fig. 3.19B and E) 
injected cells contained less stress fibres than RhoA-V14 injected cells (Fig. 3.19C and F). To 
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assess the level of stress fibres objectively the mean fluorescence intensity of each injected cell 
was measured (section 2.2.11.3) and as cells containing more stress fibres displayed higher 
mean fluorescence intensity values these could be used to compare control, RhoA-N19 and 
RhoA-V14 cells (Fig. 3.19G and H). In experiments using 0.15 μg/μl RhoA protein for 
microinjections the groups’ stress fibre levels differed significantly (P<0.0001, one-way 
ANOVA) and the post-hoc Bonferroni’s multiple comparison test detailed that while control 
(37.1 ± 2.0 mean fluorescence intensity) and RhoA-N19 (39.8 ± 2.3) injected cells did not differ 
from each other, RhoA-V14 cells (53.0 ± 2.0) were significantly different to both of them (Fig. 
3.19G). The same was observed for experiments conducted with 0.3 μg/μl RhoA protein (mean 
fluorescence intensity 37.1 ± 2.0 (control), 36.8 ± 1.9 (RhoA-N19), 75.0 ± 5.5 (RhoA-V14); 
P<0.0001, one-way ANOVA; Fig. 3.19H). These results demonstrated that the purified and 
cleaved mutant RhoA proteins, RhoA-V14 and RhoA-N19, affected the cytoskeleton as 
expected. 
 
 Figure 3.19 Microinjection of purified constitutively active RhoA-V14, but not purified inactive 
RhoA-N19, into Swiss-3T3 cells stimulates the formation of stress fibres. Representative images of 
serum-starved Swiss-3T3 cells microinjected with 10 μg/μl TRITC alone (control, A and D), purified RhoA-
N19 (B and E) or purified RhoA-V14 (C and F). Injected cells were identified by TRITC, which was also 
microinjected alongside purified RhoA proteins (A–F, lower panels). Actin was labelled using Alexa Fluor 
488 phalloidin (0.25 U; A–F, upper panels). Scale bar 20 μm. Microinjections with purified RhoA were 
performed using a protein concentration of either 0.15 μg/μl or 0.3 μg/μl. To compare stress fibre levels 
between control, RhoA-N19 and RhoA-V14 injected cells the mean fluorescence intensities of each 
injected cell was measured (section 2.2.11.3). (G) Comparison of stress fibre levels between control 
(37.1 ± 2.0, n=30), 0.15 μg/μl RhoA-N19 (39.8 ± 2.3, n=28) and 0.15 μg/μl RhoA-V14 (53.0 ± 2.0, n=72) 
(P<0.0001, one-way ANOVA). (H) Summary of stress fibre level comparison between control (37.1 ± 2.0, 
n=30), 0.3 μg/μl RhoA-N19 (36.8 ± 1.9, n=21) and 0.3 μg/μl RhoA-V14 (75.0 ± 5.5, n=27) (P<0.0001, one-
way ANOVA). In both cases (G and H) the post-hoc Bonferroni’s multiple comparison test showed that 
control and RhoA-N19 injected cells did not differ, while RhoA-V14 injected cells differed significantly 
from control as well as from RhoA-N19. * = P<0.05 and n numbers refer to the number of cells analysed 
from multiple injections. Mean values ± SEM are presented. 
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3.2.4 The effect of intracellularly applied mutant RhoA proteins on sIAHP in acute 
hippocampal slices 
Electrophysiological experiments using the purified RhoA proteins have been performed by 
Anne Boehlen. Purified and cleaved RhoA-V14 or RhoA-N19 proteins (30 μg/ml; section 2.2.7 
and 3.2.1) were added to the intracellular solution and introduced into CA1 pyramidal neurons 
in acute hippocampal slices via the patch pipette. Whole-cell voltage clamp recordings were 
carried out and the effect of the purified mutant RhoA proteins on sIAHP was assessed. Control 
recordings were performed with an intracellular solution that contained equal amounts of a 
mock purification sample (section 2.2.7). It was hypothesised that the presence of RhoA-N19 
proteins would not affect sIAHP, while RhoA-V14 would mimic the inhibitory action of 
cholinergic and glutamatergic agonists. Averaged sIAHP amplitudes of control, RhoA-N19 and 
RhoA-V14 cells are shown in the time course (Fig. 3.20). In the first 10 min of establishing 
whole-cell configuration all three groups show the typical increase of current amplitude (Zhang 
et al., 1995; Pedarzani et al., 1998). However, the maximal steady-state amplitude of sIAHP in 
cells exposed to constitutively active RhoA-V14 is significantly reduced compared to control 
and inactive RhoA-N19 (P<0.0001, two-way ANOVA 0.5–20 min). The evaluation of this effect 
at later time points was complicated by the fact that all three groups showed a run-down of 
the current from ~20 min onwards. 
 
Figure 3.20 sIAHP is partially inhibited by the application of purified constitutively active RhoA-
V14, but not by inactive RhoA-N19. Whole-cell voltage clamp recordings of CA1 pyramidal neurons in 
acute hippocampal slices were performed. The purified and cleaved constitutively active RhoA-V14 or 
inactive RhoA-N19 was added to the intracellular solution and was introduced into the neurons via the 
patch pipette. Recordings with intracellular solution containing a mock purification sample served as a 
control. sIAHP was activated by a depolarisation step to +30 mV for 100 ms. Time courses of sIAHP 
amplitude in control cells and cells with intracellularly applied RhoA-V14 or RhoA-N19 protein 
(30 μg/ml); control (n=13), RhoA-N19 (n=13) and RhoA-V14 (n=21), mean values ± SEM are presented. 
Comparing the effect of RhoA proteins on amplitude over time showed that sIAHP amplitudes of the 
three groups are not the same (P<0.0001, two way ANOVA 0.5–20 min and 0.5–62 min). Experiments 
were performed by A. Boehlen. 
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3.2.5 Summary 
The constitutively active RhoA-V14 and the inactive RhoA-N19 proteins were purified as fusion 
proteins and their ability to interact with binding partners was shown in pull-down assays with 
rhophilin and Gαq. Besides interaction studies, purified and cleaved mutant RhoA proteins 
were also tested for their effect on the actin cytoskeleton of cells. Swiss-3T3 cells 
microinjected with purified RhoA-V14 displayed plenty of stress fibres, while the actin 
cytoskeleton was not influenced by the injection with purified RhoA-N19.  It was concluded 
that the mutant RhoA proteins are biologically active and were thus used for 
electrophysiological studies. The role of RhoA in the signalling pathway mediating the 
suppression of sIAHP by cholinergic and glutamatergic agonists was investigated in 
electrophysiological experiments by introducing mutant RhoA proteins into neurons via a 
patch pipette. The intracellular application of purified constitutively active RhoA-V14 protein 
induced a significant, albeit partial, reduction of sIAHP, which could be due to a low intracellular 
concentration of RhoA-V14 or a too short exposure to the introduced protein. To establish the 
role of RhoA in the cholinergic and glutamatergic suppression of sIAHP, electrophysiological 
experiments were conducted using a different approach, namely the introduction of mutant 
RhoA into hippocampal neurons by virus infection. 
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3.3 Assessment of RhoA involvement in the cholinergic modulation of sIAHP in 
Sindbis virus infected primary hippocampal neurons  
RhoA mutants were over-expressed by virus infection in primary hippocampal pyramidal 
neurons with the ultimate aim of replicating the experiments in acute or organotypic 
hippocampal slices. The Sindbis virus was chosen to introduce mutant RhoA proteins into 
hippocampal neurons as it allows fast protein expression and displays high specificity for 
neurons. Using a modified Sindbis vector (Jeromin et al., 2003) had the additional advantage of 
containing the nsP2 mutation (S726), which has been shown to markedly reduce cytotoxicity 
(Dryga et al., 1997), and of simultaneously expressing EGFP allowing for the identification of 
infected neurons (pSinrep5-EGFP). Primary cultures of hippocampal neurons were infected 
with recombinant Sindbis virus containing RhoA-V14 or RhoA-N19 and the effect of mutant 
RhoA protein on sIAHP was investigated by whole-cell voltage clamp recordings. 
3.3.1 Sindbis virus production and functionality assay 
3.3.1.1 Recombinant Sindbis plasmid construction and RNA synthesis 
The RhoA mutants, constitutively active RhoA-V14 and inactive RhoA-N19, were cloned into 
pSinrep5-EGFP under the control of the Sindbis subgenomic promoter (PSG) to construct the 
recombinant plasmids pSinrep5-RhoA-V14-EGFP and pSinrep5-RhoA-N19-EGFP (section 
2.2.13). The helper plasmid, pHelper-DH-BB (tRNA/TE12) was constructed from the helpers 
DH-BB and DH-26S (Kim et al., 2004) and thus combined the high replication capacity seen 
with the DH-BB helper and the ability of DH-26S, a TE12 strain derivative, to infect neurons 
(Bredenbeek et al., 1993). The Sindbis expression constructs, pSinrep5-EGFP, pSinrep5-RhoA-
V14-EGFP and pSinrep5-RhoA-N19-EGFP, were linearized with PacI and the helper pHelper-DH-
BB (tRNA/TE12) with XhoI before in vitro transcription (section 2.2.10.1). RNAs were analysed 
by formaldehyde agarose gel electrophoresis and yielded products of 9 kb (SIN-EGFP, Fig. 
3.21A), 9.5 kb (SIN-RhoA-V14-EGFP and SIN-RhoA-N19-EGFP, Fig. 3.21B) and 5 kb (helper, Fig. 
3.21B). Isolated RNA of HEK293 (28S, 5 kb and 18S, 1.9 kb) and rat brain type 2 sodium channel 
α subunit RNA (NaV1.2, 6 kb), which was generated to test the RNA synthesis reaction, were 
run alongside as size markers (Fig. 3.21). Synthesised RNAs from pSinrep5-EGFP, pSinrep5-
RhoA-V14-EGFP, pSinrep5-RhoA-N19-EGFP and pHelper-DH-BB (tRNA/TE12) were used for 
virus production. 
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Figure 3.21 RNA synthesis from Sindbis expression and helper constructs. Recombinant Sindbis 
expression constructs and the helper were linearized and in vitro transcribed. Formaldehyde agarose gel 
electrophoresis of (A) SIN-EGFP (9 kb) and (B) helper (5 kb), SIN-RhoA-N19-EGFP (9.5 kb) and SIN-RhoA-
V14-EGFP (9.5 kb) alongside synthesised NaV1.2 (6 kb) RNA and RNA from HEK293 cells (28S, 5 kb, 
indicated by black arrow; 18S, 1.9 kb, indicated by grey arrow), which were used as size markers. 
3.3.1.2 Production of Sindbis virus particles 
To produce virus particles, Sindbis expression RNA, together with helper RNA, were 
electroporated into BHK-21 cells. This co-transfection of helper RNA provides the structural 
proteins necessary for packaging the recombinant RNA and leads to viral particles being 
released into the medium, where they can then be harvested and used for infection. 
Electroporation of Sindbis expression RNA alone (without the structural proteins provided by 
the helper) will not be packaged and thus expression is limited to the transfected cell. This fact 
was exploited during the electroporation set-up phase, since electroporation conditions could 
be tested and the results judged by assessing the number of EGFP expressing cells without 
producing virus particles. The electroporation of BHK-21 cells with SIN-EGFP RNA was initially 
tested using the ECM600 electroporation system (BTX) and different electroporation protocols 
(Invitrogen, manual; Wahlfors and Morgan, 2003; Ehrengruber et al., 2011) and it was 
determined that pulses of 500 V lasting 7 ms produced the highest transfection efficiency. 
However, even with these settings the number of EGFP expressing cells varied greatly across 
experiments (5–50 %; Fig. 3.22A and B) and the ECM600 was considered unsuitable for virus 
production. The experiment was repeated with a GenePulser II electroporation system (BIO-
RAD) using the mentioned optimised settings, but the transfection efficiency achieved was not 
reproducible between experiments and never high enough to be suitable for the production of 
viruses with a high-titre (1–10 %; Fig. 3.22C and D). Consistently high transfection efficiencies 
were only achieved with the GenePulser XCell (BIO-RAD) (40 %; Fig. 3.22E) and it was therefore 
used for Sindbis virus productions. 
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Figure 3.22 Electroporation of BHK-21 cells with SIN-EGFP RNA using different electroporation 
systems. BHK-21 cells were electroporated with SIN-EGFP RNA using pulses of 500 V lasting 7 ms and 
the transfection efficiency was examined 24 h later by assessing the number of EGFP expressing cells. 
Representative EGFP and corresponding bright field images showing electroporation results using the 
ECM600 electroporation system (BTX) (A and B), the GenePulser II (BIO-RAD) (C and D) and the 
GenePulser XCell (BIO-RAD) (E). Electroporations performed with the ECM600 electroporation system 
(BTX) and GenePulser II (BIO-RAD) varied between higher (A and C) and lower (B and D) transfection 
efficiencies. Electroporations with the GenePulser XCell (BIO-RAD) (E) consistently resulted in high 
transfection efficiencies and was therefore used for the virus production. Scale bar 200 μm. 
To produce virus particles, BHK-21 cells were electroporated with SIN-EGFP, SIN-RhoA-V14-
EGFP or SIN-RhoA-N19-EGFP RNA and helper RNA using the GenePulser XCell (BIO-RAD) 
protocol (section 2.2.10.2). Electroporated BHK-21 cells were plated and the medium 
containing the virions was harvested 24 h later. 
3.3.1.3 Determining the infection capability of the viral stock and the optimal amount of 
virus needed for infection 
This Sindbis expression system consists of two constructs, which need to be co-transfected to 
produce virus particles: an expression plasmid containing the nonstructural genes responsible 
for replication and the genes of interest and a helper plasmid encoding for the structural 
proteins. The generated viruses are replication-deficient, since only the Sindbis expression RNA 
is packaged but not the helper RNA, which is defective i.e. does not contain a packaging signal. 
Therefore the viruses undergo only one round of infection and infected cells express the 
proteins of interest, but cannot generate new viruses because the structural proteins provided 
by the helper RNA are missing. Consequently the virus titre cannot be determined by plaque 
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assays. The infection capability of the Sindbis viruses was therefore assessed empirically by 
infecting BHK-21 cells with dilutions of Sindbis virus generated from SIN-EGFP (EGFP control), 
SIN-RhoA-V14-EGFP (RhoA-V14) and SIN-RhoA-N19-EGFP (RhoA-N19) and by counting the 
number of EGFP expressing cells (Fig. 3.23; section 2.2.10.3). Infecting BHK-21 cells with EGFP 
control, RhoA-N19 or RhoA-V14 at a dilution of 1:10 resulted in all cells expressing EGFP (Fig. 
3.23A, C and E). At higher dilutions for example 1:1000 (Fig. 3.23B, D and F) EGFP control and 
RhoA-N19 still infected a number of cells, while hardly any EGFP expressing cells could be seen 
in infections with RhoA-V14. The concentration of viral stock was calculated (section 2.2.10.3) 
and amounted to 108–109 virions/ml on average; EGFP control being the most potent (1.7 x 109 
virions/ml), followed by RhoA-N19 (6.2 x 108 virions/ml) and then RhoA-V14 (1.9 x 108 
virions/ml). In addition the assay also determined the optimal dilutions of the viruses (1:5000 
for EGFP control, 1:1000–1:2000 for RhoA-N19 and 1:100–1:500 for RhoA-V14) to be used in 
subsequent experiments in BHK-21 cells and cultured hippocampal neurons. 
 
Figure 3.23 Infecting BHK-21 cells with diluted recombinant Sindbis virus to determine the 
infection capability of the viral stock and the optimal infection conditions for subsequent 
experiments. BHK-21 cells were infected with Sindbis virus generated from SIN-EGFP (EGFP control), 
SIN-RhoA-N19-EGFP (RhoA-N19) or SIN-RhoA-V14-EGFP (RhoA-V14) at various dilutions (section 2.2.10; 
1:10 (A, C and E) and 1:1000 (B, D and F) are shown). EGFP expressing cells were counted and used to 
calculate the concentration of the viral stock (section 2.2.10.3). Optimal dilutions of the virus were 
determined as 1:5000 for EGFP control, 1:1000–1:2000 for RhoA-N19 and 1:100–1:500 for RhoA-V14. 
Representative images, EGFP and the corresponding bright field image, are shown. Scale bar 200 μm. 
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3.3.1.4 Stress fibres formation in constitutively active RhoA-V14 infected BHK-21 cells, but 
not in inactive RhoA-N19 infected cells 
As described before RhoA is involved in the regulation of the actin cytoskeleton and the 
expression of constitutively active RhoA-V14 causes the formation of stress fibres, while no 
changes of the cytoskeleton were observed in cells expressing inactive RhoA-N19 (Ridley and 
Hall, 1992; section 3.2.3). Hence the effect of the generated RhoA Sindbis viruses on the 
cytoskeleton was tested by infecting serum-starved BHK-21 cells with diluted EGFP control 
(1:5000), RhoA-N19 (1:1000) and RhoA-V14 (1:100) virus. Actin was labelled with Alexa Fluor 
594 phalloidin and infected cells were identified by their EGFP expression. Cells infected with 
RhoA-V14 (Fig. 3.24C) contained more stress fibres than RhoA-N19 (Fig. 3.24B) or EGFP control 
(Fig. 3.24A) infected cells. The mean fluorescence intensity of infected cells was measured and 
used to compare stress fibre levels between EGFP control (54.7 ± 4.3 mean fluorescence 
intensity), RhoA-N19 (56.4 ± 6.5) and RhoA-V14 (92.2 ± 6.7; Fig. 3.24D). The intensities differed 
significantly (P<0.0001, one-way ANOVA) and the post-hoc Bonferroni’s multiple comparison 
test showed that while EGFP control and RhoA-N19 did not differ from each other, RhoA-V14 
infected cells differed significantly from both. RhoA-V14 and RhoA-N19 Sindbis viruses were 
affecting the actin cytoskeleton as expected and match the observations made with 
microinjected purified RhoA-V14 and RhoA-N19 proteins. It can therefore be concluded that 
the RhoA-V14 and RhoA-N19 viruses are functional and can be used to infect hippocampal 
neurons to study the involvement of RhoA in the modulation of sIAHP by cholinergic and 
glutamatergic agonists. 
127 
 
 
Figure 3.24 Infection with constitutively active RhoA-V14, but not inactive RhoA-N19, Sindbis 
virus induces stress fibre formation in BHK-21 cells. Representative images of serum-starved BHK-21 
cells that were infected with (A) EGFP control (1:5000 dilution), (B) RhoA-N19 (1:1000) or (C) RhoA-V14 
(1:100) Sindbis virus. Actin was labelled with Alexa Fluor 594 phalloidin (0.25 U; A–C, upper panels) and 
infected cells were identified by EGFP expression (A–C, lower panels). Scale bar 20 μm. (D) Stress fibre 
levels of infected cells were compared by measuring the mean fluorescence intensities of EGFP control 
(54.7 ± 4.3, n=13), RhoA-N19 (56.4 ± 6.5, n=13) and RhoA-V14 (92.2 ± 6.7, n=12) (P<0.0001, one-way 
ANOVA). As shown by the post-hoc Bonferroni’s multiple comparison test RhoA-V14 infected cells 
differed significantly from control and RhoA-N19 infected cells, which themselves did not differ from 
each other. * = P<0.05 and n numbers refer to the number of cells analysed from one infection. Mean 
values ± SEM are presented. 
3.3.2 sIAHP in primary cultured hippocampal neurons 
To assess the role of RhoA in the cholinergic modulation of sIAHP mutant RhoA proteins, the 
constitutively active RhoA-V14 and the inactive RhoA-N19, were expressed in primary cultured 
hippocampal neurons by Sindbis virus infection. This preparation was chosen as it presented 
an accessible environment in which infection can easily be achieved by addition of the virus to 
the culture medium. sIAHP is known to be present in primary cultures of hippocampal neurons 
(Shah and Haylett, 2000b; Gallasch, 2008) and its characteristics were examined in control 
neurons before the effects of mutant RhoA proteins on sIAHP were investigated. 
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3.3.2.1 Properties of primary cultured hippocampal pyramidal neurons are not affected by 
Sindbis virus infection 
Whole-cell patch clamp recordings of primary cultured hippocampal pyramidal neurons were 
performed and the effects of a Sindbis virus infection on the properties of hippocampal 
pyramidal neurons were examined. The morphology of pyramidal neurons with their 
triangular-shaped soma and distinctive processes was used to select neurons for patching (Fig. 
3.25A–C). Infected neurons were identified by their EGFP expression (Fig. 3.25A–C, upper 
panels) and no morphological differences between control and neurons infected with RhoA-
N19 or RhoA-V14 were observed.  
Recordings were made from control (EGFP-neg), RhoA-N19 (1:2000 dilutions, occasionally 
1:1000) and RhoA-V14 (1:100) infected pyramidal neurons. The control group included EGFP-
negative cells recorded from coverslips that had no contact with Sindbis virus (uninfected) and 
also from coverslips that had undergone infection with RhoA-N19 or RhoA-V14 virus. The 
membrane resting potential of EGFP-negative cells in uninfected coverslips amounted to 
-59.5 ± 1.7 mV (n=12), in RhoA-N19 treated coverslips to -57.6 ± 0.9 mV (n=25) and in RhoA-
V14 treated coverslips to -59.3 ± 1.2 mV (n=10) and did not differ significantly (P=0.45, one-
way ANOVA; Fig. 3.25D). The same was observed for the input resistance of EGFP-negative 
neurons, which was 558.4 ± 73.8 MΩ (n=11) in uninfected, 506.7 ± 61.8 MΩ (n=22) in RhoA-
N19 treated and 548.5 ± 70.4 MΩ (n=8) in RhoA-V14 treated coverslips (P=0.8453, one-way 
ANOVA; Fig. 3.25E). Since the passive properties of EGFP-negative neurons were not affected 
by Sindbis virus treatment, they were pooled into one control group. The resting potential of 
the combined EGFP-negative cells was -58.5 ± 0.7 mV (n=47), of RhoA-N19 infected cells 
56.7 ± 0.7 mV (n=34) and of RhoA-V14 infected cells -57.4 ± 0.7 mV (n=36) (P=0.1836, one-way 
ANOVA; Fig. 3.25F). The input resistance amounted to 528.7 ± 40.3 MΩ (n=41) in EGFP-
negative cells, 552.7 ± 60 MΩ (n=32) in RhoA-N19 infected cells and 540.5 ± 54.7 MΩ (n=34) in 
RhoA-V14 infected cells (P=0.9455, one-way ANOVA; Fig. 3.25G). It can therefore be concluded 
that the passive properties of hippocampal pyramidal neurons in primary culture were not 
influenced by the infection with RhoA-N19 or RhoA-V14 Sindbis virus. 
All neurons consistently fired overshooting action potentials, although the firing pattern 
observed for all three groups was variable, ranging from single or irregular spikes, to bursts 
and regular firing. Regular firing was most commonly observed (90 % of EGFP-negative, 56 % 
RhoA-N19 and 62 % RhoA-V14 cells). Due to the artificial nature of the pyramidal neuron 
network in culture, dedicated current clamp experiments to analyse virus induced changes in 
firing pattern and spike frequency adaptation were not carried out. 
 Figure 3.25 Properties of hippocampal pyramidal neurons in primary culture. Representative 
images of pyramidal cultures of hippocampal neurons infected with (A) EGFP control (1:5000 dilution), 
(B) RhoA-N19 (1:2000) and (C) RhoA-V14 (1:500) Sindbis virus. Scale bar 50 μm. For whole-cell 
recordings, primary cultures of hippocampal neurons were infected with RhoA-N19 at a dilution of 
1:2000 (occasionally 1:1000) or with RhoA-V14 at a 1:100 dilution, while EGFP-negative neurons served 
as control. (D) Comparison of the resting potential of EGFP-negative neurons in uninfected and in RhoA-
N19 or RhoA-V14 treated coverslips (P=0.45, one-way ANOVA). (E) Summary of the input resistance of 
EGFP-negative cells in uninfected and in RhoA-N19 or RhoA-V14 treated coverslips (P=0.8453, one-way 
ANOVA). (F) Comparison of the resting potential of combined EGFP-negative and RhoA-N19 or RhoA-
V14 infected cells (P=0.1836, one-way ANOVA) and (G) of their input resistance (P=0.9455, one-way 
ANOVA). The box plot is made up of the median (horizontal line in the middle of box), 25th and 75th 
percentile of the data (upper and lower edges of the box), maximum and minimum values of the data 
(top and bottom of the whiskers) and the mean value (“+” in the box). All recordings were made in the 
presence of 25 μM D-(-)-2-amino-5-phosphonopentanoic acid and 5 μM 2,3-dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo(f)quinoxaline-7-sulfonamide.  
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3.3.2.2 Unmasking of sIAHP in primary cultured hippocampal neurons  
Neurons were voltage-clamped at -50 mV and sIAHP was recorded following a 200 ms-long 
depolarising step to +30 mV to activate voltage-gated Ca2+ channels (Fig.2.11; section 
2.2.14.2). After the depolarising step outward tail currents, generated by IAHP and sIAHP, were 
observed (Fig. 3.26A). Both currents coexist in hippocampal neurons but can be separated 
pharmacologically because IAHP is inhibited by apamin and dTC, which do not affect sIAHP 
(Stocker et al., 1999; Shah et al., 2006). The coexistence of IAHP and sIAHP was observed in the 
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majority of cells recorded (IAHP in 90% and sIAHP in 100% of EGFP-negative cells) and sIAHP could 
be seen in isolation following the application of 50–100 μM dTC, which blocks KCa2 channels 
that underlie IAHP (Fig. 3.26B and D). TTX (0.5 μM; blocker of voltage-gated Na
+ channels) and 
TEA (1 mM; blocker of a subset of KV and KCa1.1 channels, KCa2 channels are not affected at this 
concentration) were applied alongside dTC to maximize Ca2+ influx and thus sIAHP amplitude. 
The kinetic features of the sIAHP observed in cultured hippocampal pyramidal neurons matched 
the ones reported in slices i.e. activating over several hundred milliseconds and decaying over 
seconds (section 1.2.3; Lancaster and Adams, 1986; Sah, 1996) and sIAHP showed the typical 
run-up (Zhang et al., 1995; Pedarzani et al., 1998), lasting for 5–10 min, before reaching 
steady-state amplitude (Fig. 3.26D). 
 
Figure 3.26 Pharmacological isolation of sIAHP in cultured hippocampal neurons. IAHP was 
selectively blocked by d-Tubocurarine (dTC), while sIAHP was not affected. (A and B) Representative 
whole-cell voltage-clamp recordings of afterhyperpolarizing currents in an EGFP-negative neuron in the 
absence (A) and presence (B) of 0.5 μM tedrodotoxin (TTX), 1 mM tetraethylammonium (TEA) and 
100 μM dTC. (C) Superimposed traces illustrating the coexistence of IAHP and sIAHP in cultured 
hippocampal neurons. The voltage clamp protocol used to activate the afterhyperpolarizing currents is 
shown underneath the trace in (A). The dashed grey line indicates zero current (A–C). (D) Time course of 
the run-up and stabilization of the pharmacologically isolated sIAHP. (E) Time course of IAHP amplitude in 
response to application and wash out of the pharmacological blockers used in sIAHP recordings. All 
recordings were carried out in the presence of synaptic blockers, 25 μM D-(-)-2-amino-5-
phosphonopentanoic acid and 5 μM 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-
sulfonamide. 
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3.3.2.3 Regulation of sIAHP in cultured hippocampal neurons 
The activation of sIAHP by Ca
2+ has been shown in various studies (Lancaster and Zucker, 1994; 
Zhang et al., 1995; Sah, 1996). sIAHP in cultured hippocampal pyramidal neurons was tested for 
Ca2+ dependency by replacing extracellular Ca2+ with Mg2+ (5 mM; section 2.2.14.1). The 
removal of Ca2+ from the extracellular solution led to the elimination of the unclamped Ca2+ 
currents and sIAHP as seen in the example traces with or without extracellular Ca
2+ (Fig. 3.27A 
and B) and the time course of recording (Fig. 3.27D). Once Ca2+ levels in the extracellular 
solutions were restored, sIAHP recovered readily (Fig. 3.27C and D). sIAHP amplitude, which 
amounted to 22.1 ± 4.2 pA (n=5, control), was reduced to 0.2 ± 0.2 pA (n=5, 0 Ca2+) by the 
removal of extracellular Ca2+ (P=0.0062, paired t-test; Fig. 3.21E); a reduction of 99.1 ± 0.9  %. 
The effect of 0 Ca2+ was reversible and sIAHP recovered to 18.6 ± 3.6 pA (n=4, recovery; Fig. 
3.27E), which equals a recovery of 78.7 ± 7.0 %. 
 
Figure 3.27 Removal of extracellular Ca2+ abolishes isolated sIAHP. Representative current traces 
of sIAHP recorded in an EGFP-negative neuron in the presence of (A) 2 mM Ca
2+ in the extracellular 
solution (control) and (B) in its absence (0 Ca2+). sIAHP recovered once the Ca
2+ level in the extracellular 
solution was restored to (C) 2 mM Ca2+ (recovery). Insets show the corresponding Ca2+ spike observed 
during the depolarisation step that preceded sIAHP recordings. The dashed grey line indicates zero 
current (A–C). (D) Time course showing sIAHP amplitude in response to the removal of extracellular Ca
2+ 
and upon return to original conditions. (E) Bar diagram summarizing the effect of 0 Ca2+ on sIAHP 
(P=0.0062, paired t-test). sIAHP recovered to 78.7 ± 7.0 % once 2 mM Ca
2+ was again present in the 
extracellular solution. Mean values ± SEM are presented. * = P<0.05. All recordings were performed in 
the presence of 25 μM D-(-)-2-amino-5-phosphonopentanoic acid, 5 μM 2,3-dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo(f)quinoxaline-7-sulfonamide, 0.5 μM tedrodotoxin, 1 mM tetraethylammonium and 
50 μM d-Tubocurarine. 
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sIAHP is suppressed by several neurotransmitters, by monoamines like noradrenaline,  
dopamine, histamine and serotonin via PKA dependent phosphorylation and also by 
acetylcholine and glutamate (Stocker et al., 2004). The identity of sIAHP in cultured hippocampal 
neurons was therefore tested by application of the acetylcholine analogue CCh, which is not 
hydrolysed by acetylcholinesterase (Cole and Nicoll, 1984) and suppresses sIAHP, and by 
application of the membrane permeable cAMP analogue 8CPT-cAMP, which activates PKA and 
inhibits sIAHP (Pedarzani and Storm, 1993). Whole-cell voltage-clamp recordings of sIAHP were 
performed as described (section 2.2.14.2 and 3.3.2.2) and the current was reversibly 
suppressed following the addition of 2.5 μM CCh to the extracellular solution (Fig. 3.28A and 
C); the overlay of control and CCh traces show the extent of inhibition. In this recording the 
recovered sIAHP was in one experiment subsequently inhibited to a similar extent by the 
application of 8CPT-cAMP (Fig. 3.28B and C), consistent with PKA modulation of the underlying 
conductance. Average sIAHP amplitude before exposure to CCh amounted to 26.4 ± 2.3 pA (n=9, 
control) and was suppressed to 7.3 ± 2.1 pA (n=9, CCh; P=0.0003, paired t-test; Fig. 3.28D), 
which is a reduction of sIAHP amplitude to 29.1 ± 8.2 % of the original.  Wash out of CCh allowed 
sIAHP amplitude to return to 18.1 ± 1.8 pA (n=6, recovery; Fig. 3.28D), corresponding to a 
recovery of 71.7 ± 11.3 %.  Change of sIAHP was also studied by examining the current charge 
transfer (Fig. 3.28E). sIAHP charge transfer decreased from 113.5 ± 14.8 pC (n=9, control) to 
28.6 ± 11.6 pC after CCh application (n=9, CCh; P=0.001, paired t-test; Fig. 3.28F). This 
reduction of sIAHP charge transfer to 24.8 ± 9.7 % of the original by CCh was reversible and sIAHP 
charge transfer recovered to 80.9 ± 13.5 pC (n=6, recovery; Fig. 3.28F), which equals a recovery 
of 86.1 ± 20.5 %. These results agreed with previous observations of sIAHP suppression by CCh 
and 8CPT-cAMP in cultured hippocampal neurons (Gallasch, 2008) and with results obtained in 
hippocampal slices (Pedarzani and Storm, 1993). 
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Figure 3.28 sIAHP is suppressed by CCh and 8CPT-cAMP. Representative whole-cell voltage-clamp 
recordings of sIAHP in an EGFP-negative neuron in the presence of 25 μM D-(-)-2-amino-5-
phosphonopentanoic acid, 5 μM 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-
sulfonamide, 0.5 μM tedrodotoxin, 1 mM tetraethylammonium and 50 μM d-Tubocurarine. sIAHP was 
reversibly inhibited by the extracellular application of (A) the cholinergic agonist carbachol (CCh;  
2.5 μM) and (B) 8CPT-cAMP (100 μM). The dashed grey line indicates zero current (A and B). (C) Example 
time course of sIAHP amplitude in response to the application of CCh and (in this cell) 8CPT-cAMP. (D) Bar 
diagram summarising the effect of CCh on sIAHP amplitude (P=0.0003, paired t-test). sIAHP amplitude 
recovered to 71.7 ± 11.3 % of control. (E) Representative time course showing the effect of CCh and (in 
this cell) 8CPT-cAMP application on sIAHP charge transfer. (F) Summary of the change of sIAHP charge 
transfer upon CCh application (P=0.001, paired t-test). The effect of CCh was reversible and sIAHP charge 
transfer recovered to 86.1 ± 20.5 % of control. * = P<0.05. Mean values ± SEM are presented. 
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3.3.3 Effects of mutant RhoA virus infection on sIAHP in cultured hippocampal 
pyramidal neurons 
Examining the passive properties of EGFP-negative, RhoA-V14 and RhoA-N19 infected 
hippocampal neurons demonstrated that resting potential and input resistance of the cells 
were not affected by Sindbis virus infection. Furthermore, sIAHP in cultured hippocampal 
neurons displayed the same properties as described in hippocampal slices (Alger and Nicoll, 
1980; Hotson and Prince, 1980; Madison and Nicoll, 1982 and 1984; Lancaster and Adams, 
1986; Pedarzani and Storm, 1993). Firstly sIAHP was not affected by dTC, the application of 
which blocked IAHP present in these cultures. Secondly, sIAHP was Ca
2+ dependent and thirdly, 
sIAHP was suppressed by the application of CCh as well as by 8CPT-cAMP. Therefore cultures of 
hippocampal neurons present a system in which the effect of mutant RhoA infection on sIAHP 
can be studied. In neurons infected with RhoA-N19 sIAHP is expected to be present just as in 
EGFP-negative neurons, but might display a lower sensitivity to cholinergic agonists because 
RhoA-N19 is inactive and its expression might outcompete endogenous RhoA. Infection with 
constitutively active RhoA-V14 virus on the other hand should mimic the application of 
cholinergic agonist and thus neurons should show a suppressed sIAHP. 
3.3.3.1 sIAHP in RhoA-N19 and RhoA-V14 infected cultured hippocampal neurons 
Cultured hippocampal neurons were infected with recombinant Sindbis virus to express either 
the inactive RhoA-N19 or the constitutively active RhoA-V14 and whole-cell voltage-clamp 
recordings were performed as described. EGFP-negative pyramidal neurons from uninfected 
coverslips as well as from coverslips treated with Sindbis virus served as control. sIAHP was 
observed in EGFP-negative neurons (Fig. 3.29A) as well as in neurons expressing RhoA-N19 
(Fig. 3.29B), while sIAHP in RhoA-V14 infected cells was reduced displaying only flat or small 
sIAHP-shaped traces (Fig. 3.29C). Only once out of eight was a full-size sIAHP detected in cells 
infected with RhoA-V14 (Fig. 3.29D and E, RhoA-V14). The amplitude of sIAHP detected in EGFP-
negative neurons (n=13) amounted to 27.1 ± 1.8 pA, in RhoA-N19 infected neurons (n=9) to 
20.6 ± 1.6 pA and in RhoA-V14 infected neurons (n=8) to 6.2 ± 2.7 pA (P<0.0001, one-way 
ANOVA; Fig. 3.29D). The post-hoc Bonferroni’s multiple comparison test determined that sIAHP 
of EGFP-negative and RhoA-N19 infected cells did not differ, while sIAHP of RhoA-V14 infected 
cells differed significantly from both EGFP-negative and RhoA-N19 infected cells. The same was 
observed when comparing sIAHP charge transfer, which was 118.4 ± 10.8 pC in EGFP-negative 
neurons (n=13), 113.4 ± 10.9 pC in RhoA-N19 infected cells (n=9) and 39.8 ± 19 pC in RhoA-V14 
infected cells (n=8) (P=0.0006, one-way ANOVA; Fig. 3.29E). Additionally, the time to peak of 
sIAHP was analysed in EGFP-negative (0.7 ± 0.1 s, n=13) and RhoA-N19 infected (0.8 ± 0.1 s, n=9) 
neurons and did not differ significantly (P=0.1932, unpaired t-test). 
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Figure 3.29 sIAHP is present in EGFP-negative and RhoA-N19 infected cultured hippocampal 
pyramidal neurons, but not in RhoA-V14 infected neurons. Representative current traces and time 
courses of sIAHP in EGFP-negative (A) and in RhoA-N19 (B) or RhoA-V14 (C) infected neurons. The dashed 
grey line indicates zero current (A–C). Bar diagrams summarizing (D) sIAHP amplitude in EGFP-negative 
(27.1 ± 1.8 pA, n=13), RhoA-N19 (20.6 ± 1.6 pA, n=9) and RhoA-V14 (6.2 ± 2.7 pA, n=8) neurons 
(P<0.0001, one-way ANOVA) and (E) sIAHP charge transfer in EGFP-negative (118.4 ± 10.8 pC, n=13), 
RhoA-N19 (113.4 ± 10.9 pC, n=9) and RhoA-V14 (39.8 ± 19 pC, n=8) infected cells (P=0.0006, one-way 
ANOVA). The post-hoc Bonferroni’s multiple comparison tests showed that sIAHP amplitude and charge 
transfer in RhoA-V14 infected neurons differed significantly from EGFP-negative and RhoA-N19 infected 
neurons, which themselves did not differ from each other. Amplitude and charge transfer 
measurements of sIAHP were taken after the current had reached a stable baseline following the 
application of tedrodotoxin (TTX), tetraethylammonium (TEA) and d-Tubocurarine (dTC) (section 
2.2.14.2). All recordings were performed in the presence of 25 μM D-(-)-2-amino-5-phosphonopentanoic 
acid, 5 μM 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-sulfonamide, 0.5 μM TTX, 1 mM 
TEA and 50–100 μM dTC. * = P<0.05 and mean values ± SEM are shown. 
3.3.3.2 Cholinergic modulation of sIAHP in EGFP-negative and inactive RhoA-N19 infected 
cultured hippocampal neurons.  
Whole-cell voltage-clamp recordings of sIAHP were performed as described and the cholinergic 
modulation of sIAHP in EGFP-negative and inactive RhoA-N19 infected neurons was determined 
by adding 2.5 μM CCh to the extracellular solution. The overlay of control traces (black) and 
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traces under CCh application (blue) display the extent of sIAHP suppression in EGFP-negative 
and RhoA-N19 infected neurons (Fig. 3.30A and B). In EGFP-negative neurons the effect of CCh 
on sIAHP was seen to be reversible (Fig. 3.30A, time course; Fig. 3.28D), which was not observed 
in RhoA-N19 infected cells (Fig. 3.30B, time course). Changes in series resistance were 
monitored throughout the recordings and did not account for the differences observed in 
EGFP-negative and RhoA-N19 infected cells. sIAHP amplitude in EGFP-negative cells amounted 
to 26.4 ± 2.3 pA (n=9, black bar) and was significantly suppressed by CCh to 7.3 ± 2.1 pA (n=9, 
blue bar; P=0.0003, paired t-test; Fig. 3.30C). In RhoA-N19 infected cells sIAHP amplitude was 
18.9 ± 3.4 pA (n=4, black bar), which was reduced to 9.4 ± 2.2 pA (n=4, blue bar) by CCh; a 
suppression that was not significantly different (P=0.0735, paired t-test; Fig. 3.30C). The 
evaluation of sIAHP amplitude left under CCh application also showed a tendency of RhoA-N19 
infected cells to be less affected by CCh (52.8 ± 10.3 % sIAHP amplitude left) compared to EGFP-
negative cells (29.1 ± 8.2 %), but no significant difference between the two groups was 
determined (P=0.1207, unpaired t-test; Fig. 3.30D). The same was observed when examining 
sIAHP charge transfer in EGFP-negative and RhoA-N19 infected neurons. In EGFP-negative cells 
sIAHP charge transfer was 113.5 ± 14.8 pC (n=9, black bar), which was reduced to 
28.6 ± 11.6 pC following application of CCh (n=9, blue bar; P=0.001, paired t-test; Fig. 3.30E). 
sIAHP charge transfer in RhoA-N19 infected cells amounted to 99.9 ± 17.7 pC (n=4, black bar) 
and was reduced by CCh to 51.4 ± 14.7 pC (n=4, blue bar; P=0.0558 , paired t-test; Fig. 3.30E). 
Comparing the percentage of sIAHP charge transfer left under CCh application in EGFP-negative, 
24.8 ± 9.7 %, and in RhoA-N19 infected cells, 52.3 ± 10.4 %, did not result in a significant 
difference (P=0.1197, unpaired t-test; Fig. 3.30F). 
 
 Figure 3.30 The effect of CCh application on sIAHP in EGFP-negative and inactive RhoA-N19 
infected cultured hippocampal pyramidal neurons. Representative sIAHP current traces and time course 
in an EGFP-negative (A) and a RhoA-N19 (B) infected neuron showing the effect of the cholinergic 
agonist carbachol (CCh; 2.5 μM, blue) on sIAHP amplitude. The dashed grey line indicates zero current (A 
and B). (C) Bar diagram summarizing sIAHP amplitude in EGFP-negative and RhoA-N19 infected neurons 
before (black) and after (blue) the application of CCh. In EGFP-negative neurons CCh suppressed sIAHP 
amplitude significantly (P=0.0003, paired t-test; n=9), while in RhoA-N19 infected neurons the effect of 
CCh on sIAHP amplitude was less pronounced (P=0.0735, paired t-test; n=4). (D) Comparison of the 
percentage of sIAHP amplitude left during CCh application in EGFP-negative and RhoA-N19 infected 
neurons (P=0.1207, unpaired t-test). (E) Summary of sIAHP charge transfer in response to CCh application 
in EGFP-negative and RhoA-N19 infected cells. sIAHP charge transfer was significantly reduced by CCh in 
EGFP-negative neurons (P=0.001, paired t-test; n=9), but not in RhoA-N19 infected cells (P=0.0558, 
paired t-test; n=4). (F) The percentage of sIAHP charge transfer left during CCh application in EGFP-
negative and RhoA-N19 infected cells was not significantly different (P=0.1197, unpaired t-test). 
Recordings were performed in the presence of 25 μM D-(-)-2-amino-5-phosphonopentanoic acid, 5 μM 
2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-sulfonamide, 0.5 μM tedrodotoxin, 1 mM 
tetraethylammonium and 50–100 μM d-Tubocurarine. Mean values ± SEM are shown and * = P<0.05. 
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3.3.4 Summary 
Recombinant Sindbis viruses containing either the inactive RhoA-N19 or the constitutively 
active RhoA-V14 were used to infect cultured hippocampal neurons and the effect of mutant 
RhoA protein expression on sIAHP was examined in order to assess the role of RhoA in the 
signalling pathway mediating the suppression of sIAHP by cholinergic agonists. The functionality 
of the mutant RhoA proteins has been shown by their ability to regulate the cytoskeleton. 
Primary cultured hippocampal neurons presented a useful model system, because sIAHP has 
been demonstrated to have the same properties than in slices. The results show that RhoA is 
involved in the signalling pathway mediating sIAHP suppression by cholinergic agonists because 
sIAHP was suppressed in RhoA-V14 infected neurons, but was present in neurons infected with 
RhoA-N19. Expression of RhoA-V14 thus mimicked the inhibitory effect of cholinergic agonists 
on sIAHP. The modulation of sIAHP by cholinergic agonists was thought to be diminished in 
neurons infected with RhoA-N19 and the results show that the suppression of sIAHP by CCh in 
RhoA-N19 infected neurons was less pronounced, but overall did not differ significantly from 
EGFP-negative neurons. 
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4 Discussion 
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The work presented in this thesis focuses on the signal transduction pathway underlying the 
regulation of the Ca2+-dependent sIAHP by ACh. Cholinergic agonists suppress sIAHP and enhance 
the neuronal excitability of hippocampal pyramidal neurons. This regulation of network activity 
of the hippocampal formation plays a crucial role in learning and memory processes. The main 
finding of the present study identifies the small GTPase RhoA as a component of this signal 
transduction pathway and shows that RhoA acts as a binding partner of the Gq-protein α 
subunit (Gαq), through which cholinergic agonists have been shown to mediate their inhibitory 
action on sIAHP (Krause et al., 2002). This reveals a novel pathway for the regulation of sIAHP by 
neurotransmitters like ACh and glutamate acting on GPCRs coupled to the heterotrimeric Gq-
protein and an involvement of RhoA in the regulation of membrane excitability of hippocampal 
neurons presents a novel function. ACh and glutamate suppress sIAHP in hippocampal 
pyramidal neurons (Cole and Nicoll, 1983; Madison et al., 1987; Charpak et al., 1990), but the 
details of their signal transduction pathways had not been well identified. 
In contrast, the signalling cascade used by monoamine neurotransmitters is better 
characterised: monoamine neurotransmitters inhibit sIAHP by acting on GPCRs coupled to Gαs, 
which stimulates AC and subsequently results in the production of cAMP and the activation of 
PKA (Fig. 4.1; Madison and Nicoll, 1986b; Pedarzani and Storm, 1993 and 1995; Torres et al., 
1995). This has led to the hypothesis that sIAHP is suppressed through a phosphorylation step, 
whose ultimate target remains to be identified and could involve intermediate proteins or 
occur directly at the channel responsible for sIAHP. PIP2 is involved in the activation of several K
+ 
channels including Kir and KV7 channels (Suh and Hille, 2005) and the regulation of sIAHP by PIP2 
has been proposed by one study (Villalobos et al., 2011). PIP2 synthesis is catalysed by PIP5K, 
which itself is prone to phosphorylation by PKA (Park et al., 2001). Hence, the inhibition of sIAHP 
by monoamine transmitters could be mediated by the inhibition of PIP5K by PKA and the 
subsequent reduction of PIP2 levels (Fig. 4.1; Andrade et al., 2012). 
The suppression of sIAHP by cholinergic and glutamatergic agonists, however, does not involve 
the described signalling pathway via PKA (Fig. 4.1; Gerber et al., 1992; Pedarzani and Storm, 
1993; Blitzer et al., 1994; Pedarzani and Storm, 1996). In contrast, ACh and glutamate regulate 
sIAHP by activating GPCRs coupled to G-proteins of the Gq family (Dutar and Nicoll, 1988; Gerber 
et al., 1992; Offermanns et al., 1994; Blin et al., 1995; Pin and Duvoisin, 1995; Abdul-Ghani et 
al., 1996) and studies in knock-out mice have shown that the signalling pathway involves the 
G-protein α subunit Gαq, but not Gα11 (Fig. 4.1; Krause et al., 2002). However, the suppression 
of sIAHP by ACh and glutamate is not mediated by the classical pathway of GRPCs coupled to Gq-
proteins (Fig. 4.1), because neither PLCβ (Krause and Pedarzani, 2000; Young et al., 2004), PKC 
(Gerber et al., 1992; Sim et al., 1992; Engisch et al., 1996) nor IP3-sensitive stores (Krause and 
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Pedarzani, 2000) are involved. The inhibition of CamKII partially reduces the suppression of 
sIAHP by cholinergic agonists, but how CamKII is activated by mAChRs, in the absence of an 
involvement of IP3, is not established (Müller et al., 1992; Pedarzani and Storm, 1996). 
The work presented in this thesis has investigated a novel signalling pathway downstream of 
Gαq leading to the suppression of sIAHP by ACh and glutamate and the proposed signalling 
cascade is depicted schematically in Figure 4.1 (highlighted in blue). In order to determine the 
role of RhoA in the signalling pathway suppressing sIAHP, this study employed RhoA mutants, 
either constitutively active RhoA-V14 or inactive RhoA-N19. RhoA mutants were introduced 
into hippocampal pyramidal neurons either by the intracellular application of purified proteins 
or by Sindbis virus infection. Whole-cell patch clamp recordings have shown that sIAHP is 
significantly reduced in neurons expressing constitutively active RhoA-V14, hence mimicking 
the inhibitory effect of ACh and glutamate, while sIAHP is not affected in neurons expressing 
inactive RhoA-N19. Furthermore, it was investigated whether RhoA and Gαq could act in a 
common signalling pathway leading to the suppression of sIAHP in hippocampal neurons. The 
potential protein-protein interaction of Gαq and RhoA was examined by employing various 
molecular biology and imaging techniques in heterologous expression system and the work 
presented in this study has established RhoA as a signalling partner of Gαq. The proposed 
signal transduction pathway is initiated by ACh or glutamate acting on GPCRs coupled to Gαq, 
which would activate RhoA and subsequently lead to the suppression of sIAHP (Fig. 4.1). 
 
Figure 4.1 Signal transduction pathways mediating the suppression of sIAHP. Schematic depiction 
of established and proposed signal transduction pathways used by various neurotransmitters to 
suppress sIAHP. The pathway highlighted in blue was the focus of this study. Numbers correspond to a 
reference list that can be found in Table 4.1.  
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1 Monoamine 
NTs 
sIAHP suppression Benardo and Prince, 1982; Pedarzani 
and Storm, 1995 (dopamine) 
Haas and Konnerth, 1983; Pedarzani 
and Storm, 1993 (histamine) 
Madison and Nicoll, 1982; Haas and 
Konnerth, 1983; Lancaster and 
Adams, 1986; Madison and Nicoll, 
1986a; Pedarzani and Storm, 1993; 
Blitzer et al, 1994 (noradrenaline) 
Andrade and Nicoll, 1987; Colino and 
Halliwell, 1987; Pedarzani and Storm, 
1993; Torres et al, 1995 (serotonin) 
2 cAMP and 
PKA 
Monoamine NTs activate GPCRs 
coupled to Gαs leading to the 
activation of AC, cAMP production 
and activation of PKA 
Madison and Nicoll, 1986b; Pedarzani 
and Storm, 1993; Blitzer et al, 1994;  
Pedarzani and Storm, 1995; Torres et 
al, 1995 
3 PIP2 Involved in the activation of several K
+ 
channels.  Suggested to enhance Ca2+ 
sensitivity of sIAHP. PIP5K catalyses the 
production of PIP2 and is inhibited by 
PKA 
Park et al, 2001; Villalobos et al, 2011; 
Andrade et al, 2012 
4 ACh and 
glutamate 
sIAHP suppression Cole and Nicoll, 1983; Madison et al, 
1987 (ACh) 
Charpak et al, 1990 (glutamate) 
5 Gαq Involvement in sIAHP suppression by 
ACh and glutamate 
Krause et al, 2002 
6 PLCβ  No involvement in sIAHP suppression 
by ACh and glutamate 
Krause and Pedarzani, 2000; Young et 
al, 2004 
7 PKC No involvement in sIAHP suppression 
by ACh and glutamate 
Gerber et al, 1992; Sim et al, 1992; 
Engisch et al, 1996 
8 IP3 No involvement of IP3-sensitive stores 
in sIAHP suppression by ACh and 
glutamate 
Krause and Pedarzani, 2000 
9 CamKII sIAHP suppression by ACh (but not by 
glutamate) is reduced when CamKII is 
inhibited 
Müller et al, 1992; Pedarzani and 
Storm, 1996 
10 PKA No involvement in sIAHP suppression 
by ACh and glutamate 
Gerber et al, 1992; Pedarzani and 
Storm, 1993; Blitzer et al, 1994; 
Pedarzani and Storm, 1996 
11 RhoA Involvement in sIAHP suppression by 
ACh and glutamate 
P. Pedarzani, personal 
communication;  
findings of this study 
12 ROCK and 
MLCK 
No involvement of ROCK and MLCK in 
sIAHP suppression by ACh and 
glutamate 
P. Pedarzani, personal communication 
Table 4.1 Reference list for the signal transduction pathway diagram (Fig. 4.1.). 
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4.1 The small GTPase RhoA associates with the heterotrimeric G-protein α 
subunit Gαq 
The small GTPase RhoA is best known for its regulation of the actin cytoskeleton and is 
responsible for the formation of focal adhesion and stress fibres as well as for cell rounding. 
External stimuli, like the application of lysophosphatidic acid, that activate RhoA affect the 
cytoskeleton and cause the formation of stress fibres (Paterson et al., 1990; Ridley and Hall, 
1992; Naumanen et al., 2008). RhoA contributes to the regulation of the actin cytoskeleton by 
signalling to mDia, which promotes actin filament polymerization through its interaction with 
the actin-binding protein profilin (Watanabe et al., 1997). RhoA signalling via ROCK and myosin 
light chain kinase (MLCK) is responsible for the formation of stress fibres (Kimura et al., 1996; 
Ridley, 1996 and 1999; Totsukawa et al., 2000; Katoh et al., 2001). Different upstream 
regulators of RhoA, such as neurotransmitters activating GPCRs coupled to G-proteins of the 
G12 family (Buhl et al., 1995; Fromm et al., 1997; Hart et al., 1998; Fukuhara et al., 1999 and 
2000) and the Gq family (Mitchell et al., 1998; Sagi et al., 2001; Booden et al., 2002; Chikumi et 
al., 2002; Dutt et al., 2002; Lutz et al., 2005), have been identified. Furthermore, targets of 
small GTPases include ion channels (Pochynyuk et al., 2007) and RhoA is able to modulate ion 
channel function, for example, inactivating inwardly rectifying K+ channels (Kir2; Jones, 2003; 
Rossignol and Jones, 2006), inhibiting voltage-gated K+ channels (KV1.2; Cachero et al., 1998; 
Stirling et al., 2009; ERG (KV11.1); Storey et al., 2002) or stimulating epithelial Na
+ channels 
(ENaC; Staruschenko et al., 2004) and voltage-gated Ca2+ channels (CaV1; Yatani et al., 2005). 
The signal transduction pathway mediating the suppression of sIAHP by ACh and glutamate has 
been shown to include Gαq, but not its classical signalling pathway via PLCβ, and the small 
GTPases RhoA is proposed to be part of this signalling cascade (Fig. 4.1). 
The work presented in this thesis investigates the ability of RhoA to interact with Gαq using 
different molecular biology and imaging techniques. Co-immunoprecipitation experiments in 
heterologous expression system show that Gαq associates with RhoA (Fig. 3.1), but not with 
other small GTPases (Fig. 3.2). The interaction of Gαq and RhoA is detected in HEK293 cells 
expressing unmutated Gαq or constitutively active Gαq-L209, but is prevented in cells 
expressing the inactive Gαq-L209/N277 mutant, which is unable to bind GTP and thus hindered 
from binding to downstream effectors (Fig. 3.1). Moreover, unmutated and constitutively 
active Gαq are able to interact with both constitutively active RhoA-V14 as well as inactive 
RhoA-N19 (Fig. 3.1B). This is due to the fact that the inactivating mutation leaves RhoA in a 
nucleotide-free state unable to interact with downstream targets, but not interfering with its 
binding capability to upstream regulators. The interaction between Gαq and RhoA was not 
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hindered by the attachment fluorophores to the proteins (Fig. 3.8) and ECFP-tagged Gαq and 
Venus-tagged RhoA were subsequently used in imaging experiments.  
Gαq and RhoA association seems to be independent of Gαq activation, since both unmutated 
Gαq and constitutively active Gαq-L209 were able to interact with unmutated, constitutively 
active as well as inactive RhoA. Both Gαq variants had previously been investigated by testing 
their ability to activate PLCβ and measuring the subsequent IP3 formation, and cells 
transfected with constitutively active Gαq produced higher levels of IP3 than cells transfected 
with unmutated Gαq (Wu et al., 1992; Qian et al., 1993). An activation-independent interaction 
of Gαq and RhoA (Fig. 4.2A) would imply that Gαq sequesters RhoA and that both proteins are 
constitutively associated with each other. This would mean that the structural conformation of 
their binding site stays unchanged in the inactive, GDP-bound as well as in the active, GTP-
bound state and that Gαq and RhoA complex formation is also possible in the presence of the 
Gβγ dimer. Moreover, the inability of the inactive, xanthine-bound Gαq to bind RhoA then has 
to be attributed to its different structural composition and not to its inactive state. However, 
the classical binding sites of Gα subunits as well as RhoA span their switch regions (Vetter and 
Wittinghofer, 2001) and are thought to be inaccessible in the inactive state, primarily because 
of the protein’s structural conformation and in the case of Gα also because of Gβγ binding, 
which speaks for an activity-dependent interaction (Fig. 4.2C). In order to align an activity-
dependent association of Gαq and RhoA (Fig. 4.2C) with the results obtained in the co-
immunoprecipitation experiments, the activation of the unmutated Gαq in the cells would 
have been required. In either case, the co-immunoprecipitation experiments presented in this 
thesis have established the protein-protein interaction of Gαq and RhoA. In general, successful 
co-immunoprecipitations in heterologous expression system are regarded as a direct 
interaction between the expressed proteins. However, the detected association could also be 
mediated by an endogenously expressed protein that forms part of a multi-protein complex 
for example a RhoGEFs (Fig. 4.2B and C; Fig. 4.3). 
The presented models of Gαq and RhoA interaction (Fig. 4.2) summarize the results of this 
thesis as well as findings described in the literature. Experiments performed in this thesis 
identified an interaction between Gαq and RhoA in the unmutated as well as in the 
constitutively active state, which suggests an activity-independent interaction (Fig. 4.2A and 
B). However, the literature describes an activation-dependent interaction between Gα and 
small GTPases (Fig. 4.2C), in which the activation of Gα leads to the interactions with RhoGEFs, 
which then serve as activators for small GTPases (Hart et al., 1998; Kozasa et al., 1998; 
Fukuhara et al., 1999 and 2000; Booden et al., 2002; Lutz et al., 2005). The binding sites of Gα 
subunits as well as small GTPases are thought to only become accessible in the active state and 
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crystallography has revealed a protein complex Gαq-p63RhoGEF-RhoA (Fig. 4.3) suggesting that 
the simultaneous binding of Gαq to the Gβγ dimer and to a RhoGEF is not possible (Lutz et al, 
2007).  
 
Figure 4.2 Potential models of Gαq and RhoA interaction. (A) In this study Gαq has been shown 
to associates with RhoA in both its unmutated as well as constitutively active form suggesting an 
activity-independent interaction. How this can be consolidated with Gα being bound to the Gβγ dimer in 
the inactive state needs to be determined. (B) Whether it is possible for a RhoGEF to be a constitutive 
part of this protein complex has to be investigated. Information gained from the crystal structure of 
Gαq-p63RhoGEF-RhoA suggests that the simultaneous binding of Gαq to the Gβγ dimer and to a RhoGEF 
is not possible (Lutz et al, 2007). (C) Activation-dependent model of Gαq and RhoA interaction based on 
the literature on the activation of small GTPases (Hart et al., 1998; Kozasa et al., 1998; Fukuhara et al., 
1999 and 2000; Booden et al., 2002; Lutz et al., 2005). * indicates active proteins 
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FRET experiments were performed to investigate the association of Gαq and RhoA by other 
means and also had the advantage that the direct interaction of proteins can be established, 
since FRET only takes place when donor and acceptor fluorophores are within 10 nm (100 Å) of 
each other i.e. over distances the size of proteins (Vogel et al., 2006). FRET efficiency depends 
on the distance between fluorophores and increases the closer the proximity of the two 
fluorophores, and FRET only occurs when the fluorophores are not oriented perpendicular to 
each other (Vogel et al., 2006). FRET has been used to determine Gαq and RhoA functions in 
other studies, for example, a FRET sensor (RhoA-YFP-linker-CFP-Rho binding domain) was used 
to investigate RhoA activity during cell migration (Pertz et al., 2006). The interaction of Gαq 
with downstream targets PLCβ (Dowal et al., 2006) and PI3K (Golebiewska and Scarlata, 2008) 
was also investigated using FRET. The FRET results between Gαq and RhoA obtained in this 
thesis indicate an interaction of the two proteins and substantiate the findings of co-
immunoprecipitation and co-localisation experiments. FRET depends on the distance between 
two proteins, so the detection of intermediate FRET efficiency values for the ECFP-tagged Gαq 
and Venus-tagged RhoA (E = 4–10 %; Fig. 3.11 and 3.12) compared to E = 21 % for the positive 
FRET control CFP-YFP (Fig. 3.10) could imply that the distance between the two fluorophores is 
only just in the detectable range. FRET would be reduced if the fluorophores happen to be 
located on opposite ends of the Gαq-RhoA-complex and unable to come into the close 
proximity necessary for the detection of high FRET efficiency values or if an intermediate 
protein such as RhoGEFs (Fig. 4.3) causes Gαq and RhoA to be further apart from each other 
within the protein complex. Furthermore, FRET would also be reduced if the fluorophores 
were not properly orientated to each other, something that can only be influenced by inserting 
ECFP and Venus at different sites of the proteins. By performing FRET experiments with ECFP-
tagged Gαq that was either carboxyl-terminal or loop-tagged different labelling strategies were 
tested that could have affected the orientation of the donor and acceptor fluorophores to 
each other and thus impacted on the FRET signal. However, the results show that the detected 
FRET signal was not influenced by the different ECFP-tag positions. 
This study employed the FRET method of acceptor photobleaching, which measures an 
increase in donor fluorescence upon the destruction of the acceptor fluorophore if FRET had 
been occurring. Acceptor photobleaching avoids the disadvantage of sensitized emission, 
another widely used FRET method. In sensitized emission cross-talk between the two 
fluorophores is caused by the excitation of the donor fluorophore in order to measure the 
energy transfer to the acceptor fluorophore and needs to be controlled extensively (Vogel et 
al., 2006; Piston and Kremers, 2007). Acceptor photobleaching allows for the direct 
measurement of FRET without needing to remove any cross-talk components necessary when 
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using sensitized emission to measure FRET. This is also true for FLIM-FRET, which monitors the 
lifetime of the donor fluorescence in the absence and presence of a donor and which will 
become shorter when FRET is taking place (Vogel et al., 2006; Piston and Kremers, 2007). Thus 
FLIM-FRET also prevents the problem of cross-talk and avoids any potential damage to the 
donor fluorophore that could arise with the acceptor photobleaching method, but specialized 
equipment to measure the changes in fluorescence lifetime on a nanosecond timescale is 
needed to perform FLIM (Vogel et al., 2006; Piston and Kremers, 2007). In this study, the FRET 
measurements performed between ECFP-tagged Gαq and Venus-RhoA have repeatedly 
resulted in negative FRET efficiency values, an observation that has also been described by 
others using the method of acceptor photobleaching (Karpova et al., 2003). Negative FRET 
efficiency values can be caused by the bleaching of the donor ECFP-tagged Gαq itself during 
image acquisition or by cross-excitation, even though unlikely (section 3.1.7), and damage of 
ECFP by the 514 nm laser line that was used to excite and bleach the acceptor Venus-RhoA. 
Negative as well as positive FRET measurements were obtained under the same experimental 
conditions and on the same day and what exactly caused the bleaching of CFP in this study 
could not be determined. In addition, the detected FRET efficiency values for any of the 
investigated ECFP-Gαq variants and Venus-RhoA combinations were rather variable in their 
strength. In the light of these observations and different advantages and disadvantages of the 
various FRET methods, repeating the investigation using a different FRET method like FLIM-
FRET could enhance our understanding of the nature of the interaction between Gαq and 
RhoA. 
The interaction of Gαq and RhoA with their signalling partners takes place at the plasma 
membrane to which both proteins are bound through lipid modifications and in the case of 
Gαq also through its association with the Gβγ dimer (Seabra, 1998; Chen and Manning, 2001; 
Hughes et al., 2001). In the heterologous expression system used in this study only loop-tagged 
Gαq-ECFP-Gαq was localised at the plasma membrane of HEK293 cells, while carboxyl-
terminally tagged Gαq-ECFP and both constitutively active, looped-tagged Gαq-ECFP-Gαq-C183 
or L209 were expressed throughout the cytoplasm (Fig. 3.5). The cytosolic localisation of 
carboxyl-terminal tagged Gαq has been reported before (Witherow et al., 2003) and loop-
tagged Gαq have been developed (Hughes et al., 2001; Witherow et al., 2003) to avoid 
interference with the functionally important amino- and carboxyl-termini (Conklin and Bourne, 
1993; Hepler et al., 1996). On the other hand, Venus-tagged RhoA was localised throughout 
the cytoplasm (Fig. 3.5), which is in line with previous reports (Adamson et al., 1992b; 
Michaelson et al., 2001) and with the fact that GDIs sequester inactive Rho-GTPases in the 
cytoplasm (Boguski and McCormick, 1993). Activated RhoA, upon the separation from GDIs 
148 
 
and the exchange of GDP for GTP, has been described to translocate from the cytoplasm to the 
plasma membrane (Bokoch et al., 1994; Keller et al., 1997; Kranenburg et al., 1997). The 
predominantly cytosolic expression of Venus-tagged RhoA and several ECFP-tagged Gαq 
variants observed in this study made it impossible to differentiate any potential plasma 
membrane signal. However, a degree of plasma membrane localisation of constitutively active, 
looped-tagged Gαq-ECFP-Gαq-C183 was revealed when soluble proteins were extracted by 
Triton X-100 treatment (Hughes et al., 2001). On the other hand, the R183C but not the Q209L 
mutation has been reported to decrease the ability of Gαq to interact with the Gβγ dimer and 
would therefore interfere with its membrane targeting (Hughes et al., 2001; Evanko et al., 
2005), which could be part of the reason for the observed difference in localisation of the 
constitutively active, loop-tagged Gαq-ECFP-Gαq-C183 compared to loop-tagged Gαq-ECFP-Gαq. 
That targeting of Gαq to the plasma membrane requires its association with the Gβγ dimer and 
following GTP binding the switch regions of Gα undergo a conformational change that causes 
dissociation from the Gβγ dimer has been described (section 1.3). Constitutively active Gαq 
mutants cannot hydrolyse GTP and thus the bound GTP could hinder the association of Gαq 
with the Gβγ dimer and therefore plasma membrane localisation. Furthermore, the level of 
endogenous Gβγ might have not been sufficient to aid plasma membrane localisation of the 
exogenously expressed Gαq variants. But the fact that unmutated Gαq-ECFP-Gαq was able to 
localise at the plasma membrane (Fig. 3.12) do not support this explanation. Plasma 
membrane association of Gαq-ECFP-Gαq was also not affected following its activation by the 
co-expressed mAChR M3, which had been activated by the cholinergic agonist CCh (Fig. 3.12). 
Nevertheless, over-expression of the fusion proteins might influence their localisation as the 
association of Gα proteins with the plasma membrane has been reported to be more easily 
observed in cells expressing lower amounts of protein (Witherow et al., 2003). On the other 
hand, the predominantly cytosolic expression of RhoA was preserved in cells stably expressing 
RhoA at much lower levels than could be achieved with a transient transfection (Michaelson et 
al., 2001). FRET was measured for all Venus-RhoA and ECFP-tagged Gαq combinations in their 
respective locations: at the plasma membrane for Gαq-ECFP-Gαq and in the cytoplasm for all 
other ECFP-tagged Gαq variants. Overall, similar FRET efficiency values were obtained for all of 
the different ECFP-tagged Gαq variants in combination with Venus-RhoA. 
FRET experiments were performed using constitutively active Gαq mutants as well as 
unmutated Gαq, which was either used on its own or in combination with the mAChR M3. Since 
co-immunoprecipitation experiments have shown that Gαq and RhoA interact regardless of 
whether unmutated or constitutively active proteins were co-expressed, only unmutated RhoA 
was used in FRET experiments in order to avoid major changes to the actin cytoskeleton by 
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constitutively active RhoA (Ridley and Hall, 1992; Kranenburg et al., 1997). The expression of 
unmutated Gαq-ECFP-Gαq and M3, which was activated by CCh, in combination with Venus-
RhoA did not affect the FRET efficiency values compared to the ones obtained with unmutated 
Gαq-ECFP-Gαq alone (Fig. 3.12) or with constitutively active ECFP-tagged Gαq variants 
(Fig. 3.11). This is in agreement with the results obtained from co-immunoprecipitation 
experiments and indicates that the interaction of Gαq and RhoA is activity-independent 
(Fig. 4.2A). On the other hand, an activity-dependent interaction of Gαq and RhoA (Fig. 4.2C) 
would imply that, in the experiments presented in this thesis, unmutated Gαq had been 
activated in the cell. In this case, the comparable FRET efficiency values, obtained from 
unmutated Gαq, constitutively active Gαq mutants and receptor-activated Gαq, would imply 
that unmutated Gαq was indeed in an active, GTP-bound state during the FRET experiments. In 
either case, the interaction of Gαq and RhoA that was identified by co-immunoprecipitation 
was substantiated in the FRET experiments and thus, by definition, indicating their direct 
interaction. However, since the FRET efficiency values obtained in this study were of 
intermediate strength, it might be advisable to characterise the interaction of Gαq and RhoA 
using another FRET method like FLIM as described above or investigate the possibility of an 
indirect interaction that is mediated by an intermediate protein present in the Gαq-RhoA 
complex for example a RhoGEF (Fig. 4.2B and C; Fig. 4.3). 
The data presented in this thesis identify Gαq and RhoA as interaction partners in heterologous 
expression systems and indicates that the two proteins could also be part of a common 
signalling pathway mediating the suppression of sIAHP by ACh and glutamate in hippocampus. 
RhoA has been established to act as a downstream effector of GPCRs (Seasholtz et al., 1999; 
Sah et al., 2000) and notably of GPCRs coupled to the heterotrimeric Gq-protein (Mitchell et al., 
1998; Sagi et al., 2001; Booden et al., 2002; Chikumi et al., 2002; Dutt et al., 2002; Lutz et al., 
2005). Using cell lines, these studies have shown that the activation of GPCRs coupled to G-
proteins of the Gq family, or the expression of constitutively active Gαq mutants, enhances 
GTP-bound RhoA levels as well as serum response factor-dependent gene transcription and 
induces changes in the actin cytoskeleton as identified by the formation of stress fibres. 
Furthermore, crystallography has revealed a protein complex that includes Gαq and RhoA as 
well as a GEF p63RhoGEF (Fig. 4.3; Lutz et al., 2007) and the direct activation of p63RhoGEF by 
Gαq has also been determined (Shankaranarayanan et al., 2010). Other RhoGEFs have also 
been shown to be targets of Gαq, including Lbc (Sagi et al., 2001) and LARG (Booden et al., 
2002). 
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Figure 4.3 Crystal structure of the Gαq-p63RhoGEF-RhoA protein complex. Gαq (blue) was 
shown to form contacts with p63RhoGEF at its pleckstin homology (purple) and Dbl homology (yellow) 
domains, but not with RhoA (green). (from Lutz et al., 2007) 
RhoGEFs of the Dbl family are characterised by a Dbl homology (DH) domain, which catalyses 
GDP to GTP nucleotide exchange of Rho-GTPases, and a pleckstrin homology (PH) domain that 
is responsible for the correct positioning of the DH domain, for plasma membrane targeting 
and for the interaction with the Gα subunit (Fig. 4.3; Zheng, 2001; Hoffman and Cerione, 2002; 
Rossman et al., 2005; Aittaleb et al., 2010). Gαq interacts primarily with the PH domain of 
RhoGEFs of the Dbl family (Fig. 4.3; Lutz et al., 2007; Rojas et al., 2007). The Gαq binding sites 
for p63RhoGEF and PLCβ are almost identical (Waldo et al., 2010) and over-expression of 
p63RhoGEF reduces PLCβ activation (Bodmann et al., 2014), which could explain how sIAHP 
suppression can be mediated by a signalling pathway comprising p63RhoGEF and RhoA, but be 
independent of PLCβ activation. GEFs like p63RhoGEF are endogenously expressed in HEK293 
cells (Lutz et al., 2005) and could have acted as intermediate binding partners of the Gαq-RhoA 
complex in the co-immunoprecipitation described in this thesis. According to the crystal 
structure (Fig. 4.3; Lutz et al., 2007) p63RhoGEF links Gαq and RhoA and no contacts are 
formed between Gαq and RhoA. The presence of p63RhoGEF in the protein complex would 
increase the distance between the two proteins and might consequently account for the 
intermediate FRET efficiency values obtained in the FRET experiments. The possibility of 
RhoGEFs acting as intermediate proteins between Gαq and RhoA can neither be confirmed nor 
excluded by the experiments undertaken in this study. The crystallography study (Lutz et al., 
2007) presents a Gαq-p63RhoGEF-RhoA complex without the direct binding of Gαq and RhoA, 
but whether RhoGEFs are also involved in the signalling transduction pathway leading to the 
inhibition of sIAHP by ACh and glutamate needs to be determined by investigating RhoGEFs 
directly (section 4.4). 
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4.2 The small GTPase RhoA is involved in the cholinergic suppression of sIAHP 
In addition to its characteristic role in the regulation of the actin cytoskeleton, RhoA is also 
involved in various other cellular processes and contributes to the regulation of cell cycle, gene 
transcription, microtubule organization, vesicular transport, cell growth and motility, and 
enzymatic activities (Takai et al., 2001; Jaffe and Hall, 2005). The proposed involvement of 
RhoA in the suppression of sIAHP by ACh in hippocampal pyramidal neurons, and thus in the 
regulation of membrane excitability on a relatively fast time-scale, would be a novel function 
for the small GTPase. The data presented in this and other studies (Krause and Pedarzani, 
2000) have shown that the suppression of sIAHP by cholinergic agonists occurs within a few 
minutes (2.1 ± 0.3 min; Fig. 3.28 and 3.30), which is in agreement with the time course 
reported for RhoA activation by CCh through GPCRs coupled to Gq-proteins showing (earliest 
detection at 0.5 min; Chikumi et al., 2002).  
In order to identify an involvement of RhoA in this pathway, constitutively active RhoA-V14 or 
inactive RhoA-N19 protein was purified and introduced into CA1 pyramidal cells of acute 
hippocampal slices, a system in which sIAHP is well characterised (Alger and Nicoll, 1980; Hotson 
and Prince, 1980; Madison and Nicoll, 1982 and 1984; Lancaster and Adams, 1986; Pedarzani 
and Storm, 1993). The strategy of introducing purified proteins into cells through the patch 
pipette had been used in another study for the intracellular application of Rac1 and RhoA into 
pituitary cells (Storey et al., 2002). That study demonstrated that, in response to thyrotropin-
releasing hormone, the small GTPases regulate KV11.1 (ERG) in opposing fashion, with Rac1 
stimulating and RhoA inhibiting the channel. To determine the role of RhoA in the signalling 
cascade leading to the suppression of sIAHP, whole-cell patch clamp recordings in hippocampal 
pyramidal neurons in acute slices were performed with either RhoA-V14 or RhoA-N19 protein 
in the patch pipette and sIAHP was recorded. The data presented suggest an involvement of 
RhoA, since sIAHP is reduced in cells containing the constitutively active RhoA-V14 protein 
compared to control and RhoA-N19 cells (Fig. 3.20). At the maximal steady-state level reached 
by the current, sIAHP amplitude in RhoA-V14 cells was significantly different to sIAHP levels of 
control and RhoA-N19 cells, but overall the reduction was only partial. Generally, under 
control condition sIAHP has been reported to be stable throughout the recordings (Pedarzani 
and Storm, 1993; Pedarzani et al., 1998; but see Villalobos et al., 2011). However, an 
evaluation of the inhibiting effect of RhoA-V14 on sIAHP after ~20 min of recording was 
complicated by the run-down of the current in all three groups and a potential increase in the 
inhibitory effect of RhoA-V14 on sIAHP at later time points could not be determined. The partial 
reduction of sIAHP in neurons containing RhoA-V14 protein observed at steady-state could be 
due to the fact that the amount of protein introduced through the patch pipette was 
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insufficient to suppress sIAHP to levels observed following the application of cholinergic (Cole 
and Nicoll, 1983; Madison et al., 1987) and glutamatergic (Charpak et al., 1990) agonists. An 
inadequate diffusion of the protein into the cell could be one reason, and furthermore, whole-
cell voltage clamp recordings were performed by patching the cell body and the mutant RhoA 
proteins might have not reached their site of action if the channels generating sIAHP are located 
on the dendrites (Sah and Bekkers, 1996; Bekkers, 2000), although their somatic location has 
also been proposed (Lima and Marrion, 2007). However, sIAHP recordings from hippocampal 
pyramidal neurons dialyzed with C3-exoenzyme (P. Pedarzani, personal communication), 
which has a similar molecular weight (25 kDa; Aktories et al., 1988) as RhoA (21 kDa), or the 
catalytic subunit of PKA (38 kDa; Pedarzani and Storm, 1993) have shown that proteins of this 
size can diffuse into the neurons and affect sIAHP and its regulation. 
To circumvent limitations of the intracellular application of mutant RhoA proteins such as time 
of exposure of mutant proteins in neurons or diffusion to the correct cellular location and to 
maximize the effect of exogenous RhoA, Sindbis viruses containing mutant RhoA were 
generated and used to over-express RhoA-V14 or RhoA-N19 in hippocampal pyramidal cells. 
The Sindbis virus expression system was chosen, since it enables proteins to be expressed 
quickly and displays high specificity for neurons. Primary cultured hippocampal neurons were 
infected with Sindbis virus and the effect of the expressed RhoA mutants on sIAHP was 
investigated by whole-cell patch clamp recordings. sIAHP is present in hippocampal cultures and 
has the same features as in acute slices (Shah and Haylett, 2000b; Gallasch, 2008). 
Furthermore, it was determined that the basic membrane properties of primary hippocampal 
neurons are not affected by the infection with Sindbis virus (Fig. 3.25). The primary purpose of 
the Sindbis virus infections of mutant RhoA was to identify whether or not RhoA participates in 
the suppression of sIAHP in hippocampal neurons and the results clearly demonstrate that RhoA 
is part of the transduction cascade. In hippocampal neurons that express constitutively active 
RhoA-V14 sIAHP was almost completely inhibited, whereas in neurons expressing inactive RhoA-
N19 sIAHP did not differ from control cells in terms of current amplitude, charge transfer and 
time to peak (Fig. 3.29). Using Sindbis virus to express mutant RhoA proteins removes the 
limitations presented by the intracellular application of purified RhoA proteins, which might 
affect the passage of proteins into the neuron and their diffusion within the cell. However, 
even this system cannot prevent the possibility of varied RhoA protein expression levels in 
individual neurons. The residual sIAHP and the single occasion of a full-sized recording of sIAHP in 
neurons expressing RhoA-V14 can possibly be attributed to this fact. 
The cholinergic inhibition of sIAHP is reduced in hippocampal neurons when RhoA was inhibited 
by a synthetic peptide against its carboxyl-terminus or by the intracellular application of C3-
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exoenzyme (P. Pedarzani, personal communication). Thus it was hypothesised that the 
suppression of sIAHP by cholinergic agonists in hippocampal neurons expressing inactive RhoA-
N19 would also be diminished. This was tested by the application of CCh to hippocampal 
neurons infected with RhoA-N19 and the data presented show that sIAHP in these neurons has 
the tendency to be less affected by CCh, albeit the effect was not significantly different from 
control neurons (Fig. 3.30).  One explanation why CCh still had an effect on sIAHP in RhoA-N19 
expressing neurons could be the RhoA-N19 mutant itself, although its inactivity had been 
determined in stress fibre formation tests (Fig. 3.24). Another reason, equally to RhoA-V14 
expressing neurons, could be a varied protein expression level of RhoA-N19 in individual 
neurons. This would mean that in neurons expressing low levels of the mutant protein, 
endogenous RhoA would be able to mediate the inhibitory effect of CCh on sIAHP similar to 
control cells, whereas the suppression by CCh would be reduced in neurons expressing high 
levels of exogenous RhoA-N19. Furthermore, a better coupling of endogenous RhoA to 
mAChRs and the channels generating sIAHP with insufficient turnover and replacement by the 
RhoA-N19 mutant could be another reason. Insufficient turnover and replacement of mutant 
RhoA-N19 before recording could be addressed by allowing more time before recording from 
infected neurons. The data presented in this study were obtained at 24 h, and occasionally 
48 h, after infection and the effect of CCh on sIAHP in neurons expressing inactive mutant RhoA-
N19 was not changed over this time. Furthermore, constitutively active RhoA-V14 was shown 
to be able to affect sIAHP in this time frame. A difference between the effect of CCh on sIAHP in 
EGFP-negative and RhoA-N19 infected neurons was the observed lack of reversibility of the 
current upon the removal of CCh (Fig. 3.30). The cause of this could not be established. There 
were no apparent differences in the passive properties of the neurons between the EGFP-
negative and RhoA-N19 infected neurons, nor was there in the series resistance that was 
monitored throughout the recording. A general problem of run-down of sIAHP in RhoA-N19 
infected neurons would have to be investigated in long-term recordings without the 
application of CCh. 
The participation of RhoA in the signalling pathway leading to the suppression of sIAHP in 
primary cultured hippocampal neurons is one of the main findings of this study and a 
subsequent aim would be to replicate these Sindbis-virus experiments in organotypic or acute 
brain slices and determine the effect of RhoA mutants on sIAHP in that system and investigate 
its regulation by cholinergic agonists. 
4.3 Signalling downstream of RhoA 
The identity of the channel underlying sIAHP has not yet been identified, which makes the 
identification of the signal transduction pathways leading to its inhibition the more 
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challenging. As described above, the signalling cascade employed by monoamine transmitters 
has been determined up to the point of PKA activation and a yet unidentified phosphorylation 
step is thought to mediate the inhibition of sIAHP (Fig. 4.1). The results of this study, together 
with other preliminary data from our laboratory, have established the small GTPase RhoA as 
part of the signalling pathway used by ACh to suppress sIAHP in hippocampal pyramidal 
neurons. The actual means by which RhoA mediates the inhibition of sIAHP and which 
downstream effectors might be involved remains elusive.  
Classical targets of RhoA such as mDia, ROCK and MLCK participate in the regulation of the 
actin cytoskeleton and are responsible for actin filament assembly and stress fibre formation. 
In Swiss-3T3 cells stress fibre formation in response to the application of fetal calf serum or 
lysophosphatidic acid was observed within a few minutes and within 15 min of injecting 
constitutively active RhoA-V14 protein (Ridley and Hall, 1992). Gαq has been reported to 
induce the formation of stress fibres by activating endogenous RhoA in Swiss-3T3 cells (Dutt et 
al., 2002). In neuronal cells the activation of RhoA by Gαq causes neurite retraction and cell 
rounding (Katoh et al., 1998), which is caused by the formation of contractile actin-myosin 
filaments (Ridley, 1996; Hall, 1998). ROCK inhibitors hinder the formation of stress fibres 
caused by Gαq activation of RhoA (Dutt et al., 2002). Whether the suppression of sIAHP also 
involves ROCK was investigated by the use of ROCK inhibitors in whole-cell patch clamp 
recordings in acute hippocampal slices and it was determined that ROCK does not participate 
in the suppression of sIAHP by ACh and glutamate (Fig. 4.1; P. Pedarzani, personal 
communication). Furthermore, inhibitors of MLCK have also been shown to not affect the 
inhibitory effect of ACh and glutamate on sIAHP (Fig. 4.1; P. Pedarzani, personal 
communication). It is therefore unlikely that changes to the cytoskeleton mediated by ROCK 
and MLCK are the underlying cause for the inhibition of sIAHP following the activation of RhoA 
by ACh and glutamate, although effects on the cytoskeleton by different downstream effectors 
of RhoA cannot be excluded. In addition, no clear macroscopic changes in the morphology of 
the primary cultured hippocampal neurons have been observed in this study, but parameters 
like neurite retraction or cell rounding have not been quantified. Furthermore, only neurons 
displaying the morphology of pyramidal neurons i.e. with triangular-shaped soma and 
distinctive processes were selected for patching. 
RhoA has been implicated in the regulation of various ion channels including the inhibition of 
K+ channels (Cachero et al., 1998; Storey et al., 2002; Jones, 2003; Rossignol and Jones, 2006; 
Stirling et al., 2009). These findings give rise to the possibility that RhoA could mediate the 
suppression of sIAHP by acting directly on the underlying channel or by signalling to 
intermediate proteins, which in turn affect the channel. In the case of KV1.2, yeast two-hybrid 
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and co-immunoprecipitation experiments have established the association of RhoA with the 
amino-terminus of KV1.2 and the over-expression of constitutively active or inactive RhoA 
mutants or the inhibition of RhoA by C3-exoenzyme has shown that RhoA (Cachero et al., 
1998) also mediates the tyrosine kinase-dependent suppression of KV1.2 by the muscarinic 
acetylcholine receptor M1 (Huang et al., 1993). Moreover, the suppression of KV1.2 by RhoA 
involves the endocytosis of the channel via a ROCK-dependent pathway (Stirling et al., 2009). A 
role of ROCK was also suggested in the inhibition of KV11.1 by RhoA (Storey et al., 2002), 
whereas the suppression of Kir2.1 by RhoA was not affected by the inhibition of ROCK (Jones, 
2003). RhoA also enhances the activity of Na+ channels of the ENaC family; RhoA initiates a 
signal transduction pathway that activates ROCK, whose stimulation of PIP5K catalyses the 
production of PIP2 (Oude Weernink et al., 2000 and 2004) and a PIP2 increase promotes the 
expression of ENaC at the plasma membrane (Staruschenko et al., 2004). While the signalling 
partnership of RhoA and ROCK seems to present a powerful system in the regulation of some 
ion channels, the cases of Kir2.1 and sIAHP, whose regulation does not involve ROCK, show that 
other downstream effectors of RhoA must also be implicated. 
4.4 Future directions 
The interaction of Gαq and RhoA has been identified in heterologous expression system and its 
validation in neuronal tissue has been attempted by performing co-immunoprecipitations of 
the endogenous proteins. However, the available RhoA antibody merely allowed the detection 
of endogenous RhoA in brain lysates (Fig. 3.4). Co-immunoprecipitations from brain tissue 
should therefore be re-attempted once an antibody of sufficient avidity becomes available. 
This thesis has established the involvement of RhoA in the signalling pathway leading to the 
suppression of sIAHP in primary cultured hippocampal neurons. This finding should be validated 
in brain slices by performing whole-cell patch clamp recordings of sIAHP in slices that have been 
infected with the Sindbis virus to introduce the RhoA mutants. Initial experiments in 
organotypic slices have been undertaken (P. Pedarzani, personal communication). 
GPCR signalling via Gαq to RhoA has been implicated to involve RhoGEFs, such as p63RhoGEF, 
Lbc and LARG (Sagi et al., 2001; Booden et al., 2002; Lutz et al., 2005; Shankaranarayanan et 
al., 2010), and the crystal structure of a Gαq-p63RhoGEF-RhoA complex has been determined 
(Lutz et al., 2007). The potential involvement of RhoGEFs in the signalling pathways leading to 
the suppression of sIAHP by ACh and glutamate in hippocampal neurons should thus be 
examined. The three RhoGEFs named above present a good starting point as they are the only 
members of the vast RhoGEF family that have been identified to act downstream of Gαq. 
p63RhoGEF, for example, is present mainly in the brain and the heart (Souchet et al., 2002; 
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Lutz et al., 2004). An antibody for p63RhoGEF is available (Wuertz et al., 2010) and could be 
used to verify the interaction of endogenous p63RhoGEF with Gαq and RhoA. In order to 
identify the role of RhoGEFs in the suppression of sIAHP, whole-cell patch clamp recordings 
could be performed in hippocampal pyramidal neurons, in which candidate RhoGEFs are 
inhibited, for example, by antibodies directed against them or by the intracellular application 
of mutant RhoGEFs such as p63RhoGEF-E301 (Souchet et al., 2002). Moreover, candidate 
RhoGEFS could be downregulated in siRNA experiments or in potential knock-out mice. A 
reduction in the suppression of sIAHP by ACh and glutamate would indicate the involvement of 
RhoGEFs in the signalling cascade. 
Furthermore, the role of G-proteins of the G12 familiy (Gα12 and Gα13) in the suppression of 
sIAHP by ACh and glutamate should be investigated. The hypothesis arises from the finding that 
the cholinergic and glutamatergic inhibition of sIAHP in Gαq knock-out mice is only reduced by 
~50% (Krause et al., 2002) and from the fact that G-proteins of the G12 family are known to 
signal to Rho-GTPases and can be coupled to mAChRs (Buhl et al., 1995; Fromm et al., 1997; 
Hart et al., 1998; Fukuhara et al., 1999 and 2000; Siehler, 2009). Gα12/13 have also been shown 
to activate RhoA through RhoGEFs (Hart et al., 1998; Fukuhara et al., 1999 and 2000; Suzuki et 
al., 2003; Kozasa et al., 2011). Mice lacking the G-protein α subunit Gα12 or Gα13 (Offermanns 
et al., 1997; Dettlaff-Swiercz et al., 2005) could be used to perform whole-cell patch clamp 
recordings in hippocampal pyramidal neurons and the effect of cholinergic and glutamatergic 
agonists on sIAHP investigated. Their inhibitory action ought to be reduced should Gα12 or Gα13 
be involved. Thus the suppression of sIAHP by ACh and glutamate could be mediated by two 
converging pathways onto RhoA. 
By determining neuronal excitability and firing patterns of hippocampal pyramidal neurons, 
sIAHP contributes to the regulation of the network activity of the hippocampal formation that 
underlies learning and memory processes. sIAHP is responsible for spike frequency adaptation 
by restricting the repetitive firing of action potentials, thus contributing greatly to the control 
of neuronal excitability. sIAHP is suppressed by various neurotransmitters including ACh, 
glutamate and the monoamine neurotransmitters dopamine, histamine, noradrenaline and 
serotonin (Storm, 1990; Sah, 1996) and its modulation shapes the intrinsic properties of 
hippocampal pyramidal neurons that are essential in learning and memory processes. sIAHP 
thus presents a target for multiple pathways aiming to regulate neuronal excitability and firing 
properties. Irregularity in the control of sIAHP can lead to epileptic activity (Alger and Nicoll, 
1980). Establishing the nature of the signalling pathways underlying the suppression of sIAHP is 
therefore central to our understanding of the regulation of network activity involved in the 
processes of memory and learning.  
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Abbreviations 
4-AP  4-aminopyridine 
8-Br cAMP 8-bromoadenosine 3’,5’-monophosphate 
8CPT-cAMP 8-(4-chlorophenylthio) adenosine 3’,5’-cyclic monophosphate 
AA/BA  Acrylamide/Bisacrylamide 
AC  Adenylyl Cyclase 
ACh  Acetylcholine 
AMPA  α-amino-3-hydroxy-5-methyl-isoxazole-propionic acid 
APS  Ammonium Persulfate 
APV  D-(-)-2-Amino-5-phosphonopentanoic acid 
ATP  Adenosine Triphosphate 
BHK  Baby Hamster Kidney 
BSA  Bovine Serum Albumin 
CA  Cornu Ammonis 
CaM  Calmodulin 
cAMP  Cyclic Adenosine Monophosphate 
cGMP  Cyclic Guanosine Monophosphate 
CCh  Carbachol 
CFP  Cyan Fluorescent Protein 
CTP  Cytidine Triphosphate  
DAG  Diacylglycerol  
DEPC  Diethyl Pyrocarbonate 
dH2O  Deionised H2O 
DH  Dbl Homology 
DIV  Day in vitro 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO  Dimethyl Sulfoxide 
dTC  d-Tubocurarine 
DTT  Dithiothreitol 
ECFP  Enhanced Cyan Fluorescent Protein 
EDTA  Ethylenediaminetetraacetic Acid 
EE-tag  Glu Glu epitope-tag 
EGFP  Enhanced Green Fluorescent Protein 
EYFP  Enhanced Yellow Fluorescent Protein 
fAHP  Fast Afterhyperpolarization 
FBS  Fetal Bovine Serum 
FLIM  Fluorescence Lifetime Imaging Microscopy 
FRET  Fluorescence Resonance Energy Transfer 
GAP  GTPase Accelerating Protein 
GDI  Guanine Nucleotide Dissociation Inhibitor 
GDP  Guanosine Diphosphate 
GEF  Guanine Nucleotide Exchange Factor 
GFP  Green Fluorescent Protein 
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GPCR  G-protein Coupled Receptor 
GRK   G-protein-coupled Receptor Kinase 
GST  Glutathione-S-Transferase 
GTP  Guanosine Triphosphate 
HBSS  Hank’s Buffered Salt Solution 
HEK  Human Embryonic Kidney 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic Acid 
HRP  Horseradish Peroxidase 
ICQ  Intensity Correlation Quotient 
IMS  Industrial Methylated Spirit 
IP3  Inositol 1,4,5-Triphosphate 
IPTG  Isopropyl β-D-Thiogalactopyranoside 
KGluc  Potassium Gluconate 
KMeSO4 Potassium Methylsulphate 
LB  Luria Broth 
LTP  Long-Term Potentiation 
mAHP  Medium Afterhyperpolarisation 
mGluR  Metabotropic Glutamate Receptor 
mAChR  Muscarinic Acetylcholine Receptor 
MAPK  Mitogen-Activated Protein Kinase 
MEM  Minimum Essential Medium 
MLCK  Myosin Light Chain Kinase 
MOPS  3-(N-Morpholino)propanesulfonic Acid 
mRFP  Monomeric Red Fluorescent Protein 
nAChR   Nicotinic Acetylcholine Receptor 
NGS  Normal Goat Serum 
NBQX  2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-sulfonamide 
NMDA  N-methyl-D-aspartate 
NMDAR N-methyl-D-aspartate Receptor 
nsP  Nonstructural Protein 
OD  Optical Density 
PBS  Phosphate Buffered Saline 
PCR  Polymerase Chain Reaction 
PDM  Product of the Difference of the Mean 
PFA  Paraformaldehyde 
PH  Pleckstrin Homology 
Pi  Inorganic Phosphate 
PIP2  Phosphatidylinositol 4,5-bisphosphate 
PIP5K  Phosphatidylinositol 4 phosphate 5-Kinase 
PKA  Protein Kinase A 
PKC   Protein Kinase C 
PKI  Walsh Peptide PKA Inhibitor 
PKN  Protein Kinase N 
PLC  Phospholipase C 
190 
 
PMSF  Phenylmethylsulfonyl Fluoride 
PMT  Photomultiplier Tube 
PSG  Subgenomic Promoter 
RGS  Regulator of G-protein signalling 
ROCK  Rho-Kinase 
ROI  Region of Interest 
Rp-cAMP Rp-adenosine-3’,5’-cyclic monophosphorothioate 
sAHP  Slow Afterhyperpolarization 
SDS  Sodium Dodecyl Sulfate 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
SEM  Standard Error of the Mean 
SOB  Super Optimum Broth 
SOC  Super Optimum Broth with Catabolite Repression 
TAE  Tris Acetate EDTA 
TBE  Tris Borate EDTA 
TBS  Tris Buffered Saline 
TBST  Tris Buffered Saline with Tween-20 
TEA  Tetraethylammonium 
TEMED  N,N,N’,N’-tetramethylethylenediamine 
TRITC  Tetramethylrhodamine Isothiocyanate 
TTX  Tedrodotoxin 
UTP  Uridine Triphosphate 
Venus  YFP derivative 
YFP  Yellow Fluorescent Protein 
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A.1 List of Materials 
A.1.1 Consumables 
Item  Company Cat.-No. 
Cellophane Sheets  Novex NC2380 
Centrifuge Tubes 12 ml Greiner 163270 
 10 ml, polycarbonate Beckman 355630 
Coverslips 24 x 60 mm BDH 406.0181.02 
 22 x 22mm  Menzel-Glaeser 406.0187.35 
 10 mm Ø Menzel-Glaeser CB00100RA1 
Cryotube  Nunc 343958 
Cuvettes  Sarstedt 67.742 
Electroporation Cuvettes 4 mm, BTX model 640 Harvard Apparatus 45-0126 
 1 mm, BTX model 610 Harvard Apparatus 45-0124 
Films BioMax MR-1 Kodak 873-6936 
 Hyperfilm ECL GE 28-9068-40 
Filters Syringe filter, 0.22 μm Millipore SLGP033RS 
 Stericup 150, 0.22 μm Millipore SCGPU01RE 
 Stericup 500, 0.22 μm Millipore SCGPU05RE 
 VectaSpin Micro, 0.2 μm Whatman 6830-0203 
Glass Capillaries Borosilicate Harvard 300044 
 1.2 mm OD, 0.69 mm ID, 100 mm L 
 Borosilicate Kimble Chase 34500-99 
 1.5–1.8 mm OD, 1.3–1.6 mm ID, 100 mm L 
Microcentrifuge Tubes 0.5 ml Sarstedt 72.699 
 1.5 ml  72.690 
 2 ml  72.695 
Nitrocellulose Membranes Protran BA83, 0.2 μm Whatman 10401396 
 Hybond ECL, 0.2 μm GE RPN3032D 
PCR Reaction Tube 0.2 ml Applied Biosystems N8010540 
Plastic Tubes 15 ml Sarstedt 62.553.001 
 50 ml  62.547.004 
Plastic Tube with Snap-Cap 14 ml Falcon 352059 
Serological Pipettes 5 ml Sarstedt 86.1253.001 
 10 ml  86.1254.001 
 25 ml  86.1685.001 
Tissue Culture Flasks T25 Sarstedt 83.1810.002 
 T75 Nunc 156499 
 T225 Nunc 159933 
Tissue Culture Dishes Ø 3.5 cm Nunc 153066 
 Ø 6 cm  150288 
 Ø 10 cm  150350 
 6-well dish Nunc 140675 
 4-well dish Nunc 176740 
Transfer Pipettes 3.5 ml Sarstedt 86.1171.001 
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A.1.2 Equipment 
Item  Company 
Anti-vibration Table  TCM 
Centrifuges 5415R/5424/5702R Eppendorf 
 Megafuge 1.0 & 1.0R Heraeus 
 J2-M1 Beckman 
Electrophoresis Cell mini-PROTEAN II BIO-RAD 
 SE 600 Hoefer 
Electroporation Systems GenePulser XCell BIO-RAD 
 ECM 600 BTX 
Gel Dryer Model 583 BIO-RAD 
Glass Homogeniser  Glas-Col 
Heat Block Thermomixer compact Eppendorf 
Hoods BioMAT2 CAS 
 Class II MSC Walker 
  Envair 
ImageQuant LAS4000 mini GE 
Incubators  Heraeus 
Microelectrode Puller L/M-3P-A List Medical 
 P-97 Flaming/Brown Sutter 
Microinjector FemtoJet Eppendorf 
Micromanipulator 5171 Eppendorf 
Mixer  IKA 
Osmometer Vapro 5520 Wescor 
Patch Clamp Amplifier EPC10 HEKA 
pH Meter RL150 Russell 
 766 Knick 
Power Supply EV261 Consort 
 PowerPac 300 BIO-RAD 
 PowerPac 3000 BIO-RAD 
Pressure Control Unit MPCU-3 Lorenz 
Pump Dymax 30 Charles Austen 
  KNF Neuberger 
Rotors JA-14/JA-17 Beckman 
Scales  Delta Range 
Sequencer 3100-Avant Applied Biosystems 
Semi-Dry Transfer Cell V20-SDB Scie-Plas 
Shaker, orbital 3005 GFL 
Shaker, incubator Innova4230 New Brunswick Scientific 
 G25 Brunswick Scientific 
Sonicator SonoPuls Bandelin 
Spectrophotometer NanoDrop 1000 Labtech International 
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 SmartSpec Plus BIO-RAD 
Tank Transfer Cell mini Trans-Blot BIO-RAD 
Thermal Cycler 2720 Applied Biosystems 
Thermal Printer P91 Mitsubishi 
UV lamp UV (254 nm) IBI 
 UVL-24 (4 W, 365 nm) UVP 
X-Ray Film Processor RG II Fuji 
A.1.3 Microscopes 
Item       Company 
Axiophot      Zeiss 
 Filter Set 10 (GFP, Alexa Fluor 488)  Zeiss 
  Excitation: BP 450-490, Beam Splitter: FT 510, Emission: BP 515-565 
 Filter Set 15 (TRITC, mRFP, Alexa Fluor 594) Zeiss 
  Excitation: BP 546/12, Beam Splitter: FT 580, Emission: LP 590 
 HBO Mercury Short-Arc Lamp, 103W/2  Osram 
 Micropublisher CCD Camera    QImaging 
 Objectives (Plan Neofluar)   Zeiss 
  10x/0.3NA, 20x/0,5NA, air-immersion 
  40x/1.3NA, 63x/1.25NA, oil-immersion 
 QCapture Software    QImaging 
Axiovert 135M      Zeiss 
 Objectives (Plan Neofluar and Achrostigmat) Zeiss 
  5x/0.5NA, 20x/0.3NA, 32x/0.4NA air-immersion 
Axiovert 200      Zeiss 
 HBO Mercury Short-Arc Lamp, 103W/2  Osram 
 Longpass Filter (EGFP)    Chroma 
  Excitation: HQ 480/40, Beam Splitter: DCLPQ505, Emission: HQ510LP 
 Objective (Epiplan Neofluar)   Zeiss 
  20x/0.5NA, air-immersion 
DM IBR       Leica 
 Filter Set L5 (GFP)    Leica 
  Excitation: BP 480/40, Beam Splitter: 505, Emission: BP 527/30 
 Filter Set N2.1 (Cy3, TRITC)   Leica 
  Excitation: BP 515-560, Beam Splitter: RKP580, Emission: LP 590 
 HBO Mercury Short-Arc Lamp, 103W/2  Osram 
 Objectives (N Plan and N Plan L)   Leica 
  10x/0.25 NA, 20x/0.4 NA, 40x/0.55 NA air-immersion 
 OpenLab software, v.5.5.2   Improvision 
 ORCA-HR CCD camera, C4742-95  Hamamatsu 
 
195 
 
TCS SP5 Confocal     Leica 
 Argon laser, 100 mW 
 Acquisition settings 
  CFP; Excitation: 458 nm, Emission: 462–500 nm 
  YFP; Excitation: 514 nm, Emission: 520–600 nm 
  Cy5; Excitation: 633 nm, Emission: 650–750 nm 
 LAS AF software    Leica 
 Objective (HCX Plan Apochromat)  Leica 
  63x/1.4 NA, oil-immersion 
A.1.4 Kits, reagents and chemicals 
A.1.4.1 Kits 
Item  Company Cat.-No. 
BigDye Terminator v2.0  Applied Biosystems 4314414 
ECL Western Blotting Detection Reagents GE RPN2106 
Bradford Protein Assay Dye Reagent Concentrate BIO-RAD 500-0006 
mMESSAGE mMACHINE SP6  Ambion AM1340 
Nucleobond PC 100/500  Macherey-Nagel 740573/4 
NucleoSpin Extract-II  Macherey-Nagel 740609.50 
NucleoSpin Plasmid  Macherey-Nagel 740588.50 
ProLong Antifade  Molecular Probes P7481 
SP6 TNT Coupled Reticulocyte Lysate System Promega L4600 
SuperSignal West Pico Chemiluminescent Substrate Pierce 34079 
T7 TNT Quick Coupled Transcription/Translation System Promega L1171 
A.1.4.2 Reagents and chemicals 
Item  Company Cat.-No. 
8CPT-cAMP-Na  Sigma C3912 
30 % Acrylamide/Bisacrylamide (AA/BA) BIO-RAD 161-0158 
Acetic Acid  VWR 20104.334 
Agar Select  Gibco 30391-023 
Agarose, Ultra Pure  Invitrogen 15510-027 
Ammonium Persulfate (APS) Sigma A3678 
Ampicillin  Boehringer Mannheim 835269 
APV  Ascent Scientific ASC-004 
Aprotinin  Sigma A1153 
ATP-Na  Sigma A2383  
Autofluor  National Diagnostics LS-315 
B27, 50x  Gibco 17504-044 
Benzamidine  Sigma B6506 
β-Mercaptoethanol  BDH 436022A 
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2-Butanol  BDH 27500 
Boric Acid  BDH 44390 
Bovine Serum Albumin (BSA) Sigma A3294 
Bovine Serum Albumin (BSA) (protein standards) Pierce 23209 
  First Link UK Ltd 40-00-410 
Bromphenol Blue  Sigma B5525 
Carbenicillin  Melford C0109 
Carbachol (CCh)  Sigma C4382 
Chloroform  BDH 100776B 
Coomassie Brilliant Blue R250 Biomol 03285 
Diethyl Pyrocarbonate (DEPC) Sigma D5758 
DMEM  Gibco 21969-035 
DMEM/F-12  Gibco 21331-020 
Dimethyl Sulfoxide (DMSO)  Sigma D2650 
d-Tubocurarine-Cl (dTC)  Sigma 93750 
Dithiothreitol (DTT)  Biomol 04010.100 
Ethylenediaminetetraacetic Acid (EDTA) IBI Technical IB70180 
Ethanol  BDH 101074F 
Ethidium Bromide (10mg/ml) Sigma E1510 
Fetal Bovine Serum (FBS)  Gibco 10500-064 
Ficoll 400  GE 17-0300-10 
Formaldehyde  Calbiochem 344198 
Formamid  Fluka 47671 
FuGene 6  Roche 11814443001 
Glucose  Fisher Scientific 10141520 
  Merck 1.08337.1000 
Glucose (tissue culture, 45 %) Sigma G8769 
Glutathione Agarose  Sigma G4510 
Glycerol  Sigma G7893 
Glycine  BIO-RAD 161-0724 
  SIGMA G8898 
GTP-Na  Sigma G8877 
H2O (cell culture)  Baxter UKF7113 
H2O (intracellular solution)  Romil H951 
HBSS, 10x  Gibco 14180-046 
HEPES  Fluka 54461 
HEPES (tissue culture, 1 M)  Gibco 15630-049 
Horse Serum  Gibco 26050-070 
Industrial Methylated Spirit (IMS) VWR 302444E 
Isopropanol  BDH 102245K 
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Isopropyl β-D-Thiogalactopyranoside (IPTG) Biomol 05684.1 
Kanamycin  Sigma K4000 
Potassium Gluconate (KGluc) SIGMA G4500 
Potassium Methylsulphate (KMeSO4) ICN 215481 
L-Glutamine  Gibco 25030-024 
Leupeptin  Calbiochem 108975 
Lipofectamine 2000  Invitrogen 11668-019 
MEM  Gibco 21090-022 
MEM alpha (with Ultraglutamine and nucleosides) Lonza BE02-002F 
MEM alpha (without L-Glutamine) Lonza BE12-169F 
Methanol  VWR 20846.326 
[35S] methionine, 1000 Ci/mMol PerkinElmer                NEG009T001MC 
Miller’s Luria Broth (LB) Base Invitrogen 12795-027 
Mowiol 4-88 (polyvinyl alcohol) Calbiochem 475904 
Milk Powder  Marvel 
  Merck 1153630500 
MOPS  Sigma M3183 
NBQX  Ascent Scientific ASC-046 
Neurobasal  Gibco 21103-049 
Normal Goat Serum (NGS)  Gibco 16210-072 
NP-40  Sigma N0896 
Opti-MEM  Gibco 51985-034 
Paraformaldehyde (PFA)  SIGMA P6148 
  EMS 19208 
PBS, pH 7.2  Gibco 20012-019 
Penicillin/Streptomycin  Gibco 15140-148 
Pepstatin  Calbiochem 516481 
Phenol f. RNA (buffered pH 7.5) Gibco-BRL 15513-013 
Phenylmethylsulfonyl Fluoride (PMSF) Sigma P7626 
Poly-D-Lysine  Sigma P0899 
Protein A/G Plus Agarose  Santa Cruz SC-2003 
Protein A Sepharose Fast Flow GE 17-5138-01 
Protein G Sepharose Fast Flow GE 17-0618-01 
SeaKem LE Agarose  Lonza 50009 
Sodium Dodecyl Sulfate (SDS) USB US75819 
Sodium Pyruvate  Gibco 11360-039 
Streptomycin Sulphate  Melford S0148 
Sucrose  Sigma S7903 
TAE  National Diagnostics EC-872 
TEA  Sigma T2265 
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N,N,N’,N’-tetramethylethylenediamine (TEMED) BDH 443083G 
Tris Base  Sigma T1503 
  BIO-RAD 161-0716 
Triton X-100  Fluka 93426 
Trypan Blue  Sigma T8154 
Trypsin 0.05 %/EDTA (cell culture) Gibco 25300-054 
Trypsin 2.5 % (tissue culture) Gibco 15090-046 
Tryptone  Difco 0123-01-1 
TTX  Latoxan L8503 
Tween-20  Calbiochem 655205 
Yeast Extract  Difco 0127-01-1 
All other chemicals were purchased from BDH, Fluka, Merck, Sigma and VWR. 
A.1.5 Enzymes 
Item  Company Cat.-No. 
Alkaline Phosphatase  Roche 10713023001 
KOD Hot Start DNA polymerase Novagen 71316 
Lysozyme  Boehringer Mannheim 1243004 
PreScission Protease  GE 27-0843-01 
T4 DNA Ligase  Roche 10481220001 
Tag Polymerase  Invitrogen 10342-020 
All restriction enzymes, aside from PacI (New England Biolabs) and NdeI (GE) were purchased 
from Roche. 
A.1.6 Antibodies and dyes 
Item  Company Cat.-No. 
RhoA Mouse Monoclonal, Clone 26C4 Santa Cruz SC-418 
 Rabbit Polyclonal Santa Cruz SC-179 
Gαq Rabbit Polyclonal Santa Cruz SC-393 
Gαq/11 Rabbit Polyclonal Santa Cruz SC-392 
Myc Mouse Monoclonal, Clone 9E10 Roche 11667149001 
 Mouse Monoclonal, Clone 4A6 Millipore 05-724 
 Rabbit Polyclonal Santa Cruz SC-789 
HA Mouse Monoclonal, Clone 12CA5 Roche 11583816001 
EE Rabbit Polyclonal Abcam 18585 
 
Mouse Cy5 conjugated (source: goat) Jackson IR 115-175-003 
Mouse HRP conjugated (source: goat) BIO-RAD 170-6516 
Mouse HRP conjugated (source: sheep) GE NA931 
Rabbit HRP conjugated (source: goat) BIO-RAD 170-6515 
Rabbit HRP conjugated (source: donkey) GE NA934 
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Alexa Fluor 488 Phalloidin conjugated Molecular Probes A12379 
Alexa Fluor 594 Phalloidin conjugated Molecular Probes A12381 
Tetramethylrhodamine Isothiocyanate (TRITC) Dextran Sigma T1287 
A.1.7 DNA and protein molecular weight ladders 
Item  Company Cat.-No. 
100 bp DNA Ladder Invitrogen 15628-019 
 2072, 1500, 1400, 1300, 1200, 1100, 1000, 900, 800, 700, 600, 500, 400, 300,
 200, 100 bp 
1 kb DNA Ladder Invitrogen 15615-016 
 12216, 11198, 10180, 9162, 8144, 7126, 6108, 5090, 4072, 3054, 2036, 1636,
 1018, 506/517, 396, 344, 298, 220, 201, 154, 134, 75 bp 
All Blue PrecisionPlus Protein Marker BIO-RAD 161-0373 
  250, 150, 100, 75, 50, 37, 25, 20, 15, 10 kDa 
Low Range Marker BIO-RAD 161-0304 
 97, 66, 45, 31, 21, 14 kDa 
A.1.8 Primers 
M13 GTAAAACGACGGCCAGT 
P5 GATCGATCCAGACATGATAAGATACATTGATG 
SP6 GATTTAGGTGACACTATAG 
T3 ATTAACCCTCACTAAAGGGA 
T7 TAATACGACTCACTATAGGG 
P1417 CTTTCCACAGGCAACATCACCAACAATCAC 
P1496 TAGAAGGCACAGTCGAGG 
P2014 CCGGGAGCTGCATGTGTCAGAGG 
P2135 TAGGCGTGTACGGTGGGAGGTC 
P2136 ATGTGGTATGGCTGATTATG 
P2137 CGTCGCCGTCCAGCTCGACCAG 
P2139 CGGCGCGGGTCTTGTAGTTGC 
P2187 GCATGGGATCCAAGGGCGAGGAGCTGTTCAC 
P2188 TCCATGCCGAGAGTGATCCCGGCGGCGGTCACGAACTCCAGC 
P2189 CTGGTGGATCCCTTGTACAGCTCGTCCATGCCGAGAGTGATCCCG 
P2191 GGGTATTCGATGATCCCTGT 
P2222 CGCGGGTCTAGACCACCATGGCTGCCATCCGGAAGAAACTG 
All primers were purchased from Eurofins MWG Operon. 
